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O-GlcNAc is a post-translational modification (PTM) of a single N-acetylglucosamine sugar 
attachment on serine or threonine residues of nuclear, cytoplasmic, and mitochondrial proteins. 
Two opposing enzymes facilitate the modification; O-GlcNAc transferase (OGT) adds the 
modification, while O-GlcNAcase (OGA) removes it. The addition and the removal of O-
GlcNAc, termed O-GlcNAc cycling, is often a dynamic process sensitive to changes in the 
cellular environment. Disruptions in O-GlcNAcylation contribute to diseases such as diabetes, 
cancer, and neurodegeneration. Accumulative chronic dysfunctional mitochondria also lead to 
the development of disease; and importantly, O-GlcNAcylation regulates mitochondrial function.  
In order to test our first hypothesis that disruptions in O-GlcNAc cycling affect 
mitochondrial function by changing the mitochondrial proteome, we employed a proteomics 
screen using SH-SY5Y neuroblastoma cells. We found that OGT and OGA overexpression 
severely disrupted the mitochondrial proteome, including proteins involved in the respiratory 
chain and TCA cycle. Furthermore, mitochondrial morphology in the over-expressing cells had 
disorganized cristae and altered shape and size.  Both cellular respiration and glycolysis is 
impaired. These data support that O-GlcNAc cycling was essential for the proper regulation of 
mitochondrial function.  
We next investigated how sustained elevations in cellular O-GlcNAc levels would alter 
the metabolic profile of the cell. We elevated cellular O-GlcNAc levels by either treating SH-
SY5Y cells with low levels of glucosamine (GlcN), the metabolic substrate of OGT, or the OGA 
inhibitor Thiamet-G (TMG). We found cellular respiration was altered and ATP levels were 
lower in these cells with sustained elevated O-GlcNAc. Additionally, these cells produce 
significantly less reactive oxygen species (ROS). Both GlcN and TMG treated cells have 
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elongated mitochondria, while mitochondrial fusion/fission protein expressions were decreased. 
RNA-sequencing analysis showed that the transcriptome is reprogrammed and NRF2 anti-
oxidant response is down-regulated. Importantly, sustained O-GlcNAcylation in mice brain and 
liver validated the metabolic phenotypes seen in cells, whereas liver OGT knockdown elevated 
ROS levels, impaired mitochondrial respiration, and increased NRF2 anti-oxidant response. 
Furthermore, we discovered from an indirect calorimetric study that sustained elevated O-
GlcNAc promoted weight loss and lowered respiration, skewing mice toward using 
carbohydrates as their main energy source. Here, our results demonstrated that sustained 
elevation in O-GlcNAcylation, coupled with increased OGA expression, reprograms energy 
metabolism and can potentially impact the development of metabolic diseases. Altogether, these 
studies provide new evidence supporting the role of O-GlcNAc as a critical regulator of 
mitochondrial function and energy metabolism. 
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Chapter 1: Introduction 
1.1 Overview 
Chronic mitochondrial deterioration resulting in uncontrolled reactive oxygen species 
(ROS) generation can impair cellular energy metabolism and lead to the development of 
complex metabolic diseases. These diseases include Alzheimer’s (AD), diabetes and cancer [1-
3]. Therefore, mitochondria must acquire different regulatory mechanisms to properly maintain 
their function. Phosphorylation and acetylation regulate mitochondrial function, and these 
modifications are altered during disease states [4-7]. For example, high levels of mitochondrial 
acetylation negatively impact mitochondrial function, as acetylation predominantly deactivates 
proteins involved in the electron transport chain (ETC), tricarboxylic acid cycle (TCA) and ROS 
detoxification [8]. However, emerging evidence points to O-GlcNAc as a key regulator of 
mitochondrial function.  
O-GlcNAcylation is a post-translational modification (PTM) involving the attachment of 
a single β-N-acetylglucosamine to serine/threonine amino acid residues of nuclear, cytoplasmic, 
and mitochondrial proteins. The modification is dynamically regulated by the opposing functions 
of two specific enzymes: O-GlcNAc transferase (OGT) adds the modification, whereas O-
GlcNAcase (OGA) removes it. Furthermore, the OGT metabolic substrate, UDP-GlcNAc, is 
synthesized via the hexosamine biosynthetic pathway (HBP) linking several metabolic inputs 
with O-GlcNAcylation (Figure 1) [9]. Ultimately, these metabolic inputs make O-GlcNAc a 
nutrient sensor capable of influencing many cellular processes, including transcription, 
translation, and mitochondrial function.  
Indication that O-GlcNAc regulates mitochondrial function comes from initial studies 
demonstrating that both OGT [10] and OGA [11] localize to the mitochondria. Furthermore, the 
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pyrimidine nucleotide carrier 1 (PNC1) transports UDP-GlcNAc into the mitochondria to 
provide substrate for OGT [11], allowing electron transport chain (ETC) subunits to be modified 
by O-GlcNAc [12]. Potentially, O-GlcNAcylation of ETC complexes modulates both the ETC 
function and energy metabolism. Importantly, aberrant O-GlcNAcylation is also linked to 
metabolic diseases [13, 14]; however, it is still unclear what is the role of O-GlcNAcylation in 
relation to these metabolic diseases. Evidence supports O-GlcNAc cycling as a global regulator 
for energy metabolism, and delineating O-GlcNAc’s regulatory roles in mitochondrial function is 
essential. 
1.2 Mitochondria: Metabolic Factories 
Mitochondria are key cellular organelles that harbor several important metabolic pathways such 
as the tricarboxylic acid (TCA) cycle, the urea cycle, and oxidative phosphorylation. More than 
just harvesting chemical energy from nutrients to make adenosine triphosphate (ATP), the 
mitochondria are responsible for an array of cellular functions. These functions include sugar and 
fatty acid catabolism, amino acid metabolism, calcium homeostasis, synthesis of heme, iron-
sulfur (Fe-S) clusters and steroids, and apoptosis regulation [15]. The intermediates generated 
through different metabolic pathways of the mitochondria, such as ATP [16], acetyl CoA [17], 
and succinyl CoA[18], are important substrates for the different PTMs, including 
phosphorylation, acetylation and succinylation. Additionally, mitochondria are the main site for 
free radical generation, which are major signaling molecules in cell [19]. Therefore, 
mitochondria are major metabolic hubs in controlling cellular function.  
Chronic impairment in mitochondrial functions can lead to the development of complex 
metabolic diseases, such as Alzheimer’s and cancer. For example, one evolving hypothesis, the 




chronic mitochondrial deterioration. The mitochondrial cascade hypothesis is based on the idea 
that an individual’s baseline mitochondrial function is defined by gene inheritance, and that 
inherited and environmental factors determine the rates of mitochondrial functional changes [20]. 
And as we age, the efficacy of mitochondrial respiration diminishes. The increased electron 
leakage from the electron transport chain increases ROS generation and lowers ATP generation. 
The progressive mitochondrial deterioration leads to global cellular damage and enhances 
diseases progression [1-3]. In support of this hypothesis, several studies demonstrate that in the 
brains of AD patients and AD mice prior to the formation of amyloid plaques, the TCA cycle and 
oxidative phosphorylation are suppressed, and the elevation of free radical production increases 
oxidative stress [21-24]. Subsequently, the prolonged exposure to large concentrations of ROS in 
neurons can have a deleterious effect on DNA, RNA and proteins, and more importantly, this 
phenomenon also induces cross-linking of Aβ and APP fragments for further aggregation [25, 
26]. Furthermore, studies using various AD models, such as AD brain and human platelet 
mitochondria, have also reported that deficiencies in the fission and fusion of mitochondria, and 
in enzymes involved in the electron transport chain (ETC) and tricarboxylic acid cycle (TCA), 
are present in AD [27, 28]. Altogether, these studies have provided strong evidence for the 
important role of improper mitochondrial regulation in the development of AD. 
1.3 O-GlcNAc: A Nutrient/Stress Sensing Modification 
Broadly defined, nutrient sensing is a cell’s ability to determine the concentrations of 
metabolites, and to act accordingly to change cellular function. Most PTMs are derived from 
metabolites that are linked to metabolic inputs used to signal appropriate cellular action [2]. O-
GlcNAc is a PTM of the attachment of a single N-acetylglucosamine to serine/threonine residues 
of nuclear, cytoplasmic and mitochondrial proteins. Both OGT and OGA are nutrient sensors 
 4 
that facilitate the addition and removal of O-GlcNAcylation in response to changes in cellular 
nutrients and metabolic state. Importantly, O-GlcNAc acts as a nutrient sensing modification 
through the activity of the hexosamine biosynthetic pathway (HBP). The HBP is tightly 
regulated by its rate-limiting enzyme glutamine fructose-6-phosphate aminotransferase 1 
(GFAT1). This pathway integrates signals from glucose, amino acid, fatty acid and nucleotide 
metabolisms (Figure 1) to synthesize the substrate of OGT, UDP-GlcNAc. Because UDP-
GlcNAc synthesis relies on the integration of multiple metabolic pathways, O-GlcNAcylation 
can sense changes in nutrients [29]. Since O-GlcNAc regulates mitochondrial function, changes 
in nutrients could lead to changes in mitochondrial function. Potentially, chronic disruptions in 
O-GlcNAc’s nutrient sensing ability could mediate mitochondrial deterioration leading to the 
development of metabolically related diseases. In spite of this, the mechanism is unclear in 
which O-GlcNAc regulates mitochondrial function and warrants further investigation. 
1.4 O-GlcNAc Regulates Metabolism 
Cumulative evidence supports O-GlcNAc as essential in controlling mitochondrial function 
influencing energy metabolism. Both O-GlcNAc cycling enzymes, OGT [10] and OGA, localize 
to the mitochondria [11]. OGT substrate, UDP-GlcNAc, is transported into the mitochondria by 
pyrimidine nucleotide carrier 1 (PNC1) [11]. Furthermore, majority of the ETC subunits are 
modified by O-GlcNAc, and changes in O-GlcNAcylation levels alter mitochondrial respiration. 
For example, when O-GlcNAcylation is elevated via short-term high glucose treatment, ETC 
activity is suppressed in rat cardiomyocytes [30]; whereas, short-term OGA inhibition increased 
mitochondrial respiration in rats [12]. Recently, several studies also demonstrated genetic 




phenotypes [31-33]. Together, these data demonstrate that O-GlcNAc is essential for the proper 





Figure 1: Schematic representation of the Hexosamine Biosynthetic Pathway (HBP) and O-
GlcNAc modification. 






Chapter 2: O-linked β-N-Acetylglucosamine Cycling is Important in Regulating 
Mitochondrial Function 
Reproduced with permission from Tan, E.P., Villar, M.T., E, L., Lu, J., Selfridge, J.E., Artigues, 
A., Swerdlow, R.H., and Slawson, C. (2013). Altering O-linked β-N-Acetylglucosamine Cycling 
Disrupts Mitochondrial Function. The Journal of Biological Chemistry 289(21):14719-30 
2.1 Introduction 
O-GlcNAc is the post-translational addition of a single N-acetylglucosamine residue to 
cytoplasmic and nuclear proteins [34].  The O-GlcNAc modification is ubiquitously found in all 
higher eukaryotes. O-GlcNAc transferase (OGT) is the enzyme responsible for the addition of O-
GlcNAc to intracellular proteins, while O-GlcNAcase (OGA) removes the modification from 
intracellular proteins [35].  These enzymes are expressed in all mammalian cells, with highest 
expression levels in brain [34].  The addition or removal of O-GlcNAc is termed O-GlcNAc 
cycling, and altering O-GlcNAc cycling rates affects metabolic pathways, stress response, and 
cell cycle progression [34-36].   
 In the past several years, multiple groups have demonstrated links between metabolic 
disorders and O-GlcNAcylation.  For example, several proteins involved in insulin signaling, 
including IRS1, are modified by O-GlcNAc.  OGT localizes to the plasma membrane shortly 
after insulin binding to the insulin receptor, suggesting that relocation of OGT to the membrane 
suppresses insulin signaling by O-GlcNAcylating IRS1 [37-40].  Elevated glucose levels impair 
glycogen synthase function through increased O-GlcNAcylation of glycogen synthase [41].  
Furthermore, chronic hyperglycemia causes an increase in O-GlcNAcylation of CRTC2 (cyclic 
adenosine monophosphate response element–binding protein 2), thereby promoting increased 
gluconeogenesis through interactions with the CREB transcription factor [42].  Concomitantly, 
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the transcription factor FOXO1 is O-GlcNAcylated, which increases the transcription of 
gluconeogenesis genes such as glucose-6-phosphatase and phosphoenolpyruvate carboxykinase 
[43].  Together, these data demonstrate the importance of O-GlcNAcylation in regulating 
metabolic function. 
Mitochondrial function is also regulated by O-GlcNAc. Several respiratory chain proteins 
are modified by O-GlcNAc, and increased O-GlcNAcylation impairs respiration [44, 45].  A 
splice variant of OGT (mOGT) localizes to the mitochondria [44, 46, 47], and in INS-1 cells 
mOGT over-expression causes cellular apoptosis [48].  Recently, several studies suggest that 
chronic hypoglycemia increases O-GlcNAcylation, and promotes metabolic disease by inducing 
mitochondrial dysfunction [49, 50]. For example, changes in cellular glucose levels in cardiac 
myocytes are linked to altered O-GlcNAcylation, which in turn leads to changes in mitochondrial 
function [44, 51].  Rats selected for low running capacity had increased mitochondrial O-
GlcNAcylation, suggesting that increased mitochondrial O-GlcNAcylation impair respiration 
[52].  Together, these data demonstrate a critical role for O-GlcNAcylation in the regulation of 
mitochondrial function. 
To more fully address how alterations in O-GlcNAc processing enzymes affect 
mitochondrial function, we performed a proteomics based study in a neuronal cell line in which 
we quantified changes in mitochondrial protein expression after over-expression of OGT or 
OGA. Over-expression of either enzyme caused alterations in the expression of proteins involved 
in the respiratory chain, as well as a reduction in several TCA cycle proteins.  Mitochondrial 
morphology was greatly altered, and cellular respiration and glycolysis rates were significantly 




mitochondrial and cytosolic bioenergetic fluxes and infrastructure.  Our data imply that 
mitochondrial function is sensitive to O-GlcNAc cycling. 
2.2 Methods 
2.2.1 Antibodies 
All antibodies were used at a 1:1000 dilution for immunoblotting unless otherwise noted.  COX 
IV antibody was purchased from Invitrogen (A21348).  The following antibodies were purchased 
from Abcam: Metaxin-1 (AB104966), ACADM (AB92461), NDUFA5 (AB183706), NDUFA9 
(AB14713).  Actin (A2066) and GFP (G6539) were from Sigma. Antibodies for OGT (AL-28, 
Al-35), OGA (341), and O-GlcNAc (110.6) were a kind gift from the laboratory of Gerald Hart 
in the department of Biological Chemistry at the Johns Hopkins University School of Medicine. 
2.2.2 Cell Culture 
SY5Y neuroblastoma cells were cultured in DMEM (Sigma) supplemented with 10% Fetal 
Bovine Serum (FBS, Gemini) and 1% penicillin/streptomycin (Invitrogen).  For SILAC culture, 
SY5Y cells were cultured in DMEM (Cambridge Isotope, DMEM-500) supplemented with 
unlabeled arginine, lysine, and tyrosine (Sigma A8094, L5501, T8566), DMEM supplemented 
with 13C6-arginine, 4,4,5,5-D4-lysine, and tyrosine (Cambridge Isotope CLM-2265 and DLM-
2640), or DMEM supplemented with 13C6-15N4-arginine, 13C6-15N2-lysine, and tyrosine 
(Cambridge Isotope CNLM-539 and CNLM-291).  All SILAC media were supplemented with 
10% dialyzed Fetal Bovine Serum (Gemini 100-108) and 1% penicillin/streptomycin.  Cells 
were passaged at least 5 times in labeled media before performing an experiment.  Cells were 
infected with OGT, OGA, or GFP virus at a multiplicity of infection (MOI) of 75.  Cells were 
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then harvested for either MS analysis or respiration analysis 48 or 24 hours post-infection 
respectively. 
2.2.3 Mitochondrial Isolation 
All mitochondria were isolated using the modified nitrogen cavitation method described by 
Gottlieb and Adachi [53].  At least 2 x 108 cells were used. The cells were digested off the plate 
with trypsin, washed twice with pre-chilled PBS, and resuspended into 3 mL of the isolation 
medium (225 mM mannitol, 75 mM sucrose, 5 mM Hepes, 1 mM EGTA, pH 7.4 at 4 °C). The 
cell suspension was collected into a pre-chilled cavitation chamber (nitrogen bomb; Parr 
Instrument Company, Moline IL) and was subjected to 900 psi for 15-min period. The collected 
cell suspension from the cavitation chamber was centrifuged at 1500 x g for 3 min to pellet the 
cell debris (heavy particles, or fractions of cells). The supernatant was collected and centrifuged 
at 20,000 x g for 10 min. The pellet (crude mitochondrial fraction) was washed three times with 
500 µl of isolation medium. The final pellet was resuspended in 100 µl of NP-40 Lysis Buffer 
(20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 40 mM GlcNAc, and 1% 
NP-40, all reagents from Sigma) and lysed on ice for 30 min with occasional vortexing. 
2.2.4 Peptide Identification and Computational Analysis 
Peaks Studio (version 7.0 BSI, Waterloo, ON, Canada) was used to analyze the mass spectra. 
The following criteria were used for the searches: data refinement was performed with no 
merged scans, with precursor charge correction and with no filtering. De novo sequencing was 
performed with a mass tolerance of 25 ppm for the parent and 0.4 for the fragment ions, using 
trypsin as enzyme specificity, carbamidomethyl cysteine as a fixed modification and variable 
modifications of oxidation (M), deamidation (N, Q), pyroGlu from Q. Since proteins were 




respectively) and R (+6.02 and 10.02 for medium and heavy label, respectively) were also 
considered. A maximum of 3 variable modifications and 2 missed cleavages per peptide were 
allowed. The resulting peptide sequences were searched against a human IPI protein database 
(version 3.87). Estimation of false discovery rate (FDR) was conducted by searching all spectra 
against a decoy-fusion (inverted) database. Peptide identifications were accepted if they could be 
established at a FDR less than 1%. For protein identification, proteins were accepted if they 
could be established at a Peaks protein probability score (-10lgP) better than 20 with a minimum 
of two unique peptides per protein. Proteins that contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principle of 
parsimony, only the top ranked protein sequence was reported in the results section. For protein 
quantification the Peaks Q module included in the Peaks Studio (Peaks studio v7.0) was used. 
For precursor ion quantification, the mass tolerance was set to 0.2 Da and a retention time 
tolerance of 1 min, using an upper bound charge state of 4. For each experimental data set, 
protein ratios were calculated relative to the control (GFP cells) and were calculated on the 
average of total peak intensities of the top 3 unique peptides identified per protein group. For 
each protein group, the data of at least 2 experimental data sets from all searches were combined 
and averaged. Only proteins that showed a 1.5-fold expression change were considered 
noteworthy. 
2.2.5 Electron Microscopy 
SY5Y cells were cultured on Thermanox® Coverslips and infected with a 75 MOI of GFP, 
OGT, or OGA adenovirus 24 hours prior to fixation. Cells were fixed with 2% glutaraldehyde in 
0.1 M cacodylate buffer, pH 7.4, and were post-fixed with 1% osmium tetroxide/0.3% potassium 
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ferricynide. The cells were then dehydrated in a graded series of 50, 70, 80, 95 and 100% 
ethanol. Cells on coverslips were embedded in 100% epoxy resin, and the resin was cured 
overnight at 60°C. Thin sections of 70-90 nm were cut on a Reichert Ultracut-S (Reichert 
Technologies, Buffalo, NY), stained with uranyl acetate and lead citrate. Images were captured 
at 80kV with JEOL JEM-1400 Transmission Electron Microscope (JEOL USA Inc., Peabody, 
MA) equipped with a Lab6 gun at the University of Kansas Medical Center EM Core laboratory. 
2.2.6 Cellular Respiration and Glycolysis Measurement 
To measure cellular respiration and glycolysis, we used an XF24 flux analyzer (Seahorse 
Bioscience, North Billerica, MA). All cellular respiration and glycolysis assays were performed 
in a Seahorse 24-well cell culture plate in conjunction with an XF24 sensor cartridge at least 
three separate times. SY5Y cells were seeded as a monolayer with a density of 65,000 cells per 
well and were infected with OGT, OGA, or GFP virus for 24 hours prior to experimental assays. 
For respiration assays, cells were incubated in unbuffered DMEM (DMEM 8.3 g/L Sigma 
D5030-1L pH 7.4), 25 mM glucose, Phenol Red (15 mg/L Sigma P-5530), 200 mM GlutaMax-1, 
NaCl (1.85 g/L), at 37° in a CO2  free incubator for 1 hour prior to loading the plate in the XF24 
to allow temperature and pH equilibrium. The oxygen consumption rate (OCR) was measured 
over a period of 100 min during which oligomycin (0.5 µM), FCCP (0.3 µM), and both 
antimycin A (0.2 µM) and rotenone (0.1 µM) were sequentially added to each well at specified 
time points.  For glycolysis assays, cells were incubated in glycolysis stress test base glucose free 
medium (DMEM 8.3 g/L Sigma D5030-1L pH 7.4) containing 40 µM Phenol Red (Sigma P-
5530), 2 mM L-glutamine, and NaCl (1.85 g/L) at 37 °C in a CO2 free incubator for 1 hour prior 
to loading the plate in the XF24 to allow temperature and pH equilibrium. The extracellular 




oligomycin (1 µM), and 2-Deoxy-D-glucose (2-DG) (100 mM) were added to each well 
sequentially at specified time points during the assay. 
2.2.7 Statistical Analysis 
For comparisons of data containing three groups, we used one-way ANOVA followed by 
Tukey’s post hoc tests to compare mean differences of groups at a significance threshold of P < 
0.05. 
2.3 Results 
2.3.1 OGT/OGA Overexpression Alters Mitochondrial O-GlcNAcylation and Protein 
Expression 
In order to determine how changes in O-GlcNAc cycling affect mitochondria protein expression, 
we over-expressed either OGT or OGA through adenoviral-mediated infection.  Importantly, we 
chose to use the full length OGT over the mitochondrial form of OGT because we wanted to 
determine how changes in O-GlcNAc cycling would affect expression of both nuclear encoded 
mitochondrial genes and subsequently any mitochondrial-encoded genes.  Since neuronal 
function is highly dependent on oxidative metabolism, we used as a model cell line SY5Y 
neuroblastoma cells.  We selected this line because of its rapid expansion, its ease of over-
expression, its neuronal background (OGT and OGA expression is robust in brain), and because 
SY5Y cells are relatively sensitive to changes in mitochondrial function [54].  After over-
expression we isolated a heavy membrane preparation enriched for mitochondria, and measured 
O-GlcNAcylation levels.  Green Fluorescent Protein (GFP) was used as a control for adenoviral 
infection.  GFP-expressing control mitochondria contained numerous O-GlcNAcylated proteins. 
Both OGT and OGA expression robustly increased in the respectively transfected cells. Over-
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expressing the nuclear-cytoplasmic form of OGT dramatically increased O-GlcNAc levels while 































OGT or OGA over-expression alters mitochondrial O-GlcNAcylation. 
Mitochondria were purified from SY5Y cells expressing GFP, OGT, or OGA and probed for 
total O-GlcNAc.  As expected, total O-GlcNAc levels are increased in OGT expressing cells and 
decreased in OGA expressing cells.  COX IV was used as a loading control. 
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 Next, we generated SILAC (Stable Isotope Labeling of Amino Acids on Cell Culture) 
labeled SY5Y cells in order to determine how OGT/OGA over-expression changes the 
expression of mitochondrial proteins.  Labeled cells expressing GFP (grown in light isotopic 
medium), OGT (grown in medium isotopic medium), or OGA (grown in heavy isotopic medium) 
were lysed, mitochondria purified, and equal amounts of mitochondrial proteins were combined 
and separated via gel electrophoresis.  In gel-digestion of stained proteins was performed, 
followed by a cleanup step using a protein trap and reverse phase HPLC separation.  Separated 
proteins were then injected into a high mass accuracy Thermofinnigan FT-LTQ mass 
spectrometer.  Both sequence composition and quantitative information were collected in a 
single scan.  Peptide and protein identifications below a false discovery rate of 1% are reported. 
PEAKS Software suite was used for identification and quantification analysis (Figure 3A).  We 
repeated this experiment two more times, but switched SILAC labels for the cells expressing 
GFP, medium media, OGT, heavy media, or OGA, light media, for example. From each 
experimental set, we were able to identify numerous proteins from each in-gel digested band 





























Figure 3: Purification of SILAC labeled mitochondria from SY5Y cells.   
(A) Schematic of SILAC sample processing. Mitochondria from light, medium, and heavy 
labeled SY5Y cells were purified and combined in equal protein amounts.  The samples were 
separated by gel electrophoresis, stained, and bands excised.  The excised bands were processed 
by in-gel trypsin digestion.  Peptides were separated via HPLC and analyzed by a FT-LTQ mass 
spectrometer.  SILAC quantification was performed using the PEAKS software package. (B) 
Image of Coomassie blue-stained gel after electrophoretic separation. The bar graph on the right 





In the first experiment, we determined a total of 507 protein identifications in the crude 
mitochondrial preparation; experiment 2 yielded 350 protein identifications; and experiment 3 
yielded 768 protein identifications (Figure 4A). 152 of the identified proteins were found in all 
experimental replicates. We identified a total of 234, 146, and 242 mitochondrial proteins, 
respectively, from the 3 experimental replicates (Figure 4B).  We grouped the identified 
mitochondrial proteins into classes according to function (Figure 5).  Of the 345 unique 
mitochondrial proteins identified, the most abundant class included those that mediate 
mitochondrial protein translation, while proteins involved in cellular respiration were the next 




Figure 4: Proteomic identification of isolated proteins.   
(A) Venn diagram indicating the total number of identified proteins from 3 independent replicate 
experiments.  (B) Venn diagram showing the total number of mitochondrial proteins identified 





Figure 5: Functional class distribution of identified mitochondrial proteins.  
Identified proteins were distributed into biological functional class.  Components of 




2.3.2 OGT/OGA Overexpression Impacts Electron Transport Chain and TCA Protein 
Expression 
Next, we quantified the differences in protein expression of the OGT or OGA over-expressing 
cells compared to the GFP expressing control cells. Including non-mitochondrial proteins, from 
the combined replicates we were able to quantify 1102 total proteins. We considered proteins 
whose expression changed greater than 1.5-fold to be noteworthy, with 571 proteins showing 
large expression changes in the total extract (Figure 6A), while 107 proteins changed in the 
mitochondrial extract (Figure 6B).  In most cases the increase or decrease in protein expression 








Figure 6: Quantification of SILAC labeled mitochondrial proteins from OGT and OGA 
over-expressing SY5Y cells 
(A-B) The relative fold changes in total quantified proteins (A) or mitochondrial proteins (B) 
were plotted after OGT over-expression (dark green) or OGA over-expression (light orange).  





OGA and OGT over-expressing cells demonstrated similar patterns of mitochondrial 
protein change.  Almost all the mitochondrial protein functional categories demonstrated a 
decrease in protein expression, although some transport and apoptosis proteins were increased in 
the over-expressing cells (Figure 7 and Table 1).  Next, we performed orthogonal validation via 
western blots on several mitochondrial proteins whose expression changed in the proteomic 
study. Again, we enriched mitochondria from SY5Y cells, but we also included the cytosolic 
fraction as well on the gels.  By including the cytosolic fraction, we could determine if protein 
transport into the mitochondria was altered and potentially a mechanism for changes in protein 
expression.  We then blotted for a variety of proteins.  We determined no change in COX4 
(Cytochrome c oxidase subunit 4) according to the proteomics; therefore, we used COX4 as a 
mitochondrial protein load control (Figure 8). The complex 1 protein NDUFA9 (NADH 
dehydrogenase [ubiquinone] 1 alpha subcomplex) was decreased in the OGA over-expression 
proteomics and validated via western blotting.  On the other hand, complex 1 protein NDUFA5 
was increased in OGT over-expressing cells but decreased in the OGA over-expressing cells.  
Showing expression decreases in both OGT/OGA over-expressing cells was the outer 
mitochondrial membrane protein Metaxin-1 (MTX1). The β-oxidation protein ACADM 
(Medium-chain specific acyl-CoA dehydrogenase) was decreased in OGT over-expressing cells 





Figure 7: OGT/OGA over-expression alters mitochondrial protein expression 
Heat map of proteins demonstrating a greater than 1.5-fold expression change in the OGT/OGA 
over-expressing cells normalized to GFP control cells.  Heat map scale ranges from increased 
protein expression (orange) to decreased protein expression (teal).  Proteins were grouped 




































Figure 8: Orthogonal validation of mitochondrial protein expression 
Mitochondria and cytosolic fractions were prepared from SY5Y cells.  Samples were separated 
on SDS-PAGE and probed for specific proteins.  COX4 is used as a mitochondria load control 
while actin was a cytoplasmic load control.  ACADM, NDUFA9, NDUFA5, and MTX1 
expression mirrored the expression changes in the proteomic studies. 
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Table 1: Complete list of protein expression changed after OGT/OGA overexpression 
 














Apoptosis@inducing!factor!1_!mitochondrial! 4.06! 1.89! Apoptosis/
Tax_Id=9606!Gene_Symbol=BAX!Isoform!Sigma!of!
Apoptosis!regulator!BAX! 2.15! 1.78! Apoptosis/
Tax_Id=9606!Gene_Symbol=DIABLO!Isoform!2!of!Diablo!
homolog_!mitochondrial! 3.47! _! Apoptosis/
Tax_Id=9606!Gene_Symbol=FAM162A!










































































































































shock!protein!HSP!90@alpha! _! 0.63! Chaperone/
Tax_Id=9606!Gene_Symbol=HSPA2!Heat!shock@related!70!
kDa!protein!2! 0.09! 0.64! Chaperone/
Tax_Id=9606!Gene_Symbol=PPIF!Peptidyl@prolyl!cis@
trans!isomerase!F_!mitochondrial! _! 0.61! Chaperone/
Tax_Id=9606!Gene_Symbol=AFG3L2!Similar!to!AFG3!
ATPase!family!gene!3@like!2!(Fragment)! 0.38! 0.64! Degradation/
Tax_Id=9606!Gene_Symbol=CLPX!ATP@dependent!Clp!
protease!ATP@binding!subunit!clpX@like_!





























































































ES1!protein!homolog_!mitochondrial! _! 1.59! Other/
Tax_Id=9606!Gene_Symbol=PMPCB!Mitochondrial@
processing!peptidase!subunit!beta! 0.33! 0.35! Other/
Tax_Id=9606!Gene_Symbol=SCCPDH!Probable!











dehydrogenase_!mitochondrial! 1.51! _! TCA/Cycle/
Tax_Id=9606!Gene_Symbol=OGDH!cDNA!FLJ59557_!highly!
similar!to!2@oxoglutarate!dehydrogenase!E1!component_!
mitochondrial! 0.56! _! TCA/Cycle/
Tax_Id=9606!Gene_Symbol=ACO2!Aconitate!
hydratase_!mitochondrial! 0.64! 0.63! TCA/Cycle/
Tax_Id=9606!Gene_Symbol=ACO2!cDNA!FLJ50886_!highly!




dehydrogenase!complex_!mitochondrial! 2.12! 0.35! TCA/Cycle/
Tax_Id=9606!Gene_Symbol=IDH3A!Isoform!2!of!
Isocitrate!dehydrogenase![NAD]!subunit!alpha_!
mitochondrial! _! 1.55! TCA/Cycle/
Tax_Id=9606!Gene_Symbol=SUCLG1!Succinyl@CoA!ligase!
[GDP@forming]!subunit!alpha_!mitochondrial! 1.71! _! TCA/Cycle/
Tax_Id=9606!Gene_Symbol=SUCLG2!Uncharacterized!










S29_!mitochondrial! 2.26! _! Translation/
Tax_Id=9606!Gene_Symbol=DAP3!28S!ribosomal!protein!
S29_!mitochondrial!isoform!2! 2.53! _! Translation/
Tax_Id=9606!Gene_Symbol=GFM1!Isoform!1!of!
Elongation!factor!G_!mitochondrial! _! 1.77! Translation/
Tax_Id=9606!Gene_Symbol=MRPL11!Isoform!1!of!39S!
ribosomal!protein!L11_!mitochondrial! _! 0.60! Translation/
Tax_Id=9606!Gene_Symbol=MRPL22!Isoform!1!of!39S!
ribosomal!protein!L22_!mitochondrial! _! 0.47! Translation/
Tax_Id=9606!Gene_Symbol=MRPL41!39S!ribosomal!
protein!L41_!mitochondrial! 0.65! 1.53! Translation/
Tax_Id=9606!Gene_Symbol=MRPL9!cDNA!FLJ59179_!
highly!similar!to!39S!ribosomal!protein!L9_!
mitochondrial! _! 1.53! Translation/
Tax_Id=9606!Gene_Symbol=MRPS17!28S!ribosomal!
protein!S17_!mitochondrial!precursor! _! 0.64! Translation/
Tax_Id=9606!Gene_Symbol=MRPS22!Uncharacterized!





protein!S23_!mitochondrial! 0.64! 0.55! Translation/
Tax_Id=9606!Gene_Symbol=MRPS28!Uncharacterized!
protein! _! 0.53! Translation/
Tax_Id=9606!Gene_Symbol=MRPS5!Isoform!1!of!28S!
ribosomal!protein!S5_!mitochondrial! _! 0.58! Translation/
Tax_Id=9606!Gene_Symbol=MRPS7!28S!ribosomal!
protein!S7_!mitochondrial! _! 0.65! Translation/
Tax_Id=9606!Gene_Symbol=MRPS9!28S!ribosomal!
protein!S9_!mitochondrial! _! 0.64! Translation/
Tax_Id=9606!Gene_Symbol=MRRF!Isoform!3!of!
Ribosome@recycling!factor_!mitochondrial! _! 1.60! Translation/
Tax_Id=9606!Gene_Symbol=VARS!Valyl@tRNA!synthetase! _! 0.66! Translation/
Tax_Id=9606!Gene_Symbol=VDAC3!Uncharacterized!
protein! 0.64! _! Transport/
Tax_Id=9606!Gene_Symbol=LOC285556!hypothetical!
protein!LOC285556! 0.18! 0.44! Transport/
Tax_Id=9606!Gene_Symbol=MTX1!Isoform!2!of!
Metaxin@1! 0.41! 0.43! Transport/
Tax_Id=9606!Gene_Symbol=SCP2!non@specific!lipid@
transfer!protein!isoform!4!proprotein! 1.63! _! Transport/
Tax_Id=9606!Gene_Symbol=SCP2!non@specific!lipid@
transfer!protein!isoform!8!proprotein! 6.53! 5.55! Transport/
Tax_Id=9606!Gene_Symbol=SCP2!non@specific!lipid@
transfer!protein!isoform!8!proprotein! 6.53! 5.55! Transport/
Tax_Id=9606!Gene_Symbol=SLC25A22!Uncharacterized!
protein! 0.55! _! Transport/
Tax_Id=9606!Gene_Symbol=SLC25A3!Isoform!B!of!
Phosphate!carrier!protein_!mitochondrial! 0.58! 0.64! Transport/
Tax_Id=9606!Gene_Symbol=SLC25A3!Isoform!B!of!
Phosphate!carrier!protein_!mitochondrial! 0.58! 0.64! Transport/
Tax_Id=9606!Gene_Symbol=SLC25A3!Uncharacterized!
protein! 2.02! _! Transport/
Tax_Id=9606!Gene_Symbol=TIMM17B!Mitochondrial!
import!inner!membrane!translocase!subunit!Tim17@B! _! 0.60! Transport/
Tax_Id=9606!Gene_Symbol=TOMM20!Mitochondrial!




Both OGT and OGA over-expressing cells caused similar expression changes in 
mitochondrial metabolic pathways.  For example, several TCA cycle proteins had altered 
expression.  First, the protein PDHX (pyruvate dehydrogenase protein X component) of the 
pyruvate dehydrogenase complex, the entry point for acetyl-CoA into the TCA cycle, was 
deceased in OGT over-expression cells (Figure 9).  OGA over-expressing cells reduced 
SUCLG2 (succinyl-CoA ligase GDP-forming beta) of the succinyl-CoA synthetase complex 
expression while increasing IDH3A (isocitrate dehydrogenase [NAD] subunit alpha) expression 
of the isocitrate dehydrogenase complex.  OGT over-expressing cells increased the expression of 
both subunits of the α-ketoglutarate dehydrogenase complex, although, one isoform of OGDH 
(2-oxoglutarate dehydrogenase) was decreased in the OGT over-expressing cells.  Both over-
expressing cell types exhibited reduced aconitase (ACO2) expression.  Not only did OGT/OGA 
over-expression affect the TCA cycle, but several respiratory chain subunits also had altered 
expression levels. Complex 1, 4, and ATP synthase subunits showed reduced expression (Figure 
10).  Importantly, protein expression of other subunits of complex 1 and the ETF (electron 





Figure 9: TCA cycle protein expression is altered in OGT/OGA over-expressing cells 
Cartoon of the TCA cycle shows enzymes of the cycle shown in blocks.  Teal blocks list proteins 
whose expression decreased in OGT or OGA over-expressing cells.  The fold change induced by 
either OGT or OGA is listed in the box as well.  Green blocks indicate no expression changes 
while proteins in white blocks were not identified.  
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Figure 10: Components of the electron transport chain are altered in OGT or OGA over-
expressing cells 
In the schematic, electron transport chain proteins (circles) are categorized according to 
respiratory complex.  Green circles indicate identified proteins whose expression does not 
change; teal circles are proteins whose expression decreases, and orange circles are proteins 





2.3.3 Altered O-GlcNAc Cycling Disrupts Mitochondrial Morphology 
Next, we used transmission electron microscopy to assess if mitochondrial morphology was 
disrupted in the OGT/OGA over-expressing cells. Mitochondria from these cells showed a lack 
of cristae or apparent errors in fission or fusion when compared to GFP control mitochondria 
(Figure 11A).  After quantification, OGT/OGA over-expressing cells contained 40-50% 
































Figure 11: Mitochondrial morphology is disrupted in OGT/OGA over-expressing cells 
(A) Mitochondria morphology was observed after GFP, OGT, or OGA adenoviral infection by 
transmission electron microscopy.  Scale bars are indicated on each image. (B) Mitochondria 
from the over-expression cells with aberrant morphology and lack of cristae were quantified. The 
percentage of abnormal mitochondria were calculated and plotted.  Counted mitochondria 





2.3.4 OGT/OGA Overexpression Impairs Cellular Respiration and Glycolysis 
Since OGT and OGA over-expression altered respiratory chain protein expression and 
mitochondrial morphology, we measured cellular respiration using an XF24 analyzer.  First, we 
determined the basal respiration rate in these cells. OGA over-expressing cells had significantly 
decreased baseline oxygen consumption rates compared to GFP control cells (Figure 12A).  
Following this measurement oligomycin, an ATP synthase inhibitor, was added. This compound 
allows for the measurement of the proton leak rate, which determines mitochondrial 
thermogenesis. Thermogenesis was modestly reduced in the OGT and OGA over-expressing 
cells (Figure 12B).  From this set of data, we calculated the percentage of total mitochondrial 
oxygen consumption used for ATP production. Under basal conditions, the percentage of 
mitochondrial oxygen consumption supporting ATP production was slightly lower in OGA over-
expressing cells (Figure 12C).  Next, we added FCCP (Carbonyl cyanide 4-trifluoromethoxy-
phenylhydrazone) in order to depolarize the membrane. From these data, we calculated the 
mitochondria reserve capacity.  OGT/OGA over-expressing cells had little reserve capacity as 
compared to control cells (Figure 12D).   Accordingly, the absolute maximal respiration rate was 
significantly reduced in the OGT/OGA over-expressing cells (Figure 12E). Overall, these cells 
appeared to be bioenergetically stressed even under basal conditions, as the amount of oxygen 
they consumed under those conditions represented a higher percentage of their total oxygen 
consumption capacity (Figure 12F). 
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Figure 12: OGT/OGA over-expressing cells have reduced cellular respiration 
(A) Basal mitochondria respiration (OCR) is measured in SY5Y over-expression cells using an 
XF24 analyzer. (B) ATP synthase inhibitor oligomycin is added to the cells to block ATP 
production, allowing for the measurement of the proton leak rate.  (C) The percentage of oxygen 
consumed to generate ATP under basal respiration conditions was calculated from the proton 
leak and basal respiration measurements. (D) FCCP, which depolarizes the mitochondrial outer 
membrane, was added to cells to measure the maximal increase in oxygen consumption.  Reserve 
capacity was calculated by subtracting maximal oxygen consumption from basal consumption  
(E) Antimycin and rotenone, which inhibits complex I and II of the ETC, was added to measure 
the non-mitochondrial oxygen consumption.  Maximal respiration was calculated by subtracting 
non-mitochondrial respiration from the highest rate of oxygen consumption.  (F) The respiration 








 Lastly, we measured cell glycolysis flux to ascertain if the over-expressing cells were 
shifting towards a more anaerobic pattern of energy production.  Cells were placed into the XF24 
analyzer and starved of glucose for 1 hour.  After starvation, glucose was added back to cells and 
the extracellular acidification rate was measured.  Both OGT and OGA over-expressing cells had 
significantly lower basal glycolysis rates (Figure 13A).  After the addition of oligomycin, we 
measured the glycolysis rate that resulted when mitochondrial ATP production was inhibited, 
and used this parameter to calculate the glycolysis reserve capacity.  These cells had a lower 
glycolysis capacity than control cells (Figure 13B), and    OGA over-expressing cells did show a 
significant reduction in maximal capacity compared to control cells (Figure 13C).  Finally, we 
calculated the percentage of glycolysis capacity being used by these cells under unstressed 
conditions. No significant difference was found between the control and over-expression cells 
(Figure 13D).  Therefore, with over-expression of either OGT or OGA the basal and maximal 





Figure 13: Glycolysis is lower in OGT/OGA over-expressing cells 
(A) Extracellular acidification rate (ECAR) was measured after the addition of glucose to starved 
SY5Y over-expression cells allowing for the glycolysis calculation.  (B) ATP synthase inhibitor 
oligomycin was added to block ATP production causing an increase in extracellular acidification 
rate. Glycolytic reserve capacity was calculated by subtracting the maximal ECAR from the 
basal ECAR.  (C) The addition of 2-deoyglucose blocks glycolysis, allowing for the 
measurement of the non-glycolytic ECAR.  Maximal glycolytic rate was calculated by 
subtracting non-glycolytic ECAR from maximal ECAR.  (D) Glycolytic capacity use under basal 
condition was calculated by using the ratio of basal glycolysis over the maximal glycolysis. 




Increasing evidence points to a critical role for OGT and OGA in regulating mitochondrial 
function. We decided to explore how increased OGT or OGA cellular expression affects 
mitochondrial protein expression and function. By employing a proteomics-based approach to 
explore how O-GlcNAc cycling affects mitochondria function, we demonstrate that OGT or 
OGA over-expression resulted in altered mitochondrial protein expression. Proteins showing the 
greatest expression changes were protein transport, translation, and respiration chain proteins.  
The alteration in mitochondrial protein expression had a deleterious effect on the morphology of 
the mitochondria; furthermore, the respiration capacity was dramatically impaired after 
OGT/OGA over-expression.  Together these data suggest a complicated and important role for 
O-GlcNAc cycling in the homeostasis of mitochondrial protein expression and function. 
As expected, mitochondrial proteins identified in the SILAC experiment were composed 
primarily of proteins critical for mitochondrial function, such as respiration, translation, and 
transport proteins.  Since we over-expressed either the nuclear/cytoplasmic forms OGT or OGA, 
then protein expression changes are likely due to a variety of cellular defects.  Altered O-
GlcNAc cycling affects both transcription and translation.  Both OGT and OGA are important in 
modulating gene transcription [55].  For example, RNA polymerase II is modified by O-GlcNAc 
[56], and O-GlcNAcylation of RNAP promotes the formation of the transcriptional preinitiation 
complex [57]; however, for transcriptional elongation to proceed, OGA needs to remove the O-
GlcNAc to facilitate the phosphorylation of the RNAP C-terminal tail and elongation [57].  O-
GlcNAcylation is also important for proper protein translation, with alterations to cellular O-




Potentially, transcriptional or translational changes in mitochondrial transport proteins 
such as the Translocase of the Mitochondrial Outer Membrane (TOMM) family can then have a 
secondary effect on mitochondrial protein expression.  In fact, we measured declines in 
TOMM20 as well as TIMM17B (Translocase of Mitochondrial Inner Membrane).  We can 
envision impairment of mitochondrial protein transport into the mitochondria causing an increase 
of mitochondrial proteins in the cytoplasm and a decrease within the mitochondria.  Although, 
the proteins examined in the orthogonal validation were altered in the mitochondria; cytoplasmic 
expression appeared to mirror the mitochondrial expression, suggesting that the proteins we 
validated did not appear to have problems entering the mitochondria (Figure 8).  Besides 
potential expression changes being caused by alterations in transcription, translation or protein 
transport into the mitochondria, OGT/OGA over-expression could lead to alternative processing 
of mRNA transcripts, leading to expression changes in isoforms or splice variants of a given 
protein.  We potentially see this occurring with proteins such as the TCA cycle protein OGDH 
and ACADM, which is involved in fatty acid β-oxidation. 
The expressions of numerous respiratory chain proteins are also regulated by O-GlcNAc 
cycling (Figure 10). We identified 24 NADH dehydrogenase ubiquinone 1 (NDUF) members 
from complex 1 of the electron transport chain.  The expression of several of these family 
members was altered in the OGT/OGA over-expression cells. For example, NDUFA9 protein 
expression was decreased in OGA over-expression cells; interestingly, NDUFA9 is O-
GlcNAcylated at Ser156 [44]. O-GlcNAcylation of NDUFA9 was increased in cardiac myocytes 
exposed to high glucose conditions, which correlated with impaired mitochondrial function.  
Mitochondrial function and a decrease in NDUFA9 O-GlcNAcylation were partially restored 
under these high glucose conditions after adenoviral-mediated expression of OGA [44]. Similar 
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to our study, OGA over-expression also lowered NDUFA9 expression in these cells [44], 
suggesting that OGA expression influences NDUFA9 expression.  These data also suggest an 
important role for maintaining homeostatic levels of O-GlcNAc in the regulation of Complex 1 
proteins.  Complex 1 deficiency is the most common electron transport chain defect [59].  
Mutations in complex 1 proteins or gain/loss of expression alter complex 1 assembly and impair 
the electron transport chain, leading to numerous physiological consequences [59]. Disease or 
age-related changes to the O-GlcNAc cycling rate, therefore, could profoundly affect complex 1 
subunit expression and holoenzyme function.  
Morphologic disruption of the mitochondria (Figure 11), manifesting here as perturbed 
cristae formation, would associate with abnormal respiration chain formation.  Not surprisingly, 
the measured declines in respiratory chain protein expression and disrupted mitochondrial 
morphology lead to a reduced basal oxygen consumption in the over-expression cells (Figure 
12).  Further, overexpression of OGA pushed basal mitochondrial respiration towards its 
maximum capacity, which was itself reduced.   Interestingly, OGT and OGA over-expressing 
cells did not attempt to compensate for this apparent respiration stress by increasing glycolysis, 
as overall glycolysis flux in these cells is decreased (Figure 13).  Therefore, the net effect of 
altered O-GlcNAc cycling is a reduction in both the oxidative metabolism infrastructure and 
glycolysis, a combination expected to place cells in a state of relative bioenergetic jeopardy. 
In conclusion, we have demonstrated that altered O-GlcNAc cycling rates impact 
mitochondrial protein expression, morphology, and respiration.  We show that over-expression 
of the O-GlcNAc cycling enzymes OGT or OGA cause, respectively, an increase or decrease in 
O-GlcNAc levels.  Importantly, OGT/OGA over-expression will increase the rate of addition and 




impairs cellular function [60]. These data argue that mitochondrial function is directly related to 
the rate of O-GlcNAc cycling, and alteration of basal O-GlcNAc cycling rates either by disease 
or aging would have a profound effect on mitochondrial function.  Moving forward, subsequent 
investigation into how altered O-GlcNAcylation affects mitochondrial protein expression and 
function in metabolic diseases such as diabetes, Alzheimer’s, or cancer should be a high priority 
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Chapter 3: O-GlcNAc is a Critical Regulator for Mitochondrial Function and Energy 
Metabolism 
Reproduced with permission from Tan, E.P., McGrea, S.R., Graw, S., Tessman, R., Koppel, S.J., 
Dhakal, P., Zhang, Z., Machacek, M., Zachara, N.E., Koestler, D.C., Peterson, K.R., Thyfault, 
J.P., Swerdlow, R.H., Krishnamurthy, P., DiTacchio, L., Apte, U., and Slawson, C. (2017). 
Sustained O-GlcNAcylation Reprograms Mitochondrial Function to Regulate Energy 
Metabolism. Submitted.  
3.1 Introduction 
Chronically impaired mitochondrial respiration and uncontrolled reactive oxygen species (ROS) 
generation contribute to complex, chronic diseases [61]. Treatment with glucosamine (GlcN), a 
common amino-sugar, improved mitochondrial function and extended lifespan in both C. 
elegans and mice. GlcN treatment increased mitochondrial respiration and transiently induced 
mitochondrial ROS generation, followed by a significant reduction in ROS [62]. The initial 
transient ROS induction promotes mitochondrial biogenesis and improves anti-oxidant response, 
resulting in lifespan extension [62]. Interventions that improve mitochondrial function and 
reduce uncontrolled ROS production will have widespread clinical applications in the treatment 
of chronic disease. Here, we assert that O-GlcNAc regulates mitochondrial function and the 
oxidative stress response. 
O-GlcNAc post-translational modifications connect nutrient sensing with mitochondrial 
dysfunction. O-GlcNAcylation is the addition of a single O-linked β-D-N-acetylglucosamine 
sugar moiety to serine or threonine residues in nuclear, cytoplasmic, and mitochondrial proteins 
[63]. O-GlcNAcylation is facilitated by two functionally opposing enzymes, O-GlcNAc 




hydrolyzes the modification [63]. During catalysis, OGT uses the nucleotide sugar UDP-GlcNAc 
generated from the hexosamine biosynthetic pathway (HBP). The HBP is tightly regulated by the 
enzyme glutamine fructose-6-phosphate aminotransferase 1 (GFAT1). GlcN feeds into the HBP 
downstream of GFAT1 and increases cellular O-GlcNAcylation by elevating the synthesis of 
UDP-GlcNAc [64]. Therefore, GlcN influence on mitochondrial function and lifespan extension 
could be mediated by O-GlcNAc. Because UDP-GlcNAc synthesis relies on the integration of 
multiple metabolic pathways, O-GlcNAcylation can reflect changes in nutrients [29]. Chronic 
disruptions in O-GlcNAcylation due to nutrient imbalance influences metabolic diseases [13, 
14].   
O-GlcNAc is a key regulator of mitochondrial function. Both OGT [10] and OGA 
localize to the mitochondria [11], and the Pyrimidine Nucleotide Carrier 1 (PNC1) transports 
UDP-GlcNAc into the mitochondria, providing substrate for OGT [11]. Electron transport chain 
(ETC) subunits are modified by O-GlcNAc [12], suggesting that O-GlcNAc modulates ETC 
activity. Short-term high glucose treatment elevates O-GlcNAcylation but suppresses ETC 
activity and ATP production in rat cardiomyocytes [30], whereas, short-term OGA inhibition in 
rats increased oxygen consumption in isolated mitochondria [12]. OGT or OGA overexpression 
in SH-SY5Y neuroblastoma cells alters the mitochondrial proteome, including several TCA 
cycle and ETC proteins [65]. The loss of ETC protein expression adversely affected 
mitochondrial shape and impaired respiration. These data indicate O-GlcNAc is essential for the 
proper regulation of mitochondrial function and energy metabolism. 
Here, we report that increasing O-GlcNAcylation in cell lines and mice by inhibiting 
OGA or GlcN supplementation reprograms mitochondrial function and changes energy 
metabolism. Sustained elevation in O-GlcNAc lowered respiration and reduced ROS generation. 
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These changes were due to transcriptional reprograming of the proteome and a decrease in the 
transcription factor Nuclear factor (erythroid-derived)-like 2 (NRF2)-mediated oxidative stress 
response.  In contrast, OGT liver knockdown severely impaired mitochondrial function, 
increased ROS levels, and activated the NRF2 antioxidant response. Together, these data 
demonstrates distinct roles for O-GlcNAc in modulating mitochondrial function, and provides 
new insights into how pharmacological targeting of O-GlcNAc protects against aging and 
metabolic diseases. 
3.2 Methods 
3.2.1 Cell Culture 
Both SH-SY5Y and NT2 cells were cultured in DMEM media (Sigma), 44 mM sodium 
bicarbonate (Sigma), 5 mM galactose (Fisher), 15 mg/L phenol red (Sigma), and supplemented 
with 10% fetal bovine serum (FBS; Gemini), 1% penicillin/streptomycin (Sigma), 1% 
GlutaMAX (Gibco). First, cells were adapted to the 5 mM galactose media for two weeks prior 
to treatment with 10 µM Thiamet-G (TMG, S.D. Specialty Chemicals) or 0.35 mM glucosamine 
(GlcN, Sigma) for at least three weeks prior to experiments. Media were replenished daily. 
3.2.2 Animal Protocols and Models 
The University of Kansas Medical Center Animal Care and Use Committee approved all 
experiments in this study. Two-month-old male C57Bl/6J mice were purchased from Jackson 
Laboratory (Bar Harbor, ME). All mice were housed using a standard 12 h light/dark cycle with 
access to chow and water ad libitum. Mice were treated with a 50 mg/kg Thiamet-G intraparietal 
injection every other morning for 15 days for a total of 8 doses per mouse. After completion of 
dosing, mice were fasted for 16 hrs before isoflurane (Fisher) anesthesia assisted cervical 




Ogttm1Gwh mice were obtained from Natasha Zachara, PhD at John Hopkins University 
and liver specific KO of OGT was performed by treating male mice with 5.0x1011 virus particles 
of AAV8.TBG.PI.Cre.rBG vector (University of Pennsylvania vector core) dissolved in 200uL 
of sterile PBS via IP injection. 
3.2.3 Cell Lysis and Immunoblotting 
Cells were lysed, samples prepared for SDS-PAGE, and immunoblotted as described previously 
[65]. At least three independent experiments were repeated for all immunoblotting. Relative 
protein levels were analyzed using ImageJ 3.2 (NIH) and were normalized to actin or GAPDH 
[66]. 
3.2.4 Cell Respiration, Isolated Mitochondrial Respiration and Glycolysis Measurement 
An XF24 analyzer (Agilent Seahorse XF Technology, Santa Clara, CA) was used to measure 
cellular respiration and glycolysis. 75,000 control, TMG, or GlcN treated cells were seeded per 
well in a Seahorse 24-well cell culture plate 24 h prior to experimental assay. For respiration 
assays, cells were incubated in unbuffered DMEM (Sigma), 25 mM Glucose (Sigma), Phenol 
Red (Sigma), 200 mM GlutaMax-1 (Gibco), NaCl (Fisher), at 37°C in a CO2 free incubator for 1 
h prior to loading. OCR was measured over a period of 100 min. Drugs oligomycin (0.5 µM, 
Sigma), FCCP (0.5 µM, Sigma), antimycin A (0.2 µM, Sigma) and rotenone (0.1 µM, Sigma) 
were added to each well sequentially at various time points during the assay [65].  
For animal tissues, 15 µg per well of mouse liver or brain mitochondria was prepared in 
mitochondrial assay solution (MAS) [67]. Respiration was initiated by adding mitochondria, 
followed by sequential addition 6 mM ADP (Sigma), 1 µM FCCP (Sigma), 1 µM oligomycin 
(Sigma) and 4 µM antimycin A (Sigma) [67]. 
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For glycolysis assays, ECAR was measured over a period of 100 min. Glucose (25 mM) 
oligomycin (1 µM), and 2-Deoxy-D-glucose (2-DG, 100 mM, Sigma) were added at specific 
time points during the assay [65]. 
3.2.5 Statistical Analysis 
Statistical significance of all results, with the exception of the 24-hour time-point Avg RER, 
locomotion, and Avg EE, were assessed using a two-sample t-test with p < 0.05 considered to be 
statistically significant. All data were generated using at least three independent experiments and 
were represented as mean ± standard error. The 24 h time point Avg RER, locomotion, and Avg 
EE were assessed using permutation test with p < 0.05 considered to be statistically significant. 
3.2.6 Antibodies 
All primary and secondary antibodies used for immunoblotting were used at a concentration of 
1:1,000 and 1:10,000 dilution respectively.  Anti-O-linked N-acetylglucosamine antibody (RL2, 
ab2739) was purchased from Abcam.  Both anti-OGT (AL-34) and OGA (345) were gracious 
gifts from the Laboratory of Gerald Hart in the Department of Biological Chemistry at the Johns 
Hopkins University School of Medicine. Anti-actin (A2066), NRF2 (ab62352), mTFA 
(ab47517), GAPDH (ab9484), Oxidative Stress Defense (Catalase, SOD1, TRX, smooth muscle 
Actin) Cocktail (ab179843), PRX Pathway (TRX, TXNRD1, PRX1) Cocktail (ab184868), 
Citrate Synthase (ab96600) and NADPH Oxidase 4 (ab79971) were purchased from Abcam. 
Anti-DLP1 (611113) was purchased from BD Biosciences, anti-Mfn1 (sc-50330) and anti-p53 
(sc-126) were purchased from Santa Cruz. Anti-cleaved PARP (9542) and anti-lamin B1 
(D4Q4Z) were purchased from Cell Signaling Technology, and anti-Mfn2 (M6444) was 




3.2.7 Mitochondrial Purification from Cells and Tissues. 
Mitochondria were isolated from SH-SY5Y cells using the modified cavitation method described 
previously [65]. Briefly, 2 x 108 cells were trypsin-digested off the plate and washed twice with 
pre-chilled PBS, then resuspended into 3 mL of the mitochondrial isolation medium. The cell 
suspensions were transferred into a pre-chilled cavitation chamber (nitrogen bomb; Parr 
Instrument Company, Moline, IL) and subjected to 900 psi for 15 min. Subsequently, the 
pressurized cell suspension was collected from the cavitation chamber, followed by 
centrifugation at 1,000 x g for 10 min to pellet the cell debris. The clear supernatant was 
collected and centrifuged at 12,000 x g for 15 min. Crude mitochondrial pellet was washed three 
times with 500 µl of isolation medium. Washed pellet was lysed with NP-40 lysis buffer.  
Both mouse brain and liver mitochondria were isolated using the modified method of two 
differential centrifugations [67]. Promptly after euthanasia (brain < 30 s, liver < 1 min), tissues 
were rinsed twice with ice cold PBS, homogenized (Teflon glass homogenizer with 15 strokes), 
and extracted in  ~10 volumes of mitochondrial isolation buffer (MSHE+BSA). All subsequent 
steps were performed on ice. Homogenate was centrifuged at 800 x g for 10 min at 4 °C. 
Supernatant was decanted through 2 layers of cheesecloth to a new tube, followed by further 
centrifugation at 8,000 xg for 10 min at 4 °C. Mitochondrial pellet was washed once with 
MSHE+BSA and final pellet was resuspended with minimal volume of MSHE+BSA. Total 
protein concentration was determined using BCA protein assay kit (Thermo Fisher Scientific) 
per manufacturer’s instruction. 
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3.2.8 Total RNA Isolation and Reverse Transcription (RT)-PCR 
Total RNA was isolated by using TRI reagent solution (Ambion) per manufacturer’s instruction. 
Approximately 2 x 106 cells were resuspended in 1 mL TRI reagent solution; then 200 µl of 
chloroform (Fisher) was added to extract RNA. Upon centrifugation, an equal amount of 
isopropanol (Fisher) was added to the upper layer solution containing RNA. RNA pellets were 
precipitated by centrifugation, washed once with 70% ethanol, air-dried, and the pellet was 
dissolved in nuclease free water (Life Technologies) [68]. 
RNA concentration was measured using a Nanodrop 2000c (Thermo) and 1 µg of total 
RNA was reverse transcribed using iScript Reverse Transcription Supermix (Bio-rad) per 
manufacturer’s instruction. Total volume of 20 µl of each completed reaction mix was incubated 
in a thermal cycler (Model 2720, Applied Biosystems). Protocol was as followed: priming 5 min 
at 25 °C, RT 30 min at 42 °C, and RT inactivation 5 min at 85 °C. cDNA products were diluted 
with nuclease free water, 1:10 dilution, and analyzed by qPCR [68]. 
3.2.9 qPCR Assay 
qPCR assays on cDNA samples were done using SsoAdvanced Universal SYBR Green 
Supermix (Bio-Rad) per manufacturer’s instruction. 2 µl of cDNA were used with a total 
reaction volume of 20 ul. Primers used for OGT were: F, CATCGAGAATATCAGGCAGGAG; 
R, CCTTCGACACTGGAAGTGTATAG [68]; OGA were: F, 
TTCACTGAAGGCTAATGGCTCCCG; R, ATGTCACAGGCTCCGACCAAGT [68]; GAPDH 
were: F, CCACATCGCTCAGACACCAT; R, CCAGGCGCCCAATACG; GFAT1 were: F, 
AGCCCTCTGTTGATTGGTGT; R, TCCATCTGGAGTGTTTGCAC; Nrf2 were: F, 
CCAGCACATCCAGTCAGAAA; R, GCATGCAGTCATCAAAGTACAAA; TXNRD1 were: 




GAGCAGCTTCGCAAAGAA; R, AGGATCCTCTCCAGAACG; TFPI2 were: F, 
CAGGTTTCCAGATGAAGCTACT; R, GAGTCACATTGGCAGAGCA; ATF4 were: F, 
GAGAGAAGATGGTAGCAGCAAA; R, TTCTTCTGGCGGTACCTAGT; and IGF2 were: F, 
CCTGGAGACGTACTGTGCTA; R, GACTGCTTCCAGGTGTCATATT. A 96-well PCR plate 
(Midsci) with the reaction mixture was loaded onto CFX96 Touch Real-Time PCR Detection 
System (Bio-Rad). The protocol was as follow: polymerase activation and DNA denaturation 30 
s at 95 °C, amplification denaturation 5 s at 95 °C and annealing 30 s at 60 °C with 40 cycles, 
and melt curve 65-95 °C with 0.5 °C increment 5s/step. 
3.2.10 OGA Activity Assay 
Whole cell extract samples (60 µg/reaction) were lysed using NP-40 lysis buffer. O-GlcNAcase 
activity was assayed in a total reaction volume of 200 µl (including 10 µl of 500 mM sodium 
cacodylate (Sigma), pH 6.4, 3% BSA (Sigma), 2 µl of 100 mM p-Nitrophenyl-N-acetyl-β-D-
glucosaminide (Sigma), water, and cell extract) at 37 °C for up to two hours. Reactions were 
stopped with 100 µl of 500 mM sodium carbonate (Sigma) every 30 min subsequently and the 
absorbance at 400 nm was measured using a plate reader (BioTek Instrument). One unit is the 
amount of enzyme required to catalyze the release of p-nitrophenyl from 1 pmol of pNP-O-
GlcNAc/min at 37°C [69]. These samples were assayed in a 96-well plate (pureGrade S-781671, 
BRANDplates). 
3.2.11 JC-1 Staining for Mitochondrial Membrane Potential 
Mitochondrial membrane potential was analyzed with the potential-dependent dye JC-1 (Life 
Technologies). 2 µM of JC-1 in Hanks’ Balanced Salt solution (HBSS, Sigma) was added to 2 x 
106 cells per sample at 37 °C, 5% CO2 for 30 min. Cells were washed once and resuspended in 
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500 µl of warm HBSS. Cells were analyzed by flow cytometers with 488 nm excitation and 
gated for singlet cells excluding cell debris. JC-1 dye exhibits a potential-dependent 
accumulation in mitochondria via a fluorescence emission shift from green (~529 nm) to red 
(~590 nm). Mitochondrial polarization was determined by red/green intensity ratio. 
3.2.12 Transmission Electron Microscopy 
Long-term TMG and GlcN treated SY5Y cells were prepared for electron microscopic 
experiments as previously described [65]. Cells were seeded and cultured on Thermanox (Fisher) 
coverslips 24 h prior to fixation. Cells were fixed with 2% glutaraldehyde in 0.1 M cacodylate 
buffer, pH 7.4, and post fixed with 1% osmium tetraoxide/0.3% potassium ferricyanide. Cells 
were dehydrated in a graded series of 50, 70, 80, 95 and 100% ethanol. Coverslips were 
embedded in 100% epoxy resin, and the resin was cured overnight at 60°C. Thin sections of 70 – 
90 nm were cut on a Reichert Ultracut-S (Reichert Technologies, Buffalo, NY) and stained with 
uranyl acetate and lead citrate. Images were captured at 80 kV using a JEOL JEM-1400 
Transmission Electron Microscope (JEOL USA, Peabody, MA) equipped with a Lab6 gun at the 
University of Kansas Medical Center EM Core Laboratory. 
3.2.13 Complex I Activity Assay 
Crude isolated mitochondria were used for the complex I activity. A modified method following 
the decrease in NADH absorbance at 340 nm that occurs when ubiquinone (CoQ1, Sigma) is 
reduced to ubiquinol was used for the complex I activity assay. CoQ1 (50 µM) was used to 
initiate the reaction at 30°C. After 5 min, rotenone (10 µM) was added to obtain non-complex I 
activity. Total protein concentration was measured using the DC assay kit (Bio-rad) as instructed 
by the manufacturer. Finally, complex I activity was expressed as nano moles per min per 




3.2.14 Cytochrome c Oxidase and Citrate Synthase Activity Assays 
Complex IV (COXIV) and citrate synthase (CS) Vmax activities in TMG or GlcN treated SH-
SY5Y cells were evaluated in both whole cell and isolated mitochondria. Whole cells were 
trypsinized and washed twice with ice-cold 1X PBS, and then pelleted by centrifuging at 1,000 x 
g for 3 min. The whole cell pellets were resuspended in ice-cold PBS at a concentration of 30 x 
106 cells/mL.  Mitochondria were isolated as described before. A total of 40 x 106 cells were used 
for the mitochondrial isolation and the mitochondria pellets were resuspended in 400 µl of the 
mitochondrial isolation buffer. Both whole cell and isolated mitochondrial COXIV and CS 
Vmax activities in non-treated and TMG- or GlcN-treated SH-SY5Y cells were determined as 
previously described [71]. COXIV Vmax activity was normalized both to protein concentration 
and to CS activity. 
3.2.15 Immunofluorescence Microscopy 
Cells were cultured on microscope slides (Fisher) and were washed with 1X PBS, and fixed with 
4% Paraformaldehyde (Sigma) for 20 min. Cells were permeabilized with 0.1% Triton X-100 
(Sigma) in ice cold PBS and then blocked with a TBST blocking solution (0.2% azide, 0.2% 
powdered dry milk, 12% chicken serum, 1% BSA, 100 mM glycine, 0.1% Triton-X 100 in 
TBST, pH 7.5) for 1 h. Tom20 (1:500) in TBST blocking buffer was applied overnight. Slides 
were washed with TBST and incubated with fluorescent secondary antibodies (1:500 mouse 
Alexa-fluor 488 nm Life Technologies) for 1 h. DAPI solution (PBS, 0.01% Triton-X 100, 
0.001% DAPI, Sigma) was applied for 20 min. Finally, slides were washed and mounted on 
cover slips using ProLong Gold Anti-fade (Life Technologies) [66]. 
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3.2.16 cDNA Library Preparation 
cDNA library was prepared using Illumina TruSeq Stranded mRNA sample preparation kit 
(Illumina) as manufacturer’s instruction. Total RNA was isolated using the same method as 
previously described and 800 ng of the total RNA per reaction was used to initiate the protocol. 
 
3.2.17 RNA Sequencing Analysis 
The quality of RNA sequencing results was first assessed using FastQC (0.11.2).  Then, RSEM 
(1.2.22) was utilized to align the reads to the human reference genome HG38 and to calculate 
gene expression values.  EdgeR (3.14.0) was then used to normalize the expression values using 
the TMM-method (weighted trimmed mean of M-values), and for differential expression 
analyses. First, the negative binomial conditional common likelihood was maximized to estimate 
a common dispersion value across all genes (estimateCommonDisp). Next, tagwise dispersion 
values were estimated by an empirical Bayes method based on weighted conditional maximum 
likelihood (estimateTagwiseDisp). Finally, the differential gene expression was calculated by 
computing genewise exact tests for differences in the means between two groups of negative-
binomially distributed counts.  Hierarchical clustering analysis was determined using Euclidean 
distance. The following R-packages were utilized for calculations and visualizations: gplots and 
edgeR. 
To reduce the burden of multiple testing in differential gene expression analyses, a filter 
was initially applied to reduce the number of genes. Genes were removed if they did not present 
a meaningful gene expression across all samples; only genes with cpm (counts per million) of 




map, volcano plots, and pie chart. A cpm of >100 threshold was used for the IPA analysis. The 
Benjamini and Hochberg procedure was used to control the false discovery rate (FDR). 
3.2.18 Pathway and Gene Set Enrichment Analysis (GSEA) 
Ingenuity Pathway Analysis (IPA) software (Ingenuity® QIAGEN, www.ingenuity.com) was 
used to compare biological functions or canonical pathways in non-treated, long-term TMG- or 
GlcN-treated SH-SY5Y cells. Flexible format and Illumina HumanRef-8 v3.0 array platforms 
were the only parameters altered from default IPA settings for the Core analyses used to evaluate 
upregulated and downregulated genes (fold change > 1.3, p < 0.05). 
GSEA analysis was done using the javaGSEA desktop software. The default settings 
were used, except the permutation type was set to Gene_set with 1000 permutation type, and the 
metric for ranking genes was set to Diff_of_Classes (normalized expression data used were log2 
transformed) when executing GSEA. All five gene set collections (c1-c6, h1) were queried from 
the Molecular Signatures Database (MSigDB) version 3.1. 
3.2.19 ROS Detection Assay 
Cells were analyzed for reactive oxygen species levels using a ROS-ID Total ROS Detection Kit 
(Enzo Life Sciences) per manufacturer’s protocol. Briefly 2 x 105 cells/well of control, 
prolonged TMG- or GlcN-treated cells were seeded in a 96-well plate (pureGrade BRANDplates 
Midsci) a day prior to the assay. Cells were treated with ROS detection reagent at 37°C for 1 h 
and ROS level was measured via a fluorescence plate reader (TECAN Infinite M200, 
Switzerland) and quantified as level of fluorescence per cell. For both liver and brain, isolated 
mitochondria, superoxide levels were determined using MitoSOX (Life Technology) as 
instructed by manufacturer. Briefly, 150 µg/well of isolated mitochondria was resuspended in ice 
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cold MAS (w/o rotenone) added with substrates (5 mM succinate, 5 mM malate, 5 mM 
glutamate), then stained with MitoSOX at a concentration of 3.5 µM at 37°C for 10 min. The 
mitochondria were washed once with MAS, and transferred into a 96-well plate (pureGrade 
BRANDplates Midsci). Superoxide level was detected via fluorescence plate reader with 
excitation wavelength at 510 nm and emission wavelength at 590 nm. 
3.2.20 ATP Level Determination 
Cellular ATP level was determined by using a CellTiter-Glo Luminescent Cell Viability Assay 
Kit (Promega) per manufacturer’s instruction. Briefly 2 x 105 cells/well were seeded in a 96-well 
plate (pureGrade BRANDplates Midsci) a day prior to the assay. Cells were treated with ATP 
detection reagent at room temperature for 10 min. Cellular ATP levels were determined by 
measuring the luminescent signal on a plate reader (TECAN Infinity M200). 
3.2.21 Nuclear Extraction 
Cells were harvested and pelleted, then resuspended in hypotonic buffer (20 mM HEPES, 50 
mM NaF, 5 mM Na2P2O7 , 50 mM N-acetylglucosamine, 1 mM EDTA, 1 mM EGTA, 1 mM 
DTT, 1 mM PMSF,  protease inhibitor mixture, pH 7.5) followed by centrifugation. Supernatant 
(cytoplasmic content) was saved and nuclear pellet was washed with hypotonic buffer then lysed 
with NP-40 lysis buffer and centrifuged for 20 min at 20,000 xg. Resulting supernatants were 
used for protein determination via Bradford assay (Bio-rad). The protein levels were analyzed 
via immunoblotting, and anti-lamin B1 was used for nuclear content loading control. Actin was 
used for cytoplasmic content. 
3.2.22 Oxidative Stress and Cell Viability Assay 
Prolonged TMG- or GlcN-treated cells were incubated with different concentrations of H2O2 (50 




Technologies) and propidium iodide (PI, Life Technologies) staining. Annexin V-FITC/PI 
double labeling method was used per manufacturer’s instructions to determine cell viability after 
acute oxidative stress. Cells were digested with 2% BSA trypsin, washed once with 1X PBS and 
incubated with Annexin V/PI mixture then subjected to a BD LSR II flow cytometer (BD 
Biosciences) and analyzed with BD FACSDiva software (BD Biosciences) for cell viability 
determination. 
3.2.23 Cycloheximide Treatment 
Cells were treated with 50 µg/mL of cycloheximide (CHX, Sigma) and harvested at different 
time-points for up to 6 h. Immunoblotting was performed to determine NRF2 protein stability 
after prolonged TMG or GlcN treatment. p53 was used as positive control for the CHX 
treatment. 
3.2.24 Body Composition and Indirect Calorimetry Measurement 
Fat mass, lean mass, and water mass were measured with an EchoMRI 4 in1-1100 analyzer 
(EchoMRI; Houston, TX) 
Prior to the indirect calorimetry measurements, mice were housed individually for 5 days. 
Subsequently, mice were transferred and housed in the calorimetric chamber (Promethion High 
Definition Continuous Respiratory system for mice, Sable Systems Inc) for 3-5 days. The 
chamber measured food intake, energy expenditure, substrate utilization, and various outcomes 
of the mice for baseline measurement calibration. Then, mice were transferred back to the 
normal individual cage. 50mg/kg of TMG or saline dosage was delivered to each mouse via 
peritoneal injection every other day for up to two weeks. During the last five days of injection, 
mice were transferred back into the calorimetric chamber and parameters measured as previously 
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mentioned (saline vs TMG injection). These experiments were repeated twice and each repeat 
included eight mice. 
3.3 Results 
3.3.1 Thiamet-G (TMG) or Glucosamine (GlcN) Treatment Alter Mitochondrial Bioenergetic 
Capacity 
Prolonged treatment with GlcN improves mitochondrial function and extends lifespan in both C. 
elegans and mice [62]. We hypothesized that sustained elevation of O-GlcNAcylation would 
alter energy metabolism. To determine how O-GlcNAcylation affects energy metabolism, we 
treated SH-SY5Y neuroblastoma cells with either Thiamet-G (TMG, 10 µM) or GlcN (0.35 mM) 
for at least three weeks prior to harvesting these cells. TMG is a highly selective OGA inhibitor 
[72], while GlcN feeds into the hexosamine biosynthetic pathway after GFAT1, increasing 
cellular pools of UDP-GlcNAc [64]. In contrast to GlcN, which can influence a variety of 
metabolic pathways, TMG precisely manipulates O-GlcNAcylation by targeting OGA.  
Both TMG- and GlcN-treated SH-SY5Y cells increased total and mitochondrial O-
GlcNAc levels (Figure A.1A-B). OGT protein and transcript levels were reduced, whereas OGA 
protein and transcript levels were increased in response to elevated O-GlcNAcylation, and 
GFAT1 protein level was decreased in TMG treated cells (Figure A.1A and D) [68]. OGA 
specific activity was increased in GlcN-treated SH-SY5Y cells (Figure A.1E). Similar results 
were found in NT2 human teratocarcinoma cells treated with TMG or GlcN (Figure A.1C). 
Prolonged elevation of O-GlcNAc altered cellular respiration (Figure A.1F). TMG 
lowered baseline oxygen consumption rates (OCR), whereas GlcN increased baseline OCR 
(Figure 14A). Under basal conditions, in vivo ATP production was lower in the presence of 




rate (Figure 14B). The maximum respiratory rate was increased in GlcN cells while TMG was 
similar to control cells (Figure A.1G). SH-SY5Y cells grown in oxidative media regardless of 
TMG or GlcN-treatment have no reserve capacity (Figure A.1H) showing that these cells were 
respiring at their maximum capacity. To eliminate any cell type specific effects, we performed 
the respiration assays in NT2 cells. TMG-treated NT2 cells replicated the data from SH-SY5Y 
cells (Figure A.1K-O). GlcN-treated NT2 cells mirrored the TMG-treated results from SH-
SY5Y/NT2 cells showing lower respiration rates (Figure A.1K-P).  
The total cellular ATP levels in both TMG- and GlcN-treated SH-SY5Y cells and in 
TMG-treated NT2 cells were lower (Figure 14C, Figure A.1P). TMG treatment caused both 
SH-SY5Y and NT2 cells to produced significantly less ATP, while GlcN-treated SH-SY5Y cells 
produced and consumed more energy due to increased phosphorylation of GlcN to GlcN-6-P by 
hexose kinase (HK) [64]. Of note, GlcN had no effect on AMP activated protein kinase activity 
(data not shown). 
Since oxidative phosphorylation and glycolysis are interdependent energy producing 
pathways [73], we examined glycolytic energy production by measuring cellular glycolytic flux. 
Both TMG- and GlcN-treated SH-SY5Y cells had lower basal glycolytic rates (Figure 14D), and 
TMG-treated NT2 cells had a lower basal glycolytic rate. GlcN treated NT2 cells showed no 
changes (Figure A.1Q).  
3.3.2 TMG or GlcN Treatment Increased Complex I and Complex IV Activity and Elevated 
Cellular NAD+/NADH Ratio 
Because prolonged TMG treatment lowered cellular respiration, we postulated that the ETC 
complex activity was lower. Mitochondria isolated from both TMG- and GlcN-treated SH-SY5Y 
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cells had increased Complex I activity (Figure 14E). TMG also elevated COXIV activity 
(Figure 14F, Figure A.2A-B).  Since isolated ETC complex activity did not correspond to the in 
vitro respiration measurements, we considered whether the observed decrease in OCR was due to 
reduced concentration of NADH available for respiration. The NAD+ concentration was elevated 
in TMG but reduced in GlcN-treated cells (Figure 14G) while the NADH concentration was 
decreased in both TMG- and GlcN-treated SH-SY5Y cells (Figure 14H). The NAD+ and NADH 
ratio skewed toward NAD+ for both TMG- and GlcN-treated cells (Figure 14I). To ascertain 
whether altered cellular respiration was due to changes in mitochondrial membrane potential, we 
probed for mitochondrial membrane polarization differences in TMG or GlcN-treated SH-SY5Y 
cells. TMG significantly enhanced mitochondrial hyperpolarization (Figure 14J).  
3.3.3 Prolonged TMG or GlcN Treatment Promotes Elongated Mitochondria 
To assess whether mitochondrial morphology was changed in TMG- or GlcN-treated SH-SY5Y 
cells, we used transmission electron microscopy to visualize the mitochondria. Mitochondria 
from both treated cells were longer in shape compared to control mitochondria (Figure 14K). 
Confocal imaging data agreed with the electron microscopy data showing longer mitochondria in 
TMG- or GlcN-treated cells (Figure 14L). Mitofusin 1 (MFN1), Mitofusin 2 (MFN2), and 
Dynamin-like protein (DLP1), which facilitate mitochondrial fusion and fission, were lower in 






Figure 14: Thiamet-G (TMG) or glucosamine (GlcN) treatment altered mitochondrial 
bioenergetics, elevated cellular NAD+/NADH ratio, enhanced mitochondrial 
hyperpolarization, and promoted longer mitochondria 
(A) Basal respiration (B) leak rate in O-GlcNAc elevated SH-SY5Y cells were determined using 
XF24 analyzer (average ± SEM, n=6). (C) Relative ATP level representative plot (average ± 
SEM, n=4) showed both TMG (10 µM) and GlcN (0.35 mM) treated SH-SY5Y cells maintained 
low cellular ATP levels. Displayed relative ATP levels were average value of each replicated 
result normalized with control. (D) ECAR was measured using XF24 analyzer (average ± SEM, 
n=6). (E) Complex I Vmax (average ± SEM, n=3) normalized with total protein concentration, 
(F) complex IV (COXIV) Vmax normalized with citrate synthase (CS) activity (average ± SEM, 
n=3). (G) NAD+ and (H) NADH levels were altered (I) NAD+/NADH ratio (average ± SEM, 
n=4) normalized with protein concentration. (J) Membrane potential was measured using JC-1 
(average ± SEM, n=3) (K) Transmission Electron microscopy and (L) confocal staining with 
TOM20. * indicates significance p < 0.05.  ** indicates significance p < 0.01. *** indicates 





3.3.4 Prolonged TMG or GlcN Altered the Transcriptome 
We considered whether the observed mitochondrial changes were mediated by alterations in the 
transcriptome. Next Generation RNA-Sequencing (RNA-seq) analysis found 8793 genes 
differentially expressed in TMG- or GlcN-treated SH-SY5Y cells. Only genes with high 
sequencing counts (cpm: counts per million of >10 in at least two of the three biological replicate 
samples) were considered in the differential expression analyses (Figure A.3A-C and Table 2). 
A total of 75 genes for TMG treatment and 196 genes for GlcN treatment were elevated, while 
117 genes for TMG treatment and 269 genes for GlcN treatment were reduced (p-value < 0.05) 
(Figure 15A). Among these genes, 36 genes from TMG and 74 genes from GlcN treatment were 
increased 1.5-fold or more, while 73 genes from TMG and 200 genes from GlcN decreased 1.5-
fold or more (Figure 15A). All genes selected for orthogonal validation agreed with the RNA 
sequencing results (Tissue Factor Pathway Inhibitor 2 (TFPI2), Guanine nucleotide binding 
protein, gamma subunit 1 (GNG1), Activating Transcription Factor 4 (ATF4), and Insulin-like 
growth factor 2 (IGF2) (Figure A.3E and Table 3-4).  As a positive control (Figure A.1D), the 
RNA-Seq data showed that OGA (MGEA5) gene expression was increased in both TMG- and 
GlcN-treatment (Table 3-4) [68].  
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Table 2: Complete list of differentially expressed genes after TMG/GlcN treatment 
 
!! cnt1 cnt2 cnt3 tmg1 tmg2 tmg3 glcn1 glcn2 glcn3 
ABCB4 62.09 98.7 66.75 358.77 295.66 435.75 198.55 177.51 170.16 
ABR 777.99 936.18 1194.05 579.93 785.52 1018.91 495.58 423.16 415.56 
ACP6 160.58 190.84 126.33 60.8 42.99 47.81 168.23 143.72 78.55 
ADAMTS2 238.53 356.72 212.88 143.51 131.64 169.98 40.48 62.41 42.29 
ADAMTS3 374.2 312.73 253.78 1197.88 1298.15 1024.95 841.47 887.1 1025.98 
AES 430.28 392.41 505.72 144.26 293.84 457.87 180.71 111.7 147.56 
AFF3 68.99 71.03 72.29 224.23 320.64 256.2 66.82 35.36 85.56 
AHNAK 6340.59 9097.32 8103.01 7010.88 5679.5 8280.15 4199.07 3999.81 3130.33 
AK5 208.37 223.92 231.5 674.68 710.99 655.97 368.4 365.3 240.65 
ARHGAP36 1261.64 1623.18 1191.36 479.35 464.22 633.5 1154.25 864.98 774.28 
ARL6IP4 320.04 321.17 406.97 109.61 251.79 315.49 141.61 80.87 97.38 
ATCAY 202.52 223.98 207.51 106.63 149.63 232.14 45.23 80.24 62.42 
ATF4 1660.59 1674.92 2091.45 910.86 1108.38 1638.15 858.43 722.46 605.13 
ATP7A 1696.22 1454.64 1261.25 1943.32 1876.4 1553.37 2809.92 2937.85 3166.57 
ATRNL1 293.28 293.94 296.93 789.29 650.3 682.55 461.23 593.64 520.54 
AUP1 274.65 256.15 400.31 108.62 163.13 344.03 76.28 82.42 99.66 
BAALC 192.4 246.36 180.33 613.89 442.17 655.86 341.09 466.3 439.35 
BANF1 1504.18 1584.26 2641.16 600.92 966.2 1666.73 883.72 622.18 577.94 
BCL2 358.64 384.41 470.71 1396.21 1089.14 854.89 515.6 529.62 787.34 
BEND4 1077.08 877.99 1023.72 576.03 379.94 385.96 807.98 846.31 1060.21 
BMP7 132.59 197.63 180.4 182.52 194.76 322.21 75.87 63.92 43.3 
C11orf1 996.42 943.92 858.82 352.78 498.73 454.97 947.36 745.35 622.25 
C18orf32 1186.99 924.75 535.64 1304.44 1198.94 1081.92 1586.53 1899.48 2749.15 
C7 6170.27 7804.25 5754.6 16958.65 13564.5 14668.07 4463.96 5070.23 4173.44 
CACNA2D2 454.36 394.41 735.13 259.1 386.33 421.93 255.88 145.9 138.95 
CALM3 931.39 1091.26 2463.72 492.59 708.84 1161.81 600.56 424.03 412.53 
CALR 3749.42 4307.29 5293.28 1624.4 2638.88 4152.56 2273.08 1478.54 1552.58 
CAPNS1 1394.3 1785.39 1492.97 625.83 1297.04 2410.89 651.6 459.93 622.23 
CC2D2A 112.4 158.23 173.29 412.59 363.42 320.04 197.49 185.11 203.4 
CFL1 5928.11 7010.4 10653.88 2634.04 4933.62 9702.47 3046.63 2115.07 3030.31 
CHD3 1121.15 1333.26 1916.13 1141.07 1133.74 1815.71 727.82 619.77 505.45 
CHGB 1202.7 1382.85 1787.6 1063.34 1193.64 1207.73 899.69 572.95 436.99 
CIZ1 521.37 607.19 1053.51 204.29 436.43 496.28 358.81 220.63 202.39 
CKMT1A 226.32 175.63 207.76 107.54 225.77 305.22 63.23 53.65 24.99 
CLMP 512.67 465.63 405.25 1460.99 1067.17 850.65 511.17 845.76 850.78 
CLPB 498.29 482.71 455.01 192.33 265.12 352.75 267.66 187.58 178.22 
CNOT3 290.52 251.74 520.8 117.59 202.93 235.83 153.03 85.64 82.57 




CPEB2 161.18 184.54 245.76 686.65 505.49 485.9 383.9 475.43 611.14 
CPS1 135.09 195.03 190.31 51.83 30.64 40 175.68 181.7 225.52 
CXCL12 595.89 481.75 474.89 1178.95 1044.42 899.5 216.01 195.24 235.59 
DBH 787.46 888.83 2362.98 212.26 321.2 525.94 713.41 387.83 295.02 
DCN 550.22 627.13 579.27 1076.3 1367.46 1310.86 791.5 556.66 807.49 
DCX 602.43 572.35 580.78 3051.51 2321.19 2096.69 641.43 645.19 708.82 
DGKK 133.32 235.33 198.11 73.75 54.42 56.33 125.48 98.62 67.47 
DKK1 2552.09 2530.13 1665.43 7460.33 7138.21 6931.06 4839.77 5261.84 6437.85 
DKK2 158.01 102.2 234.33 627.84 637.29 545.42 402.56 481.97 978.62 
DLG2 898.89 765.22 1017.13 468.4 357.15 397.6 663.34 682.63 637.34 
DOCK10 69.91 60.67 70.65 271.07 293.32 238.16 93.39 88.44 78.53 
DPYD 257.27 270.19 193.09 498.29 590.84 496.5 409.09 406.66 457.1 
DUSP4 861.82 946.49 990.19 2027.03 1676.14 1949.86 1001.98 969.47 959.53 
DYNC1I1 87.99 131.74 153.3 319.9 277.25 396.41 205.75 226.75 259.76 
EIF3G 522.75 529.91 2323.32 143.49 299.22 597.03 233.08 128.76 221.49 
EPAS1 872.68 1012.27 1084.11 1096.23 1024.21 1010.01 367.11 270.79 258.76 
ERP29 1957.75 2454.79 3025.93 1089.98 1563.92 2067.58 1256.98 872.52 783.34 
ESRRG 728.4 576.39 853.01 1872.56 1779.01 1345.02 830.21 1162.95 1659.28 
FADS2 424.99 464.72 555.74 157.45 272.89 522.66 164.79 102.6 121.83 
FAM101B 290.42 400.74 478.46 1003.1 881.92 1151.32 727.87 634.19 546.17 
FAM124A 156.33 144.35 184.05 622.86 627.56 648.49 263.35 276.97 219.5 
FBN1 767.53 1202.11 1041.89 2131.68 1431.23 1666.03 548.7 490.78 397.71 
FBN2 180.36 268.4 309.58 77.73 71.97 93.43 239.98 182.54 166.13 
FEZ1 187.27 283.24 177.83 202.3 268.71 290.12 96.62 80.86 49.35 
FGL1 931.35 600.4 521.1 211.28 183.47 184.96 731.68 786.94 925.29 
FHOD3 322.34 389.52 417.44 811.31 678.67 876.48 507 479.11 363.29 
FILIP1L 69.68 75.2 103.22 252.14 260.85 199.91 98.3 120.71 130.88 
FLOT1 827.44 807.18 941.46 288 597.81 785.41 401.66 258.83 254.74 
GABRB3 25.96 26.41 52.44 355.79 290.58 230.77 16.5 34.88 59.37 
GALNT13 503.41 334.61 538.95 1566.62 1442.85 1213.15 732.9 855.73 995.77 
GAREM 268.9 210.81 345.84 1057.37 749.44 687.94 601.18 679.92 945.42 
GDI1 990.05 1064.9 2063.87 447.45 774.15 1055.48 579.6 392.18 313.14 
GNAI2 1010.34 1047.06 1636.84 544.12 949.79 1004.56 708.98 442.2 363.49 
GNAO1 167.86 166.42 307.05 134.54 141.32 184.83 80.7 75.67 72.49 
GNG11 1389.5 1217.13 1321.26 6146.85 5291.77 5138.5 2907.17 3686.59 3908.62 
GPC3 452.8 588.92 391.85 1178.94 1613.22 1484.17 1107.75 692.61 556.8 
GREM1 149.3 90.47 88.3 705.58 764.69 449.84 14.3 54.63 71.46 
GYG2 229.47 266.84 180.96 112.61 122.92 155.07 79.29 50.88 56.38 
HAND1 1914.94 2254.88 2957.52 1217.8 2059.18 1613.91 1238.62 905.7 839.73 
HGS 146.77 179.26 341.46 64.77 115.92 178.59 70.28 56 70.47 
 70 
HMGA1 270.74 242.01 1396.95 86.69 194.21 225.16 113.22 104.37 147.99 
HTRA1 265.47 362.62 231.03 222.24 221.17 279.48 129.01 81.38 100.68 
HYOU1 1126.2 1252.92 1937.22 597.94 779.32 1125.68 739.25 513.51 500.41 
IGF2 2305.5 2251.25 4105.37 1081.28 972.4 1001.5 1331.14 940.43 1028 
IL17RD 1192.8 1371.08 1192.53 3895.6 3018.8 3366.09 1927.9 2077.27 1826.44 
INPP5F 483.11 372.23 596.33 1315.48 1045.23 972.85 705.12 894.95 796.42 
IQGAP2 149 79.99 165.33 481.34 557.45 514.54 220.7 220.76 255.73 
ITM2A 363.24 329.89 238.77 1034.44 1049.61 1257.65 532.89 530.48 752.1 
KCNK1 75.95 42.5 76.25 249.15 221.25 199.88 50.03 90.13 124.82 
LAMP5 186.43 252.31 209.08 461.41 622.27 850.32 194.93 166.55 122.84 
LUM 327.24 261.48 196.35 516.22 727.82 595.36 636.95 659.52 923.27 
MAB21L2 2064.24 2530.54 5030.29 978.63 979.39 1228.93 1784.46 1624.73 1584.8 
MAOB 557.05 557.88 526.29 580.01 576.59 705.84 250.31 203.9 134.93 
MAP6 551.2 539.94 508.11 458.43 406.33 473.04 294.46 253.88 245.67 
MBOAT7 117.36 174.42 213.81 83.71 112.4 153.94 52.99 58 42.29 
MEIS1 488.13 509.21 492.76 997.57 936.48 858 650.59 599.33 648.41 
MEST 494.12 497.31 405.29 431.52 333.47 356.15 276.92 192.66 192.31 
MGEA5 1575.94 1529.83 1427.78 5208.08 5002.22 4842.91 3050.3 3265.57 3071.93 
MGP 594.75 802.51 483.12 837.12 1035.63 1262.92 269.12 241.97 262.78 
MGST1 132.71 151.32 164.5 501.28 529.32 511.35 332.84 350.68 381.59 
MMS19 1022.34 1022.47 1049.58 497.28 692.46 984.26 615.53 396.31 415.83 
MSX2 118.01 87.99 86.47 357.77 349.36 359.3 182.7 196.08 276.86 
NAV1 802.86 1002.85 1185.33 1430.08 1125.86 1447.99 525.63 506.98 381.61 
NCALD 172.03 232.49 270.24 657.75 439.23 571.94 271.68 331.24 346.09 
NEBL 148.85 144.47 142.26 680.66 708.44 508.27 550.16 509.24 717.87 
NEFL 391.34 332.88 678.69 2168.56 1022.15 1217.42 421.81 411.73 479.25 
NEFM 544.32 460.21 768.98 1442.04 1594.7 1507.58 400.72 335.39 293 
NID1 1923.33 2568.49 2736.5 2494.42 2028.97 1968 1421.47 1258.88 1215.28 
NMNAT2 263.95 242.65 251.46 222.24 178.92 278.38 91.3 108.01 106.72 
NOVA2 465.82 845.03 907.43 416.57 480.17 505.23 420.96 208.66 185.27 
NR2F1 175.46 239.44 223.89 681.66 646.05 529.5 415.01 474.6 555.77 
NRCAM 2209.15 1898.57 2718 10059.39 8775.74 7783.81 2990.38 3757.91 3847.2 
NRIP1 214.35 227.42 190.84 73.75 103.99 55.36 201.33 219.21 200.77 
NT5E 52.72 88.29 86.97 321.9 228.08 298.67 185.99 168.05 218.47 
NUDC 1688.99 2190.09 2428.35 790.27 1204.96 1764.63 1084.95 894.11 729.98 
OLFML3 802.86 913.05 1272.9 628.83 1065.7 972.73 510.65 432.92 471.2 
PCDHGA7 65.5 82.38 143.25 319.27 297.92 445.9 223.32 145.62 158.02 
PCLO 621.61 591.02 789.29 285.02 313.49 273.22 453.99 459.5 326.23 
PDE7B 33.88 26.52 28.48 234.2 223.96 174.4 67.19 89.25 114.76 
PDGFRA 1648.03 1666.08 1938.42 2179.51 1899.99 1857.01 720.17 843.87 932.34 




PIPOX 162.15 189.83 181.54 55.78 57.09 72.16 92.58 26.85 37.26 
PITPNA-AS1 51.02 69.11 18.86 76.97 96.95 49.37 134.78 197.29 176.36 
PKM 11375.91 13099.14 23798.11 5098.45 10596.83 12734.92 8359.77 4636.07 4308.37 
PLCXD3 384.24 270.66 333.33 2324.01 2536.46 1684.2 509.98 673.17 954.48 
PLEKHA6 1222.88 1281.98 1845.03 1169.98 982.85 1215.15 736.17 815.13 670.57 
PLK2 218.72 176.83 181.87 680.67 576.64 527.36 291.23 355.98 285.95 
PLOD2 201.26 132.32 142.6 62.79 34.99 48.85 140.12 238.01 240.62 
PPEF1 60.03 29.66 59.51 272.07 267.82 226.47 114 79.77 84.57 
PRELID1 1471.13 1545.98 1842.62 418.07 735.2 1668.28 596.23 419.9 683.64 
PRICKLE1 253.96 409.57 291.27 873.45 651.93 881.29 414.67 390.94 313.96 
PROM1 151.34 135.82 166.03 472.39 312.35 337.04 274.89 253.9 254.73 
PRR14 180.52 210.22 253.65 78.72 190.78 198.61 81.76 74.02 59.41 
PSMC3 1025.51 1407.06 1177.23 575.01 906.62 1274.5 665.26 449.83 451.08 
PTGER2 500.32 432.44 237.89 1056.37 1104.18 889.92 1069.17 1081.43 1339.11 
PTMS 2737.78 3325.59 8436.18 1102.2 2614.57 3010.76 1671.83 940.34 959.54 
PTPRM 121.84 129.08 144.79 387.67 273.7 373.08 91.21 93.5 98.66 
PTX3 64.1 59.95 50.09 241.17 260.76 271.03 146.87 156.18 225.51 
RAB3IP 486.39 460.35 601.2 260.11 252.89 216.9 436.88 466.13 500.4 
RAPGEF4 142.14 157.47 111.07 411.59 354.59 362.52 235.64 227.6 232.58 
RBP1 603.72 586.56 1220.06 319.89 429.9 879.91 254.02 224.19 213.45 
RCOR2 140.18 172.67 202.09 62.78 75.41 141.08 58.54 38.15 44.3 
RD3 110.56 90.74 52.48 347.81 293.05 406 99.49 142.95 124.84 
RELN 1591.45 2660.06 2381.69 3366.42 2449.24 2747.31 1200.74 1115.46 1065.26 
RERG 48.31 30.71 34.7 236.19 213.32 216.85 51.66 22.63 55.36 
RIMS1 37.02 33.28 51.7 234.2 271.44 202.03 61.19 61.18 73.49 
RP11-481F24.3 1233.8 975.01 745.14 2707.46 2360.84 2314.47 2029.75 2590.85 2092 
RPH3A 316.32 403.02 790.36 603.92 838.29 849.39 181.1 175.17 104.72 
RPL28 1393.38 1694.68 1909.4 777.32 1098.79 1520.13 917.39 815.05 617.21 
RPS11 2914.79 3111.75 19002.77 1033.43 1638.89 7441.65 687.93 467.25 1547.49 
SCN9A 746.9 739.66 957.3 2025.45 1915.83 1512.58 1004.46 1306.34 1563.44 
SERPINF1 97.79 86.43 67.05 168.41 328.42 406.95 150.88 117.3 77.54 
SERTAD4 267.15 254.51 341.62 684.65 673.28 534.82 337.64 410.08 510.46 
SEZ6L 77.06 112.04 142.45 495.3 463.42 493.26 95.78 108.97 79.54 
SGK1 395.94 353.74 305.14 1617.44 1748.23 1849.9 474.99 479.67 534.63 
SHOX2 448.63 415.94 530 1208.85 922.38 777.26 708.44 748.85 693.72 
SLC6A2 1015.39 1034.95 997.21 1904.68 1720.76 2181.71 1762.46 1646.93 1439.06 
SLC8A3 55.34 79.72 75.12 347.81 295.82 273.25 101.48 114.13 67.47 
SSR4 441.27 366.44 388.13 104.63 196.66 301.61 192.24 109.45 87.61 
SV2C 31.02 49.06 37.6 345.82 289.64 297.67 211.38 189.3 231.57 
TFPI2 474 479.41 350.93 7765.29 7406.82 5752.03 1802.24 2203.53 3197.76 
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TKT 912.04 1219.88 1287.29 369.72 708.24 1190.39 457.34 294.37 415.82 
TMEM100 148.91 125.57 142.08 444.48 353.66 382.71 153.56 112.74 182.22 
TMEM178B 148.6 158 230.4 256.12 209.74 237.03 64.63 70.65 65.44 
TMSB10 1877.09 2226.65 3204.51 961.68 1625.92 4402.15 561.85 500.6 959.5 
TNNT2 450.4 359.48 505.66 95.66 175.58 279.27 171.59 104.35 98.68 
TRAP1 1051.21 1102.03 1664.87 334.84 705.34 772.03 685.23 367.67 367.82 
TRIB2 854.18 1187.61 898.29 2524.32 2014.04 1998.83 1326.99 1582.39 1593.85 
TSHZ2 62.02 81.26 104.66 341.84 314.48 142.37 56.35 43.3 49.43 
TUBA1B 9503.45 10830.43 14342.84 3623.41 6614.62 11027.88 3707.38 2390.08 3460.9 
TWIST1 922.23 889.05 1333.63 2586.11 1932.39 1948.87 1501.59 1750.35 2106.33 
UBA52 1633.63 2079.09 2038.32 875.28 1321.68 2712.93 759.03 660.67 893.15 
UNC5D 13.32 19.75 30.19 188.36 222.35 144.65 40.83 5.61 26.17 
UNC79 364.67 313.4 428.23 445.47 438.88 452.86 150.26 179.32 177.2 
USP11 1055.87 1096.77 1204.09 351.78 772.39 1154.28 546.04 283.28 355.42 
VAMP2 611.3 650.72 1141.64 394.64 533.73 586.74 446.74 302.17 270.85 
VAT1 1559.13 1721.33 1234.1 578 1268.28 1682.75 778.46 484.58 505.45 
VSTM2A 224.3 235.82 273.66 97.67 109.93 85.06 211.32 175.69 215.46 
VSTM4 74.15 46.78 87.63 213.28 215.92 250.8 79.66 75.58 94.63 
XYLT1 69.9 64.13 69.25 226.23 190.42 233.81 96.87 102.15 72.5 






Table 3: Genes list of significantly (p<0.05) up-regulated or down-regulated after TMG 
treatment 
 
!! logFC logCPM PValue 
TFPI2 3.974315389 7.984336724 3.40E-49 
GNG11 2.048433269 8.062998042 1.01E-22 
SGK1 2.277471985 6.065222981 2.15E-22 
PLCXD3 2.699059303 6.381448599 4.55E-20 
MGEA5 1.702261181 7.965254798 7.53E-20 
DCX 2.060765891 6.596177586 3.19E-18 
NRCAM 1.934288314 8.568472697 4.99E-17 
IL17RD 1.424414076 7.421823589 1.57E-12 
DKK1 1.644288922 8.595270368 2.21E-12 
IGF2 -1.532544968 7.026821053 1.60E-09 
CPE 1.323266754 6.765710761 2.45E-09 
RP11-
481F24.3 1.290595996 7.201935817 1.45E-08 
MAB21L2 -1.622228417 7.272067617 1.71E-08 
PEG10 1.406166131 8.206085404 2.77E-08 
TRIB2 1.124861201 6.916130214 7.63E-07 
C7 1.167612531 9.406382224 8.70E-07 
SCN9A 1.129965883 6.668730579 5.86E-06 
DUSP4 0.98720095 6.620099707 6.29E-06 
TWIST1 1.012814552 7.015622298 1.81E-05 
SLC6A2 0.902559617 6.887559136 2.20E-05 
MANF -0.97916434 7.073468586 2.93E-05 
ESRRG 1.182273941 6.54602197 3.33E-05 
ASCL1 -0.796494691 8.569181531 7.81E-05 
GPS2 -1.475796159 6.922239736 0.000127915 
FSTL1 0.764377934 8.143356395 0.000140223 
SIPA1L1 0.904099364 6.434242443 0.0001465 
FRMD6 0.906722651 6.423991918 0.000202817 
XPR1 0.842826623 8.079487425 0.000326395 
PRKCA 0.765950988 8.480749557 0.000336453 
MTUS1 -0.810318467 6.720087742 0.000351102 
AZIN1 0.835720005 9.34268067 0.000370476 
HDAC9 0.904693051 7.291180258 0.000378629 
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FAT1 -0.752040827 8.025525536 0.000465052 
CREB3L2 0.800895347 6.555216452 0.000469756 
SORCS1 0.702804894 7.704984428 0.000630729 
ITGA1 -0.72265724 7.047001389 0.000655617 
RIMS3 -0.916268416 8.579287327 0.000679593 
LIMA1 0.693236361 7.107553024 0.000755359 
AARS -1.041876727 6.681350405 0.000872145 
STAC 0.618234474 7.702113648 0.001219615 
CHRNA3 -0.723569954 9.283428145 0.001396019 
NOMO1 -0.862037417 7.771738954 0.001591809 
PPM1G -0.98249157 8.574637675 0.001938814 
ZPR1 -0.769295093 7.416296754 0.002295731 
LGR5 0.612682686 8.492114432 0.002434399 
MRPL37 -0.976214847 7.637839562 0.003333965 
EIF3C -1.026933741 10.75841222 0.00348991 
AMZ2 -0.629571914 8.460266234 0.003660173 
CSNK2B -0.82997636 7.510070449 0.004847854 
PTMS -1.134915161 7.749769069 0.005305841 
CDON -0.606847892 7.0078246 0.005528275 
ADAM22 0.574450099 8.082423309 0.005588434 
PPP1R11 -0.776560451 7.968385626 0.006083876 
ALCAM 0.619969531 8.503937758 0.006522808 
NUDC -0.772413173 6.792171458 0.007019238 
EDNRA 0.658950937 7.136645592 0.007034996 
TCF12 0.514909174 8.101024402 0.007053281 
RAD21 0.673633968 9.577534675 0.007476604 
GAR1 -0.802816833 6.7542483 0.007688859 
CDC25B -0.760981608 7.004003099 0.007946699 
RNF150 0.570552744 7.411099445 0.007960745 
CTDNEP1 -0.698431838 7.377677381 0.008055964 
UBE3C 0.516917015 7.427738308 0.008152032 
DOCK7 0.521155094 8.428808865 0.008155624 




ELAVL4 -0.660712706 8.92847878 0.008359706 
EBNA1BP2 -0.746411625 6.993256334 0.008541209 
PPFIBP1 0.526424519 7.156633307 0.009218237 
FN1 0.584957968 7.406644996 0.009453243 
TANC2 0.581402146 7.063223169 0.010169279 
MDH2 -0.876874588 6.794050353 0.010232305 
CKS2 0.6368953 7.445938462 0.010466104 
ERP29 -0.682263947 7.030170382 0.010606499 
POM121C -0.695631769 7.004598091 0.011098191 
MT-CO3 -1.227853996 13.19784594 0.011106659 
THOC5 -0.71295444 6.887044763 0.011654324 
SMC6 -0.546932292 7.222632701 0.012938452 
BRE -0.740280557 7.689313486 0.013188866 
GPC6 -0.690137144 6.794176685 0.013245586 
PTBP1 -1.183514144 7.132030275 0.013301863 
TSC22D1 0.543653501 7.287426899 0.013749817 
UBE2C -0.670668518 6.722297448 0.014793118 
TENM3 -0.590358012 7.317308789 0.015293699 
ASNS -0.596327379 8.713388339 0.015307451 
TMEM97 -0.525088624 7.312664816 0.015438755 
CD46 0.574788982 7.440134619 0.015493012 
SF3B2 -0.813660562 8.831230396 0.015602109 
TBX3 -0.54493534 8.728892988 0.015685141 
ZNF627 0.51722737 6.793599458 0.015800986 
NBEA 0.479935278 7.51802842 0.015963637 
ABHD2 0.533289827 7.302460159 0.015969993 
RET -0.533897749 8.851087406 0.01601111 
P4HB -0.706254071 7.574752079 0.016282525 
MAZ -0.712648443 8.139140992 0.016313182 
AKAP9 -0.494027396 7.697876451 0.016510384 
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UBE2L3 -0.80721758 7.589486513 0.016552814 
SUPT6H -0.774025763 7.043424732 0.01657952 
IMPDH2 -0.727170212 7.353090857 0.016751588 
PPIB -0.789567779 8.751017828 0.017175562 
ATAD2 0.475084659 7.90645691 0.017206476 
CNN3 0.504264401 8.577025795 0.017258069 
MALAT1 0.483375018 7.339203293 0.017687501 
CALR -0.691395808 7.875427446 0.018067103 
TLN2 -0.591540317 6.755797925 0.018244469 
WARS -0.563930867 7.363492942 0.018288284 
NAV2 0.502379735 6.857300206 0.019235683 
TCAF1 0.547181196 9.354532693 0.019970265 
BAG6 -0.74698734 7.464953772 0.020501202 
NEDD8 -0.57853253 7.611533897 0.020812679 
ZMIZ1 -0.635594903 7.915685255 0.021128002 
HAND1 -0.572008201 7.022438286 0.021133806 
SMARCA1 0.466729889 8.090071558 0.021270031 
DAXX -0.635336572 6.863198027 0.021664842 
FNDC3A 0.496811075 7.88847881 0.02182937 
CLIP3 -0.852965081 7.407963873 0.021843053 
ZMAT2 -0.531162094 6.909940284 0.022096076 
KLHDC3 -0.751347562 7.241338002 0.022791483 
ATF4 -0.596270729 6.611322335 0.023073957 
CLPTM1L -0.551346166 7.096490119 0.023304574 
XIST -0.531085678 9.440920395 0.023342366 
NCSTN -0.581791732 7.090979139 0.024430641 
UBAC2 -0.494430848 7.366223592 0.024664675 
CFAP97 -0.55037668 7.125539279 0.024982466 
GNG5 -0.615180579 8.544140665 0.025011986 
PPP1R10 -0.649988033 6.762570837 0.025195653 




MT-ATP6 -1.159920927 13.07305454 0.026005844 
AK2 -0.47783234 7.758020521 0.026581472 
TFAP2B 0.480740601 7.386584245 0.026771089 
LRRN3 -0.50825704 8.404482363 0.026821324 
BUD31 -0.580403107 7.74115614 0.026871668 
CHMP4B -0.58273011 6.843367991 0.027273808 
SEC23B -0.463246017 7.486818053 0.027346597 
IRF2BP2 0.5093795 7.264786382 0.028121064 
MCCC2 -0.445282251 8.015567323 0.028970421 
SSRP1 -0.655187182 8.722625177 0.028978838 
SARS -0.612948603 7.449126189 0.029090394 
H3F3B 0.512040267 9.756314258 0.029571005 
PSMC4 -0.676344975 6.788810725 0.029620917 
AFAP1 -0.485935841 6.90889694 0.029926016 
MT-CO2 -1.016751331 14.05800818 0.030375754 
UBR5 0.448036772 7.813890489 0.030994807 
POLR2H -0.555441462 6.835715306 0.031129857 
ID2 0.56325906 8.015145563 0.031274698 
PTDSS1 -0.54849364 7.499481218 0.03141721 
CETN2 -0.487230186 7.017210086 0.031601298 
TUBA1B -0.730659217 9.151440654 0.031643051 
PKM -0.79058477 9.671057409 0.031929466 
CERK -0.450201272 8.105680291 0.03218758 
PPP2R5E 0.432660442 7.900399134 0.032612417 
POLR2A -0.834773764 7.087055602 0.032742537 
MAGI2-AS3 -0.588311604 7.206015915 0.033086028 
UBAP2L -0.694194823 8.490312113 0.033545911 
NAT10 -0.552699278 7.193540109 0.03358678 
LINC00665 -0.600417696 7.421999379 0.033625882 
STT3A -0.506456737 7.677946311 0.03369268 
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RPL35 -0.609828322 6.635443688 0.034048363 
RERE -0.545363082 7.132047495 0.034649325 
PDCD11 -0.574919317 7.492894518 0.034829288 
TENM4 -0.54734415 6.697226231 0.034978287 
RAD50 -0.424015801 8.033194909 0.035811552 
KIAA0100 -0.509305854 7.980113726 0.035930253 
TRAK2 0.427916012 7.068273404 0.036327304 
CDK6 -0.629461946 9.22387697 0.036914719 
MAPK1 0.403920802 7.044887938 0.037523153 
FABP5 0.46059264 6.988679239 0.037855408 
TMX4 0.470648742 7.099597454 0.038933877 
NDFIP1 0.426255978 8.466402049 0.038995421 
PMPCA -0.539834563 6.916608077 0.039178313 
DYNLT1 -0.453987805 8.424423504 0.039964143 
CIRBP -0.523272032 6.763159124 0.040949801 
JAK1 0.398300871 7.717623211 0.042444903 
STARD4 0.560615298 6.821007386 0.043783788 
PSME1 -0.594407247 7.288375279 0.044137683 
VPS39 -0.463902402 7.351606323 0.044175796 
TLN1 -0.689618228 7.540808926 0.044426814 
PRMT5 -0.587111509 8.325262667 0.044911139 
ZC3H13 -0.425567994 8.072920026 0.046122211 
DLST 0.561831892 6.851242186 0.046333118 
ABLIM1 0.407822267 8.091731788 0.046869633 
IQGAP1 0.408367593 8.015551266 0.046887081 
ELF2 0.4393446 6.731004387 0.046964476 
EP400 -0.458006277 7.075043425 0.047077892 
GTF2A2 -0.408809607 7.680856841 0.047162908 
SNRPN -0.517187341 7.76207455 0.047188755 
DNMT1 -0.511923551 7.562221354 0.047727604 
RNF214 -0.475111191 7.194348488 0.048416562 




CCND1 0.487429487 9.323533105 0.049048184 
KCTD20 0.426584195 8.588293549 0.04934024 
GCN1L1 -0.569440023 7.3108849 0.049475995 




Table 4: Gene list of significantly (p<0.05) up-regulated or down-regulated genes after 
prolonged GlcN treatment 
  logFC logCPM PValue 
TFPI2 2.449549276 7.984336724 4.27E-22 
GNG11 1.400880484 8.062998042 8.64E-12 
MGEA5 1.029759892 7.965254798 2.20E-08 
IGF2 -1.415111687 7.026821053 2.30E-08 
DKK1 1.274701245 8.595270368 3.95E-08 
TUBA1B -1.879917667 9.151440654 7.54E-08 
RP11-481F24.3 1.162426643 7.201935817 3.10E-07 
HAND1 -1.279389647 7.022438286 3.71E-07 
ERP29 -1.376501598 7.030170382 3.76E-07 
ATF4 -1.33553956 6.611322335 5.32E-07 
PDGFRA -1.091817707 6.88888152 5.60E-07 
PTMS -2.046182301 7.749769069 9.76E-07 
ATP7A 0.994206259 7.337665669 1.41E-06 
CALR -1.354956856 7.875427446 4.83E-06 
RELN -0.99206582 7.327970415 1.42E-05 
AHNAK -1.076559642 8.917657368 1.46E-05 
TMSB10 -1.870704304 7.146039288 1.72E-05 
NUDC -1.242362228 6.792171458 1.75E-05 
NID1 -0.912566093 7.252899644 1.82E-05 
RPS11 -3.22548531 8.36363387 2.35E-05 
MYL6 -1.061201889 7.996649405 3.63E-05 
CFL1 -1.546174471 8.733514764 3.84E-05 
C18orf32 1.218130265 6.754779215 4.23E-05 
NEDD8 -1.027447717 7.611533897 4.62E-05 
PKM -1.505232604 9.671057409 5.78E-05 
UBA52 -1.333477997 6.814546944 6.44E-05 
CAPNS1 -1.451744755 6.541698801 7.24E-05 
SUPT6H -1.284650185 7.043424732 8.34E-05 





PLCXD3 1.098396638 6.381448599 0.000101694 
UBC -1.399370809 9.485955683 0.00012405 
FLNB -1.054081826 6.962606714 0.000150823 
IMPDH2 -1.156659038 7.353090857 0.000160469 
AKAP12 -0.809030747 6.787146944 0.00016659 
MPP6 0.850937415 7.235000472 0.00016691 
SSRP1 -1.133396883 8.722625177 0.000179628 
RPL7A -1.244465491 7.4213187 0.00018936 
MANF -0.871614147 7.073468586 0.000194654 
GNB2L1 -1.2240911 7.547941363 0.00021181 
GAPDH -1.262893693 10.0902515 0.000222794 
GANAB -1.023214928 8.211212754 0.000237194 
CIRBP -0.9442862 6.763159124 0.000248837 
NOMO1 -1.000695714 7.771738954 0.000257103 
UBE2I -1.049636975 8.115504563 0.000257817 
HDAC9 0.930311296 7.291180258 0.000258633 
EIF3I -1.144167785 7.376246758 0.000283796 
CDC25B -1.043907968 7.004003099 0.000293597 
FTSJ3 -1.219236098 6.969777419 0.000294765 
UBAP2L -1.186122857 8.490312113 0.000319863 
RPL29 -1.096950136 9.193880883 0.00032508 
SMARCC2 -1.087339026 7.300937992 0.000351224 
NBEA 0.712396317 7.51802842 0.000356862 
FAT1 -0.765544444 8.025525536 0.000367826 
FRMD6 0.868642632 6.423991918 0.000370383 
P4HB -1.04549002 7.574752079 0.000408307 
CLIP3 -1.317846172 7.407963873 0.000452579 
MAP1A -1.116638013 6.664603258 0.000461457 
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CHGA -1.268354165 7.438226481 0.000510925 
CD63 -0.895370821 7.839260571 0.000536769 
EIF3C -1.214081436 10.75841222 0.000582845 
RPL35 -0.993311222 6.635443688 0.000601764 
QARS -1.222550602 6.941977028 0.000603939 
CTDNEP1 -0.904537968 7.377677381 0.00062902 
MAB21L2 -0.967090374 7.272067617 0.000632616 
POLR2A -1.350853688 7.087055602 0.000633538 
SLC39A1 -0.954783093 6.691312588 0.000835626 
RPL10 -1.315804457 7.855640214 0.000840155 
AARS -1.03977848 6.681350405 0.000897923 
PPM1G -1.050372577 8.574637675 0.000936779 
ANXA2 -0.860435794 8.367700311 0.001037822 
S100A10 -0.900264302 6.924309517 0.001137347 
MCM3 -0.658699767 7.911133648 0.001173992 
MRPL37 -1.080091503 7.637839562 0.001196051 
PSMD2 -0.928406368 7.358599115 0.001314969 
NOP56 -0.726286439 7.850050755 0.001331374 
SSR2 -0.913752596 8.103371435 0.001350133 
RGS4 -0.657522844 8.401062865 0.001357951 
CKS1B -0.660488747 7.792235171 0.001390785 
TWIST1 0.752714522 7.015622298 0.001397533 
RPL18A -1.192914417 7.351885612 0.001419253 
ABCF1 -1.019670892 6.734491684 0.00154863 
RPS18 -1.058620299 10.37371853 0.001624468 
MDH2 -1.077851179 6.794050353 0.001668437 
NOMO3 -0.958839472 7.238961612 0.001688511 




PSME1 -0.929705961 7.288375279 0.001743191 
DAXX -0.868244207 6.863198027 0.001775445 
MKI67 -0.747689275 8.569323556 0.00188046 
POM121C -0.851596529 7.004598091 0.001934554 
SETDB1 -0.831736823 7.847568759 0.002017257 
RPS15A -0.837645542 9.97400285 0.00201729 
IL17RD 0.614346014 7.421823589 0.002037409 
RPL26 -0.745592051 9.701854615 0.002079022 
EEF2 -0.994067338 8.817360808 0.002097463 
CSNK2B -0.903683018 7.510070449 0.002195241 
RPLP0 -1.115316482 9.717400177 0.002236339 
SLC6A2 0.648355535 6.887559136 0.002247475 
RPS3 -0.947471519 10.54016106 0.002361594 
YIPF4 0.719401214 7.011829971 0.002412642 
PPP2R5E 0.609956712 7.900399134 0.002624983 
HUWE1 -0.806315759 8.779912743 0.002705815 
RPL41 -0.996726326 9.778364457 0.002834304 
PTDSS1 -0.762332768 7.499481218 0.00287259 
SPARC -0.646927276 8.543539304 0.002936573 
SLC4A8 -0.618033071 7.361169902 0.0030232 
NCSTN -0.767778464 7.090979139 0.003073275 
ATP5J2 -1.052840053 6.972619815 0.003076987 
CACNG4 -0.758677273 7.322199509 0.00307967 
KIF20A -0.758480324 7.237190861 0.00354331 
TENM3 -0.710714609 7.317308789 0.003554218 
RPL12 -0.943227154 9.45141067 0.003664619 
EEF1G -1.055158341 10.2400586 0.00373831 
RPS27 - 10.15260232 0.003750255 
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0.773356915 
SMN2 0.57950038 7.832268092 0.003784391 
HAT1 0.750059426 6.710903936 0.003969555 
BRD2 -0.798209445 7.085629549 0.004142737 
SEC24C -0.771494257 7.5126224 0.004161356 
SFRP1 -0.679631882 7.438536355 0.004235332 
ARF3 -0.64333804 7.630591759 0.004305669 
ACACA -0.738824251 7.683161139 0.004373437 
TLN1 -0.979205919 7.540808926 0.004516241 
EIF4A1 -0.855668751 10.70555321 0.004533314 
ATL2 0.624208475 7.353977098 0.004637697 
MMP2 -0.887883808 6.911105807 0.00477092 
RPL27 -0.789934282 8.890944811 0.004810893 
PRMT5 -0.823990018 8.325262667 0.00503439 
UBE2C -0.766146097 6.722297448 0.005459595 
FOXM1 -0.673777831 6.845013745 0.005480087 
RPS4X -0.835130403 11.59372685 0.005527749 
RPL32 -0.892950377 9.850476809 0.005590872 
SPTAN1 -0.749443924 8.406872594 0.005602003 
CEP44 0.751318747 7.946345157 0.005755674 
FDFT1 -0.676513169 8.031042705 0.005764419 
ZWILCH 0.68116595 6.991362982 0.00583738 
MZT1 0.856832499 7.200653965 0.005893811 
SNRPA -0.927066607 6.6612562 0.005920381 
CCDC25 0.598452386 6.863724597 0.005930061 
LIMA1 0.565326949 7.107553024 0.005957992 
NRCAM 0.616146235 8.568472697 0.006018163 
ACTR6 0.803625714 6.696332746 0.006032362 
TRRAP -0.600171683 7.738996983 0.006287822 
MMP16 0.709177388 6.772804339 0.006364951 
RERE -0.705083641 7.132047495 0.006449983 




ICA1 -0.575553805 7.570555811 0.006619576 
RPL36A -0.699011048 9.526002269 0.006820403 
DDX39B -0.621456332 7.975360576 0.006961993 
AGPS 0.564570998 7.704238311 0.007003106 
RAD1 0.580377877 6.955470888 0.00704437 
DCP2 0.650519857 7.125352994 0.00713944 
SLC6A15 0.577438896 6.97252449 0.00727042 
ARHGEF2 -0.78031508 6.72884992 0.007373756 
VCP -0.774321937 8.342207436 0.007428919 
DCK 0.688474788 6.96419796 0.00744561 
AATF -0.806540936 6.872945729 0.007482898 
EIF4G1 -0.706917237 8.022366495 0.007589612 
CRMP1 -0.804904001 7.462212511 0.007740171 
MAD2L1 0.6376872 8.133537319 0.007801153 
KRAS 0.684820319 6.996256626 0.00796092 
SEP6 -0.609164778 8.345705899 0.007970812 
PACS1 -0.800720499 6.783206458 0.008090056 
TRIB2 0.597201737 6.916130214 0.008262241 
SF3B2 -0.889440512 8.831230396 0.008295734 
CHD4 -0.737497657 8.841874977 0.008361105 
ESRRG 0.744728199 6.54602197 0.008581295 
RFC3 0.563171996 7.17292876 0.00860644 
TENM4 -0.681720549 6.697226231 0.008740565 
SCN9A 0.649198785 6.668730579 0.008885445 
RET -0.579482451 8.851087406 0.008977665 
PM20D2 0.638223924 7.01836256 0.009047824 
MAZ -0.773613904 8.139140992 0.009207079 
SARS -0.732181625 7.449126189 0.009273848 
ZNF512 -0.555408711 7.99040199 0.009457014 
PRPF8 -0.834760956 9.685375011 0.00963452 
PSMB7 - 7.235679873 0.009711272 
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0.727956917 
EBNA1BP2 -0.733089419 6.993256334 0.009782487 
TMEM167A 0.639409034 7.753360893 0.00983525 
DNMT1 -0.668873607 7.562221354 0.009837584 
IGF2R -0.592953568 6.870804615 0.009946033 
ACIN1 -0.642461085 7.442737952 0.010093296 
TMSB4X -0.715184758 7.855200311 0.010228081 
NDUFS5 -0.609778616 7.899946954 0.010263996 
UBA1 -0.797236696 7.079383668 0.010322846 
RPL37A -0.894477313 8.274734907 0.01039317 
IER3IP1 0.637503727 6.760418352 0.010426087 
PPP1R10 -0.743974382 6.762570837 0.010539677 
MYH10 -0.597498194 8.590632499 0.010557975 
WRN 0.57680754 6.812570166 0.010589966 
PPA2 0.584666401 7.052682313 0.010621163 
TSNAX 0.677498888 7.559712178 0.010692415 
KNTC1 0.521812007 7.385276901 0.010814285 
DDB1 -0.789183116 8.896145766 0.010824649 
PGD -0.748030067 7.024148494 0.010828651 
CERS2 -0.715389949 8.738537837 0.011048614 
MT-CO3 -1.228666502 13.19784594 0.011055031 
USP1 0.573950768 7.35725584 0.011623638 
BAG6 -0.813704696 7.464953772 0.011715432 
BUD31 -0.660381525 7.74115614 0.011898487 
NCAPG 0.538895563 7.352033599 0.011993385 
RPL18 -0.830177803 7.004954257 0.012001174 
MAP9 0.572623367 7.308828496 0.012097032 
SEH1L 0.531568546 7.626968001 0.012166801 
SND1 -0.824524663 8.593465519 0.012411452 
SOD1 -0.546118945 7.927965277 0.012532181 




CCNC 0.705235943 6.677367037 0.012675998 
YY1AP1 -0.658425462 6.924581188 0.012776883 
EP400 -0.574685737 7.075043425 0.012849797 
C6orf62 0.542806199 7.484205128 0.013342723 
CMPK1 0.66072971 6.707208464 0.013545926 
LARP1 -0.550406093 7.576201989 0.013733488 
RPS16 -0.808168435 8.022021186 0.014099674 
RPL38 -0.707950902 10.00736928 0.014156962 
UHMK1 0.586236814 7.558897537 0.014287435 
PITPNA -0.572224219 6.833321905 0.014316427 
COPA -0.614062843 8.938574056 0.014355688 
STARD4 0.681003543 6.821007386 0.014434392 
RIMS3 -0.656240482 8.579287327 0.0145643 
RB1 0.553879463 7.85310158 0.014925876 
SMC2 0.526218926 7.787049526 0.014951571 
PSMC4 -0.755834284 6.788810725 0.015230787 
BNIP2 0.554001485 6.969841001 0.015297166 
CCT3 -0.716741768 10.08242527 0.015344614 
DCAF13 0.542195013 7.830765596 0.015673761 
UBR4 -0.625690888 8.00843422 0.015761273 
TTC8 0.523502302 8.100822882 0.015828415 
ATP1A1 -0.63018381 8.6461645 0.015909115 
RNF11 0.685100389 6.727516365 0.015909417 
SMARCB1 -0.763859903 6.836947687 0.015912008 
CDK1 0.65449131 7.879598216 0.016043545 
ICE2 0.516364882 7.145945949 0.016098486 
ZPR1 -0.604940122 7.416296754 0.016265433 
CENPH 0.605621328 7.466403305 0.016496252 
MFN1 0.599206145 6.715247344 0.016720707 
SNRNP200 -0.734677044 9.625119196 0.01677819 
NCAM1 -0.55147354 7.620459395 0.016854109 
ARID1A -0.539824616 7.09999454 0.016925311 
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LAMC1 -0.538555825 8.460123093 0.017007916 
ACTR1A -0.684527826 7.508053133 0.017031741 
ZMAT2 -0.553957777 6.909940284 0.017061988 
NAT10 -0.620650527 7.193540109 0.017146121 
FTH1 -0.67921641 10.58979242 0.017158094 
PDCD11 -0.649147429 7.492894518 0.017287096 
RNF10 -0.593204373 7.342929869 0.017343642 
CEBPZ 0.475961429 7.925583275 0.017531781 
SPTBN1 -0.592042479 8.886429184 0.017570762 
SAFB -0.637424821 7.372130865 0.017633644 
FUNDC2 -0.64358153 7.768551483 0.01775531 
STIP1 -0.69127169 8.811040089 0.017783344 
THOC5 -0.669142133 6.887044763 0.017864025 
PA2G4 -0.648111642 9.112591306 0.018008156 
UBE2L3 -0.795557755 7.589486513 0.018172899 
CBFB 0.703332894 6.904897168 0.018253823 
GTF2A1 0.618844647 6.983776761 0.018352446 
FNTA 0.477656588 7.58847535 0.018391283 
CD164 0.686927483 7.260505416 0.018436526 
EIF3D -0.682392139 8.514206669 0.01848299 
UBA6 0.581579426 7.115459934 0.018486879 
MAT2B 0.550741813 7.430974584 0.018575729 
HIP1 -0.586275616 6.795428511 0.018671586 
ARL5B 0.62235564 7.385961169 0.018691811 
PHF6 0.537538285 7.927563334 0.018910978 
SCG2 -0.499942438 6.918525441 0.018961941 
C1orf112 0.476728967 6.929970554 0.018975063 
SRPR -0.623579396 6.908883782 0.019254143 
CKS2 0.581759577 7.445938462 0.019301158 
EIF1AX 0.698255698 8.298949822 0.019373384 
HOOK3 0.563931747 6.913164497 0.01940759 
NDUFB9 -0.683828572 6.973963778 0.019434354 




TMEM165 0.521524523 7.039863927 0.019887733 
DYNC1LI1 0.513185913 6.990195465 0.020007663 
SNRPN -0.606026147 7.76207455 0.020210175 
PPIA -0.662215713 10.97911734 0.020282527 
C7 -0.545587372 9.406382224 0.020391364 
GGCT 0.49424728 7.282774654 0.020448593 
GPS2 -0.881208997 6.922239736 0.020455783 
MT-ATP6 -1.208888682 13.07305454 0.020471926 
GTF3C6 0.522733675 8.29411623 0.02114604 
PPIP5K2 0.522578637 7.017621913 0.02121959 
SMAD9 0.633606902 7.717361504 0.021234545 
DR1 0.642032937 7.458048374 0.021298702 
C14orf132 -0.490692873 7.588519753 0.021445418 
PLXNA4 -0.497705128 7.804488271 0.021459352 
RPN1 -0.569862634 8.182041117 0.021565617 
RNF130 -0.528230312 6.855189249 0.02171543 
OSTC 0.553977859 7.331965259 0.021737994 
PPP1R11 -0.647721324 7.968385626 0.021929147 
TPM1 -0.517358886 9.033555243 0.021963848 
PRC1 -0.474864854 7.963396862 0.022258974 
ID2 0.595614455 8.015145563 0.022825072 
ATP11C 0.491682441 7.003226685 0.02294183 
ECHDC1 0.599902403 6.861418435 0.02295611 
KDM3B -0.479753467 7.517559129 0.023136132 
ASXL1 -0.530197124 6.976883533 0.023436778 
WDR36 0.502866781 7.172501832 0.023531701 
SOGA1 -0.632629455 6.847462532 0.023542551 
THOC3 -0.521400525 6.987629437 0.023579514 
PCNA 0.534217703 8.981790186 0.023683686 
NAE1 0.577662666 7.232312345 0.023700541 
STT3A -0.538691871 7.677946311 0.023982997 
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COX7C 0.539637674 7.033128702 0.024358263 
XPNPEP1 -0.51705682 6.814916709 0.024404862 
SRSF11 0.530030416 7.903983898 0.024554145 
LRRC58 0.643890773 6.780720558 0.024664326 
JAM2 -0.489466027 6.938709053 0.024856031 
G2E3 0.691420291 6.741750614 0.025158807 
SPCS3 0.607757251 6.966560864 0.02517903 
CCDC90B 0.59390345 6.807165431 0.025330841 
DDX24 -0.580561 8.372791718 0.025551272 
ADSS 0.453373629 7.374256693 0.025551974 
NUDCD3 -0.567178097 7.36528815 0.025557214 
GNPNAT1 0.550681541 7.591550715 0.025914652 
FAM98B 0.506125364 7.527517404 0.025988397 
ASCL1 -0.446866795 8.569181531 0.026002839 
LSM5 0.616351534 8.181851511 0.026022315 
OSBPL8 0.526478052 7.21479431 0.026100384 
TMEM106B 0.59573737 7.231479994 0.026113432 
CDON -0.485652611 7.0078246 0.026119988 
POLR2M 0.547581428 7.159183699 0.026290652 
PSMD12 0.489125873 8.249937634 0.026407304 
GCSH 0.524065189 7.310630424 0.026857462 
USMG5 0.563745341 7.377173494 0.026897771 
TMEM30A 0.55102192 7.849612154 0.026917315 
ARNT -0.448124848 7.588450097 0.027023973 
TFAM 0.536775231 7.238324589 0.027384851 
NDC80 0.515990727 6.825341431 0.027501917 
HAUS6 0.497044384 7.503734266 0.027725176 
WIPI2 -0.504375865 6.773379804 0.027746182 
SMG7 -0.532716513 8.348162119 0.027989765 
MTPN 0.585120335 10.06923325 0.028157416 
SF3B6 0.478313408 7.952346408 0.028296054 
YKT6 -0.555280612 7.535864988 0.028472171 
TWF1 0.689926572 6.927530248 0.028525407 
CYCS 0.633041606 8.419434912 0.028610661 
RPL6 -0.529514861 10.72676553 0.02865775 
DEPDC1 0.583857943 6.742471195 0.028665198 




NES -0.616366567 9.214172583 0.029100777 
UXT -0.73432444 6.787524068 0.029152751 
LTN1 0.516865405 7.2472387 0.029168979 
SAP30BP -0.562826004 7.214673687 0.029559357 
ACTB -0.629683485 11.6785997 0.029647613 
TMX3 0.588144213 6.659098527 0.029656312 
EGLN1 0.572705063 6.829437454 0.029666026 
ERC1 -0.547597571 6.73223718 0.029919791 
GSTM3 -0.7487231 6.933423974 0.029945921 
CTSB -0.632680577 7.845931199 0.029993108 
VPS13A 0.479187185 6.684107939 0.030300953 
RAD21 0.544372769 9.577534675 0.030404265 
GCN1L1 -0.627736397 7.3108849 0.030527259 
STRAP 0.473996474 8.945718768 0.030697514 
HIGD1A 0.542298614 7.0127987 0.030786342 
XPO1 0.52884387 9.370407101 0.030790216 
TP53BP2 -0.549729203 7.405747318 0.030797176 
VPS26B -0.535177871 6.854521171 0.030816934 
KMT2A -0.529556472 7.63970236 0.030830004 
EID1 0.682005873 8.279743343 0.030874475 
H2AFY2 -0.585974046 6.942115336 0.030934962 
CD46 0.511975868 7.440134619 0.031007583 
KCTD12 0.592893311 7.427404919 0.031137575 
BLOC1S6 0.454844004 7.215829354 0.031366392 
GON4L -0.588020084 6.824164549 0.031579528 
ATP11B 0.473839955 6.952190087 0.032207808 
SRP68 -0.503289134 7.790219698 0.03228419 
ZBTB44 0.501026351 7.070238659 0.033009098 
STAG2 0.475366305 8.057609458 0.033124777 
SEC14L1 -0.521427612 6.909749389 0.033626925 
CCZ1 0.438259614 8.398980931 0.033816862 
TOR1AIP2 0.449262301 7.542236873 0.033866578 
MRPL9 - 7.53490675 0.034092372 
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0.507292898 
PPIB -0.701221648 8.751017828 0.034099479 
TLE4 0.441754831 6.798673105 0.034132896 
MALAT1 0.431437911 7.339203293 0.034242072 
SLC7A2 0.441425173 7.988861349 0.034380428 
PPP2CB 0.420943412 7.416619151 0.034380807 
KDELR1 -0.605106858 6.746939746 0.03440662 
EXTL2 0.488275838 7.273557849 0.034426432 
PURB 0.495093403 8.145382898 0.034487529 
NAA15 0.458689281 8.072056543 0.034705333 
SOCS4 0.562252875 6.755806882 0.035006224 
SCRN1 -0.459078684 8.468773471 0.035567933 
RPS6 -0.564538316 9.943868117 0.035606921 
PFDN5 -0.570007782 8.145984891 0.035707386 
PRKD3 0.491728899 8.18603757 0.035882594 
ABCE1 0.528202237 8.075550887 0.035976579 
GNG12 0.486971165 7.582135339 0.036471776 
TLN2 -0.523388326 6.755797925 0.036559026 
SGK1 0.476590583 6.065222981 0.036622195 
RPL3 -0.628572575 9.54478926 0.036778936 
CAPZA2 0.610555175 7.410070211 0.03736812 
PPP1CB 0.598881591 8.552653266 0.03785458 
RFWD2 0.398954167 7.396916794 0.037885057 
MAP4 -0.564871021 8.757519887 0.037967424 
PPP3R1 0.403489288 7.954328608 0.038014055 
RPL10A -0.715157412 10.1174482 0.038324659 
STARD3NL 0.444598728 7.314185085 0.038996223 
HK1 -0.646342554 7.37144133 0.039244919 
MCM7 -0.60963435 7.244267667 0.039292398 
BZW1 0.517243924 9.483454137 0.039611884 
ADO 0.424823422 7.34393212 0.039666453 
MT-ND5 -1.08099704 11.3921962 0.039691753 
KIAA0100 -0.498778869 7.980113726 0.039947844 
RAF1 -0.42510671 7.014396999 0.039985939 
FAM208A 0.453296834 7.169718832 0.039997722 




ZNF3 -0.4695101 7.656415219 0.040392913 
SNX7 0.426471908 7.558749456 0.040409874 
CRTAP -0.499374727 8.358040186 0.040521704 
TRPM7 0.492725154 6.931745473 0.040652685 
EXOC5 0.504949385 7.532718824 0.040848328 
DNAJC10 0.444862834 7.712336112 0.041098912 
PNO1 0.510120268 6.846447503 0.041197502 
HNRNPA0 0.458595539 8.55949452 0.041372721 
PDCD4 0.429648778 7.004777498 0.041573843 
PCNP 0.536955247 8.352967408 0.041767613 
SEC24D 0.373856909 7.791125547 0.041954992 
RSBN1L 0.475478447 7.169047314 0.042187338 
SLC20A1 -0.429278338 7.197391534 0.042261343 
THUMPD3 0.44680257 6.767278038 0.042415024 
SIN3A -0.53258322 7.287836893 0.042592761 
C7orf73 0.428421556 7.511267518 0.042726276 
DENR 0.4330541 7.809993219 0.043112607 
RPS2 -0.663638592 10.29349875 0.043274444 
MT-CO2 -0.946278093 14.05800818 0.043617983 
CS -0.553999987 9.382035718 0.043618661 
UBE2Q1 -0.464233572 8.006393661 0.043746258 
NCAPD2 -0.526114564 8.199127337 0.043900763 
MRPL42 0.460995044 7.153197851 0.044020685 
COPG1 -0.522697244 6.807995611 0.044119245 
GEN1 0.521059619 7.117859347 0.044328841 
RPL27A -0.548524254 10.29231561 0.044341545 
SRSF10 0.440295505 7.998350578 0.044430204 
NDUFB6 0.777413315 7.28138122 0.044931393 
DENND5A -0.446772557 7.052297083 0.045324949 
ECT2 0.47174819 7.79343461 0.045370558 
APLP2 -0.483139339 8.767654763 0.045603705 
KPNA3 0.459516859 7.331257373 0.046168464 
SIKE1 0.483376267 6.923773785 0.046240972 
ORC2 0.385126849 7.448399315 0.046279304 
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RC3H2 0.418712468 7.339394834 0.046308889 
MSH2 0.496425736 8.146747115 0.046743655 
ARIH2 -0.465788317 6.963631321 0.046887397 
EML4 0.455868452 9.075641723 0.046956188 
CAND1 0.446081472 8.575612657 0.047091855 
GATAD2B -0.463864272 6.990985567 0.047135895 
SF1 -0.550061371 8.770854265 0.047163389 
USP33 0.417250209 7.637428035 0.047295601 
ATP13A3 0.451534212 7.684347954 0.047470236 
CH507-513H4.3 1.71524385 8.866424395 0.047488558 
CH507-513H4.4 1.715243851 8.866424395 0.047496103 
CH507-513H4.6 1.715243852 8.866424395 0.047500949 
ACTR2 0.481151912 9.322584915 0.047544539 
RPS25 -0.503202308 9.590099838 0.047663212 
SLC4A7 0.491703374 6.712520362 0.047921546 
DEK 0.498577957 8.698118689 0.048064857 
PTEN 0.457687764 7.815508876 0.04813261 
CLTA -0.498804227 8.297464041 0.049389844 
KRR1 0.493663748 6.585563324 0.049425754 
CENPU 0.418760387 7.270888839 0.049462329 
UBE4B -0.447380619 7.184125761 0.04949097 
DESI2 0.466222975 7.973720163 0.049690195 
ADAM22 0.4064219 8.082423309 0.049707012 
UBE2K 0.418281214 8.327286796 0.049916693 






13 mitochondrial-encoded polypeptides of ETC complex subunits were found. Of these 
genes, TMG treatment down-regulated 3 and GlcN treatment down-regulated 4 (Figure 15B).  
Of note, the mitochondrial transcription factor A (TFAM) level, the mitochondrial specific 
transcription factor [74], was unchanged between treatments (Figure A.3F), suggesting that O-
GlcNAc could be modulating the mitochondrial transcriptome by affecting TFAM activity or 
mitochondrial mRNA stability.   
Using gene set enrichment analysis (GSEA) [75] to compare TMG-treated with control 
gene expression data sets, we identified genes from the insulin signaling pathway, aging, and 
cancer metastasis enriched in prolonged TMG-treated cells (Figure A.3G-I).  These data 
suggested that prolonged O-GlcNAc elevation modulates the progression of chronic metabolic 
disease. 
3.3.5 NRF2-mediated Oxidative Stress Response was Down Regulated 
To define biological functions of the altered genes, we performed Ingenuity Pathway Analysis 
(IPA). A stringent threshold (cpm of > 100) was applied to the gene set to prevent false positives. 
There were 22 canonical pathways for TMG-treated (Figure 15C) and 26 canonical pathways 
for GlcN-treated cells (Figure 15D) were identified (Table 5-6). We found 13 pathways 
overlapped in both TMG and GlcN-treated cells and changed in the same predicted manner (see 
Figure 15C-D). The NRF2-mediated oxidative stress response was identified as down regulated 
in both TMG and GlcN treated SH-SY5Y cells. These data suggest that both TMG and GlcN 







Figure 15: TMG or GlcN treatment altered the transcriptome and down-regulated NRF2-
mediated oxidative stress response 
Representative Venn charts showing number of differentially expressed genes (A) up-regulated 
or down-regulated after TMG or GlcN treatment. Shown in grey are number of genes whose 
expression was changed (p < 0.05) compared to control cells. Numbers in bold represent p < 0.05 
genes changed more than 1.5-fold (n=3). (B) Schematic representation of mitochondrial-encoded 
genes that were down-regulated. Canonical pathways significantly associated with changes in 
genes expression after long-term (C) TMG and (D) GlcN treatment. 
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Table 5: TMG gene list used for IPA analysis 
!! logFC PValue 
MAB21L2 -1.622228417 1.71E-08 
IGF2 -1.532544968 1.60E-09 
GPS2 -1.475796159 0.000127915 
MT-CO3 -1.227853996 0.011106659 
PTBP1 -1.183514144 0.013301863 
MT-ATP6 -1.159920927 0.026005844 
PTMS -1.134915161 0.005305841 
AARS -1.041876727 0.000872145 
EIF3C -1.026933741 0.00348991 
MT-CO2 -1.016751331 0.030375754 
PPM1G -0.98249157 0.001938814 
MANF -0.97916434 2.93E-05 
MRPL37 -0.976214847 0.003333965 
RIMS3 -0.916268416 0.000679593 
FTSJ3 -0.884046023 0.008211142 
MDH2 -0.876874588 0.010232305 
NOMO1 -0.862037417 0.001591809 
CLIP3 -0.852965081 0.021843053 
POLR2A -0.834773764 0.032742537 
CSNK2B -0.82997636 0.004847854 
SF3B2 -0.813660562 0.015602109 
MTUS1 -0.810318467 0.000351102 
UBE2L3 -0.80721758 0.016552814 
GAR1 -0.802816833 0.007688859 
ASCL1 -0.796494691 7.81E-05 
PKM -0.79058477 0.031929466 
PPIB -0.789567779 0.017175562 





SUPT6H -0.774025763 0.01657952 
NUDC -0.772413173 0.007019238 
ZPR1 -0.769295093 0.002295731 
CDC25B -0.760981608 0.007946699 
FAT1 -0.752040827 0.000465052 
KLHDC3 -0.751347562 0.022791483 
BAG6 -0.74698734 0.020501202 
EBNA1BP2 -0.746411625 0.008541209 
BRE -0.740280557 0.013188866 
TUBA1B -0.730659217 0.031643051 
IMPDH2 -0.727170212 0.016751588 
CHRNA3 -0.723569954 0.001396019 
ITGA1 -0.72265724 0.000655617 
THOC5 -0.71295444 0.011654324 
MAZ -0.712648443 0.016313182 
P4HB -0.706254071 0.016282525 
CTDNEP1 -0.698431838 0.008055964 
POM121C -0.695631769 0.011098191 
UBAP2L -0.694194823 0.033545911 
CALR -0.691395808 0.018067103 
GPC6 -0.690137144 0.013245586 
TLN1 -0.689618228 0.044426814 
ERP29 -0.682263947 0.010606499 
PSMC4 -0.676344975 0.029620917 
UBE2C -0.670668518 0.014793118 
ELAVL4 -0.660712706 0.008359706 
SSRP1 - 0.028978838 
 100 
0.655187182 
PPP1R10 -0.649988033 0.025195653 
ZMIZ1 -0.635594903 0.021128002 
DAXX -0.635336572 0.021664842 
AMZ2 -0.629571914 0.003660173 
CDK6 -0.629461946 0.036914719 
GNG5 -0.615180579 0.025011986 
SARS -0.612948603 0.029090394 
RPL35 -0.609828322 0.034048363 
CDON -0.606847892 0.005528275 
LINC00665 -0.600417696 0.033625882 
ASNS -0.596327379 0.015307451 
ATF4 -0.596270729 0.023073957 
PSME1 -0.594407247 0.044137683 
TLN2 -0.591540317 0.018244469 
TENM3 -0.590358012 0.015293699 
MAGI2-AS3 -0.588311604 0.033086028 
MPV17 -0.588286449 0.025881037 
PRMT5 -0.587111509 0.044911139 
CHMP4B -0.58273011 0.027273808 
NCSTN -0.581791732 0.024430641 
BUD31 -0.580403107 0.026871668 
NEDD8 -0.57853253 0.020812679 
PDCD11 -0.574919317 0.034829288 
HAND1 -0.572008201 0.021133806 
GCN1L1 -0.569440023 0.049475995 
WARS -0.563930867 0.018288284 




NAT10 -0.552699278 0.03358678 
CLPTM1L -0.551346166 0.023304574 
CFAP97 -0.55037668 0.024982466 
PTDSS1 -0.54849364 0.03141721 
TENM4 -0.54734415 0.034978287 
SMC6 -0.546932292 0.012938452 
RERE -0.545363082 0.034649325 
TBX3 -0.54493534 0.015685141 
PMPCA -0.539834563 0.039178313 
RET -0.533897749 0.01601111 
ZMAT2 -0.531162094 0.022096076 
XIST -0.531085678 0.023342366 
TMEM97 -0.525088624 0.015438755 
CIRBP -0.523272032 0.040949801 
SNRPN -0.517187341 0.047188755 
DNMT1 -0.511923551 0.047727604 
KIAA0100 -0.509305854 0.035930253 
LRRN3 -0.50825704 0.026821324 
STT3A -0.506456737 0.03369268 
UBAC2 -0.494430848 0.024664675 
AKAP9 -0.494027396 0.016510384 
CETN2 -0.487230186 0.031601298 
AFAP1 -0.485935841 0.029926016 
AK2 -0.47783234 0.026581472 
RNF214 -0.475111191 0.048416562 
VPS39 -0.463902402 0.044175796 
SEC23B -0.463246017 0.027346597 
NEK1 -0.460217125 0.049477908 
 102 
EP400 -0.458006277 0.047077892 
DYNLT1 -0.453987805 0.039964143 
CERK -0.450201272 0.03218758 
MCCC2 -0.445282251 0.028970421 
ZC3H13 -0.425567994 0.046122211 
RAD50 -0.424015801 0.035811552 
GTF2A2 -0.408809607 0.047162908 
JAK1 0.398300871 0.042444903 
MAPK1 0.403920802 0.037523153 
ABLIM1 0.407822267 0.046869633 
IQGAP1 0.408367593 0.046887081 
NDFIP1 0.426255978 0.038995421 
KCTD20 0.426584195 0.04934024 
TRAK2 0.427916012 0.036327304 
PPP2R5E 0.432660442 0.032612417 
ATL2 0.434027032 0.048603872 
ELF2 0.4393446 0.046964476 
UBR5 0.448036772 0.030994807 
FABP5 0.46059264 0.037855408 
SMARCA1 0.466729889 0.021270031 
TMX4 0.470648742 0.038933877 
ATAD2 0.475084659 0.017206476 
NBEA 0.479935278 0.015963637 
TFAP2B 0.480740601 0.026771089 
MALAT1 0.483375018 0.017687501 
CCND1 0.487429487 0.049048184 
FNDC3A 0.496811075 0.02182937 
NAV2 0.502379735 0.019235683 
CNN3 0.504264401 0.017258069 
IRF2BP2 0.5093795 0.028121064 
H3F3B 0.512040267 0.029571005 
TCF12 0.514909174 0.007053281 
UBE3C 0.516917015 0.008152032 
ZNF627 0.51722737 0.015800986 
DOCK7 0.521155094 0.008155624 
PPFIBP1 0.526424519 0.009218237 
ABHD2 0.533289827 0.015969993 




TCAF1 0.547181196 0.019970265 
STARD4 0.560615298 0.043783788 
DLST 0.561831892 0.046333118 
ID2 0.56325906 0.031274698 
RNF150 0.570552744 0.007960745 
ADAM22 0.574450099 0.005588434 
CD46 0.574788982 0.015493012 
TANC2 0.581402146 0.010169279 
FN1 0.584957968 0.009453243 
LGR5 0.612682686 0.002434399 
STAC 0.618234474 0.001219615 
ALCAM 0.619969531 0.006522808 
CKS2 0.6368953 0.010466104 
EDNRA 0.658950937 0.007034996 
RAD21 0.673633968 0.007476604 
LIMA1 0.693236361 0.000755359 
SORCS1 0.702804894 0.000630729 
FSTL1 0.764377934 0.000140223 
PRKCA 0.765950988 0.000336453 
CREB3L2 0.800895347 0.000469756 
AZIN1 0.835720005 0.000370476 
XPR1 0.842826623 0.000326395 
SLC6A2 0.902559617 2.20E-05 
SIPA1L1 0.904099364 0.0001465 
HDAC9 0.904693051 0.000378629 
FRMD6 0.906722651 0.000202817 
DUSP4 0.98720095 6.29E-06 
TWIST1 1.012814552 1.81E-05 
TRIB2 1.124861201 7.63E-07 
SCN9A 1.129965883 5.86E-06 
C7 1.167612531 8.70E-07 
ESRRG 1.182273941 3.33E-05 
RP11-481F24.3 1.290595996 1.45E-08 
CPE 1.323266754 2.45E-09 
PEG10 1.406166131 2.77E-08 
IL17RD 1.424414076 1.57E-12 
DKK1 1.644288922 2.21E-12 
MGEA5 1.702261181 7.53E-20 
NRCAM 1.934288314 4.99E-17 
GNG11 2.048433269 1.01E-22 
 104 
DCX 2.060765891 3.19E-18 
SGK1 2.277471985 2.15E-22 
PLCXD3 2.699059303 4.55E-20 







Table 6: GlcN gene list used for IPA analysis  
 
!! logFC PValue 
RPS11 -3.22548531 2.35E-05 
PTMS -2.046182301 9.76E-07 
TUBA1B -1.879917667 7.54E-08 
TMSB10 -1.870704304 1.72E-05 
CFL1 -1.546174471 3.84E-05 
PKM -1.505232604 5.78E-05 
CAPNS1 -1.451744755 7.24E-05 
IGF2 -1.415111687 2.30E-08 
UBC -1.399370809 0.00012405 
ERP29 -1.376501598 3.76E-07 
CALR -1.354956856 4.83E-06 
POLR2A -1.350853688 0.000633538 
ATF4 -1.33553956 5.32E-07 
UBA52 -1.333477997 6.44E-05 
CLIP3 -1.317846172 0.000452579 
RPL10 -1.315804457 0.000840155 
SUPT6H -1.284650185 8.34E-05 
HAND1 -1.279389647 3.71E-07 
CHGA -1.268354165 0.000510925 
GAPDH -1.262893693 0.000222794 
RPL7A -1.244465491 0.00018936 
NUDC -1.242362228 1.75E-05 
MT-CO3 -1.228666502 0.011055031 
GNB2L1 -1.2240911 0.00021181 
QARS -1.222550602 0.000603939 
 106 
FTSJ3 -1.219236098 0.000294765 
EIF3C -1.214081436 0.000582845 
MT-ATP6 -1.208888682 0.020471926 
RPL18A -1.192914417 0.001419253 
UBAP2L -1.186122857 0.000319863 
IMPDH2 -1.156659038 0.000160469 
EIF3I -1.144167785 0.000283796 
SSRP1 -1.133396883 0.000179628 
MAP1A -1.116638013 0.000461457 
RPLP0 -1.115316482 0.002236339 
RPL29 -1.096950136 0.00032508 
PDGFRA -1.091817707 5.60E-07 
SMARCC2 -1.087339026 0.000351224 
MT-ND5 -1.08099704 0.039691753 
MRPL37 -1.080091503 0.001196051 
MDH2 -1.077851179 0.001668437 
AHNAK -1.076559642 1.46E-05 
MYL6 -1.061201889 3.63E-05 
RPS18 -1.058620299 0.001624468 
EEF1G -1.055158341 0.00373831 
FLNB -1.054081826 0.000150823 
ATP5J2 -1.052840053 0.003076987 
PPM1G -1.050372577 0.000936779 
UBE2I -1.049636975 0.000257817 
P4HB -1.04549002 0.000408307 
CDC25B -1.043907968 0.000293597 
AARS -1.03977848 0.000897923 




GANAB -1.023214928 0.000237194 
ABCF1 -1.019670892 0.00154863 
NOMO1 -1.000695714 0.000257103 
RPL41 -0.996726326 0.002834304 
EEF2 -0.994067338 0.002097463 
RPL35 -0.993311222 0.000601764 
RELN -0.99206582 1.42E-05 
TLN1 -0.979205919 0.004516241 
MAB21L2 -0.967090374 0.000632616 
NOMO3 -0.958839472 0.001688511 
SLC39A1 -0.954783093 0.000835626 
RPS3 -0.947471519 0.002361594 
MT-CO2 -0.946278093 0.043617983 
CIRBP -0.9442862 0.000248837 
RPL12 -0.943227154 0.003664619 
PSME1 -0.929705961 0.001743191 
PSMD2 -0.928406368 0.001314969 
SNRPA -0.927066607 0.005920381 
SSR2 -0.913752596 0.001350133 
NID1 -0.912566093 1.82E-05 
CTDNEP1 -0.904537968 0.00062902 
CSNK2B -0.903683018 0.002195241 
S100A10 -0.900264302 0.001137347 
CD63 -0.895370821 0.000536769 
RPL37A -0.894477313 0.01039317 
RPL32 -0.892950377 0.005590872 
SF3B2 -0.889440512 0.008295734 
 108 
MMP2 -0.887883808 0.00477092 
GPS2 -0.881208997 0.020455783 
MANF -0.871614147 0.000194654 
DAXX -0.868244207 0.001775445 
ANXA2 -0.860435794 0.001037822 
EIF4A1 -0.855668751 0.004533314 
POM121C -0.851596529 0.001934554 
RPS15A -0.837645542 0.00201729 
RPS4X -0.835130403 0.005527749 
PRPF8 -0.834760956 0.00963452 
SETDB1 -0.831736823 0.002017257 
RPL18 -0.830177803 0.012001174 
SND1 -0.824524663 0.012411452 
PRMT5 -0.823990018 0.00503439 
BAG6 -0.813704696 0.011715432 
AKAP12 -0.809030747 0.00016659 
RPS16 -0.808168435 0.014099674 
AATF -0.806540936 0.007482898 
HUWE1 -0.806315759 0.002705815 
HDLBP -0.805103949 0.006618269 
CRMP1 -0.804904001 0.007740171 
PACS1 -0.800720499 0.008090056 
BRD2 -0.798209445 0.004142737 
UBA1 -0.797236696 0.010322846 
UBE2L3 -0.795557755 0.018172899 
RPL27 -0.789934282 0.004810893 




ARHGEF2 -0.78031508 0.007373756 
GAP43 -0.779216082 8.61E-05 
VCP -0.774321937 0.007428919 
MAZ -0.773613904 0.009207079 
RPS27 -0.773356915 0.003750255 
SEC24C -0.771494257 0.004161356 
NCSTN -0.767778464 0.003073275 
UBE2C -0.766146097 0.005459595 
FAT1 -0.765544444 0.000367826 
SMARCB1 -0.763859903 0.015912008 
PTDSS1 -0.762332768 0.00287259 
CACNG4 -0.758677273 0.00307967 
KIF20A -0.758480324 0.00354331 
PSMC4 -0.755834284 0.015230787 
SPTAN1 -0.749443924 0.005602003 
GSTM3 -0.7487231 0.029945921 
PGD -0.748030067 0.010828651 
MKI67 -0.747689275 0.00188046 
RPL26 -0.745592051 0.002079022 
PPP1R10 -0.743974382 0.010539677 
ACACA -0.738824251 0.004373437 
CHD4 -0.737497657 0.008361105 
SNRNP200 -0.734677044 0.01677819 
UXT -0.73432444 0.029152751 
EBNA1BP2 -0.733089419 0.009782487 
SARS -0.732181625 0.009273848 
PSMB7 -0.727956917 0.009711272 
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NOP56 -0.726286439 0.001331374 
CCT3 -0.716741768 0.015344614 
CERS2 -0.715389949 0.011048614 
TMSB4X -0.715184758 0.010228081 
RPL10A -0.715157412 0.038324659 
TENM3 -0.710714609 0.003554218 
RPL38 -0.707950902 0.014156962 
EIF4G1 -0.706917237 0.007589612 
RERE -0.705083641 0.006449983 
AFAP1 -0.7039821 0.001718838 
PPIB -0.701221648 0.034099479 
RPL36A -0.699011048 0.006820403 
STIP1 -0.69127169 0.017783344 
ACTR1A -0.684527826 0.017031741 
NDUFB9 -0.683828572 0.019434354 
EIF3D -0.682392139 0.01848299 
TENM4 -0.681720549 0.008740565 
SFRP1 -0.679631882 0.004235332 
FTH1 -0.67921641 0.017158094 
FDFT1 -0.676513169 0.005764419 
FOXM1 -0.673777831 0.005480087 
THOC5 -0.669142133 0.017864025 
DNMT1 -0.668873607 0.009837584 
RPS2 -0.663638592 0.043274444 
PPIA -0.662215713 0.020282527 
CKS1B -0.660488747 0.001390785 
BUD31 -0.660381525 0.011898487 




YY1AP1 -0.658425462 0.012776883 
RGS4 -0.657522844 0.001357951 
RIMS3 -0.656240482 0.0145643 
PDCD11 -0.649147429 0.017287096 
PA2G4 -0.648111642 0.018008156 
PPP1R11 -0.647721324 0.021929147 
SPARC -0.646927276 0.002936573 
HK1 -0.646342554 0.039244919 
FUNDC2 -0.64358153 0.01775531 
ARF3 -0.64333804 0.004305669 
ACIN1 -0.642461085 0.010093296 
SAFB -0.637424821 0.017633644 
CTSB -0.632680577 0.029993108 
SOGA1 -0.632629455 0.023542551 
ATP1A1 -0.63018381 0.015909115 
ACTB -0.629683485 0.029647613 
RPL3 -0.628572575 0.036778936 
GCN1L1 -0.627736397 0.030527259 
UBR4 -0.625690888 0.015761273 
SRPR -0.623579396 0.019254143 
DDX39B -0.621456332 0.006961993 
NAT10 -0.620650527 0.017146121 
SLC4A8 -0.618033071 0.0030232 
NES -0.616366567 0.029100777 
COPA -0.614062843 0.014355688 
NDUFS5 -0.609778616 0.010263996 
MCM7 -0.60963435 0.039292398 
SEP6 - 0.007970812 
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0.609164778 
SNRPN -0.606026147 0.020210175 
KDELR1 -0.605106858 0.03440662 
ZPR1 -0.604940122 0.016265433 
TRRAP -0.600171683 0.006287822 
CASC3 -0.600136446 0.012612724 
MYH10 -0.597498194 0.010557975 
RNF10 -0.593204373 0.017343642 
IGF2R -0.592953568 0.009946033 
SPTBN1 -0.592042479 0.017570762 
GON4L -0.588020084 0.031579528 
HIP1 -0.586275616 0.018671586 
H2AFY2 -0.585974046 0.030934962 
DDX24 -0.580561 0.025551272 
RET -0.579482451 0.008977665 
ICA1 -0.575553805 0.006619576 
EP400 -0.574685737 0.012849797 
PITPNA -0.572224219 0.014316427 
PFDN5 -0.570007782 0.035707386 
RPN1 -0.569862634 0.021565617 
NUDCD3 -0.567178097 0.025557214 
MAP4 -0.564871021 0.037967424 
RPS6 -0.564538316 0.035606921 
SAP30BP -0.562826004 0.029559357 
ZNF512 -0.555408711 0.009457014 
YKT6 -0.555280612 0.028472171 
CS -0.553999987 0.043618661 




NCAM1 -0.55147354 0.016854109 
LARP1 -0.550406093 0.013733488 
SF1 -0.550061371 0.047163389 
TP53BP2 -0.549729203 0.030797176 
RPL27A -0.548524254 0.044341545 
ERC1 -0.547597571 0.029919791 
SOD1 -0.546118945 0.012532181 
C7 -0.545587372 0.020391364 
ARID1A -0.539824616 0.016925311 
STT3A -0.538691871 0.023982997 
LAMC1 -0.538555825 0.017007916 
VPS26B -0.535177871 0.030816934 
SMG7 -0.532716513 0.027989765 
SIN3A -0.53258322 0.042592761 
ASXL1 -0.530197124 0.023436778 
KMT2A -0.529556472 0.030830004 
RPL6 -0.529514861 0.02865775 
RNF130 -0.528230312 0.02171543 
NCAPD2 -0.526114564 0.043900763 
TLN2 -0.523388326 0.036559026 
COPG1 -0.522697244 0.044119245 
SEC14L1 -0.521427612 0.033626925 
THOC3 -0.521400525 0.023579514 
TPM1 -0.517358886 0.021963848 
XPNPEP1 -0.51705682 0.024404862 
MRPL9 -0.507292898 0.034092372 
WIPI2 -0.504375865 0.027746182 
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SRP68 -0.503289134 0.03228419 
RPS25 -0.503202308 0.047663212 
SCG2 -0.499942438 0.018961941 
CRTAP -0.499374727 0.040521704 
CLTA -0.498804227 0.049389844 
KIAA0100 -0.498778869 0.039947844 
PLXNA4 -0.497705128 0.021459352 
C14orf132 -0.490692873 0.021445418 
JAM2 -0.489466027 0.024856031 
CDON -0.485652611 0.026119988 
APLP2 -0.483139339 0.045603705 
KDM3B -0.479753467 0.023136132 
PRC1 -0.474864854 0.022258974 
ZNF3 -0.4695101 0.040392913 
ARIH2 -0.465788317 0.046887397 
UBE2Q1 -0.464233572 0.043746258 
GATAD2B -0.463864272 0.047135895 
UTP14A -0.460348822 0.049931014 
SCRN1 -0.459078684 0.035567933 
ARNT -0.448124848 0.027023973 
UBE4B -0.447380619 0.04949097 
ASCL1 -0.446866795 0.026002839 
DENND5A -0.446772557 0.045324949 
SLC20A1 -0.429278338 0.042261343 
RAF1 -0.42510671 0.039985939 
SEC24D 0.373856909 0.041954992 
ORC2 0.385126849 0.046279304 
RFWD2 0.398954167 0.037885057 




ADAM22 0.4064219 0.049707012 
USP33 0.417250209 0.047295601 
UBE2K 0.418281214 0.049916693 
RC3H2 0.418712468 0.046308889 
CENPU 0.418760387 0.049462329 
PPP2CB 0.420943412 0.034380807 
ADO 0.424823422 0.039666453 
SNX7 0.426471908 0.040409874 
C7orf73 0.428421556 0.042726276 
PDCD4 0.429648778 0.041573843 
MALAT1 0.431437911 0.034242072 
DENR 0.4330541 0.043112607 
CCZ1 0.438259614 0.033816862 
SRSF10 0.440295505 0.044430204 
SLC7A2 0.441425173 0.034380428 
TLE4 0.441754831 0.034132896 
STARD3NL 0.444598728 0.038996223 
DNAJC10 0.444862834 0.041098912 
CAND1 0.446081472 0.047091855 
THUMPD3 0.44680257 0.042415024 
TOR1AIP2 0.449262301 0.033866578 
ATP13A3 0.451534212 0.047470236 
BRIP1 0.452416501 0.040321359 
FAM208A 0.453296834 0.039997722 
ADSS 0.453373629 0.025551974 
BLOC1S6 0.454844004 0.031366392 
EML4 0.455868452 0.046956188 
PTEN 0.457687764 0.04813261 
HNRNPA0 0.458595539 0.041372721 
NAA15 0.458689281 0.034705333 
KPNA3 0.459516859 0.046168464 
MRPL42 0.460995044 0.044020685 
DESI2 0.466222975 0.049690195 
ECT2 0.47174819 0.045370558 
ATP11B 0.473839955 0.032207808 
STRAP 0.473996474 0.030697514 
STAG2 0.475366305 0.033124777 
RSBN1L 0.475478447 0.042187338 
CEBPZ 0.475961429 0.017531781 
SGK1 0.476590583 0.036622195 
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C1orf112 0.476728967 0.018975063 
FNTA 0.477656588 0.018391283 
SF3B6 0.478313408 0.028296054 
VPS13A 0.479187185 0.030300953 
ACTR2 0.481151912 0.047544539 
SIKE1 0.483376267 0.046240972 
GNG12 0.486971165 0.036471776 
EXTL2 0.488275838 0.034426432 
PSMD12 0.489125873 0.026407304 
ATP11C 0.491682441 0.02294183 
SLC4A7 0.491703374 0.047921546 
PRKD3 0.491728899 0.035882594 
TRPM7 0.492725154 0.040652685 
KRR1 0.493663748 0.049425754 
GGCT 0.49424728 0.020448593 
PURB 0.495093403 0.034487529 
MSH2 0.496425736 0.046743655 
HAUS6 0.497044384 0.027725176 
DEK 0.498577957 0.048064857 
ZBTB44 0.501026351 0.033009098 
WDR36 0.502866781 0.023531701 
EXOC5 0.504949385 0.040848328 
FAM98B 0.506125364 0.025988397 
PNO1 0.510120268 0.041197502 
CD46 0.511975868 0.031007583 
DYNC1LI1 0.513185913 0.020007663 
NDC80 0.515990727 0.027501917 
ICE2 0.516364882 0.016098486 
LTN1 0.516865405 0.029168979 
BZW1 0.517243924 0.039611884 
GEN1 0.521059619 0.044328841 
TMEM165 0.521524523 0.019887733 
KNTC1 0.521812007 0.010814285 
PPIP5K2 0.522578637 0.02121959 
GTF3C6 0.522733675 0.02114604 
TTC8 0.523502302 0.015828415 
GCSH 0.524065189 0.026857462 
SMC2 0.526218926 0.014951571 
OSBPL8 0.526478052 0.026100384 
ABCE1 0.528202237 0.035976579 




SRSF11 0.530030416 0.024554145 
SEH1L 0.531568546 0.012166801 
PCNA 0.534217703 0.023683686 
TFAM 0.536775231 0.027384851 
PCNP 0.536955247 0.041767613 
PHF6 0.537538285 0.018910978 
NCAPG 0.538895563 0.011993385 
COX7C 0.539637674 0.024358263 
DCAF13 0.542195013 0.015673761 
HIGD1A 0.542298614 0.030786342 
C6orf62 0.542806199 0.013342723 
RAD21 0.544372769 0.030404265 
POLR2M 0.547581428 0.026290652 
GNPNAT1 0.550681541 0.025914652 
MAT2B 0.550741813 0.018575729 
TMEM30A 0.55102192 0.026917315 
RB1 0.553879463 0.014925876 
OSTC 0.553977859 0.021737994 
BNIP2 0.554001485 0.015297166 
SOCS4 0.562252875 0.035006224 
RFC3 0.563171996 0.00860644 
USMG5 0.563745341 0.026897771 
HOOK3 0.563931747 0.01940759 
AGPS 0.564570998 0.007003106 
LIMA1 0.565326949 0.005957992 
MAP9 0.572623367 0.012097032 
EGLN1 0.572705063 0.029666026 
USP1 0.573950768 0.011623638 
WRN 0.57680754 0.010589966 
SLC6A15 0.577438896 0.00727042 
NAE1 0.577662666 0.023700541 
SMN2 0.57950038 0.003784391 
RAD1 0.580377877 0.00704437 
UBA6 0.581579426 0.018486879 
CKS2 0.581759577 0.019301158 
DEPDC1 0.583857943 0.028665198 
PPA2 0.584666401 0.010621163 
MTPN 0.585120335 0.028157416 
UHMK1 0.586236814 0.014287435 
TMX3 0.588144213 0.029656312 
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KCTD12 0.592893311 0.031137575 
CCDC90B 0.59390345 0.025330841 
ID2 0.595614455 0.022825072 
TMEM106B 0.59573737 0.026113432 
TRIB2 0.597201737 0.008262241 
CCDC25 0.598452386 0.005930061 
PPP1CB 0.598881591 0.03785458 
MFN1 0.599206145 0.016720707 
ECHDC1 0.599902403 0.02295611 
CENPH 0.605621328 0.016496252 
SPCS3 0.607757251 0.02517903 
PPP2R5E 0.609956712 0.002624983 
CAPZA2 0.610555175 0.03736812 
IL17RD 0.614346014 0.002037409 
NRCAM 0.616146235 0.006018163 
LSM5 0.616351534 0.026022315 
GTF2A1 0.618844647 0.018352446 
ARL5B 0.62235564 0.018691811 
ATL2 0.624208475 0.004637697 
CYCS 0.633041606 0.028610661 
SMAD9 0.633606902 0.021234545 
IER3IP1 0.637503727 0.010426087 
MAD2L1 0.6376872 0.007801153 
PM20D2 0.638223924 0.009047824 
TMEM167A 0.639409034 0.00983525 
DR1 0.642032937 0.021298702 
LRRC58 0.643890773 0.024664326 
SLC6A2 0.648355535 0.002247475 
SCN9A 0.649198785 0.008885445 
DCP2 0.650519857 0.00713944 
CDK1 0.65449131 0.016043545 
CMPK1 0.66072971 0.013545926 
TSNAX 0.677498888 0.010692415 
STARD4 0.681003543 0.014434392 
ZWILCH 0.68116595 0.00583738 
GULP1 0.681354217 0.028707305 
EID1 0.682005873 0.030874475 
KRAS 0.684820319 0.00796092 
RNF11 0.685100389 0.015909417 
CD164 0.686927483 0.018436526 




TWF1 0.689926572 0.028525407 
GMFB 0.690219098 0.019613501 
G2E3 0.691420291 0.025158807 
EIF1AX 0.698255698 0.019373384 
CBFB 0.703332894 0.018253823 
CCNC 0.705235943 0.012675998 
MMP16 0.709177388 0.006364951 
NBEA 0.712396317 0.000356862 
YIPF4 0.719401214 0.002412642 
ESRRG 0.744728199 0.008581295 
HAT1 0.750059426 0.003969555 
CEP44 0.751318747 0.005755674 
TWIST1 0.752714522 0.001397533 
NDUFB6 0.777413315 0.044931393 
ACTR6 0.803625714 0.006032362 
MPP6 0.850937415 0.00016691 
MZT1 0.856832499 0.005893811 
FRMD6 0.868642632 0.000370383 
HDAC9 0.930311296 0.000258633 
ATP7A 0.994206259 1.41E-06 
MGEA5 1.029759892 2.20E-08 
PLCXD3 1.098396638 0.000101694 
RP11-481F24.3 1.162426643 3.10E-07 
C18orf32 1.218130265 4.23E-05 
DKK1 1.274701245 3.95E-08 
GNG11 1.400880484 8.64E-12 
CH507-513H4.3 1.71524385 0.047488558 
CH507-513H4.4 1.715243851 0.047496103 
CH507-513H4.6 1.715243852 0.047500949 




3.3.6 Prolonged TMG or GlcN Treated Cells Generated Less Reactive Oxygen Species (ROS) 
TMG or GlcN could affect cellular ROS levels, including reactive nitrogen species (RNS), 
hydroxyl radical (!OH), hydrogen peroxide (H2O2), and superoxide (O2!-) (Figure 16A). Total 
ROS (RNS, !OH and H2O2) was reduced in both TMG- and GlcN-treated SH-SY5Y cells 
(Figure 16B). Superoxide levels were reduced in TMG-treated cells (Figure 16C). Total ROS 
and superoxide levels were lower in TMG-treated NT2 cells, while GlcN-treated NT2 cells 
trended lower (Figure A.4A-B). Because NADPH oxidase is a major source of cytoplasmic ROS 
[76], we found that both TMG and GlcN treatment decreased NADPH oxidase protein levels  in 
SH-SY5Y cells (Figure A.4C). Together, these data indicated that prolonged elevations of O-





Figure 16: TMG or GlcN cells generated less reactive oxygen species (ROS) 
(A) Representative schematic displaying cytoplasmic ROS (total ROS: HO!, H2O2, RNS!) and 
mitochondrial ROS (superoxide: O2!-). (B) Total ROS and (C) superoxide level (average ± SEM, 
n=9) were decreased. ROS assay results have been replicated in at least three independent 
experiments. * indicates significance p < 0.05.  ** indicates significance p < 0.01. *** indicates 
significance p < 0.001. 
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3.3.7 O-GlcNAc Regulates NRF2 Function 
We hypothesized that O-GlcNAc could be directly modulating NRF2 function. TMG lowered 
NRF2 protein and NRF2 transcript levels (Figure 17A-B). TMG lowered NRF2 target gene 
Thioredoxin reductase 1 (TXNRD1) transcript level (Figure 17C) and reduced Superoxide 
Dismustase 1 (SOD1) and Thioredoxin (TXN) protein levels (Figure 17D). However, TXNRD1 
and Peroxidase 1 (PRX1) protein expression were not altered (Figure A.5D). Interestingly, both 





Figure 17: O-GlcNAc regulates NRF2 Function 
Representative results shown for (A) NRF2 protein level (n=3), (B) NRF2 (n=5) and (C) 
TXNRD1 (n=4) transcript levels, and (D) SOD1 (n=7) and TXN (n=4) protein levels. (E) 
Immunoprecipitation results showed increased NRF2 O-GlcNAcylation (n=3). Protein levels 
were first normalized with loading control Actin, then normalized to control samples. Transcript 
levels were measured by qRT-PCR and normalized to GAPDH levels. * indicates significance p 
< 0.05.  ** indicates significance p < 0.01. *** indicates significance p < 0.001. 
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Because O-GlcNAcylation of transcription factors influences their cytolocalization [77], 
we fractionated the nuclear extract from the cytoplasm, and found increased O-GlcNAcylation 
did not alter the nuclear-NRF2 protein levels. TMG did reduce the cytoplasmic NRF2 protein 
levels (Figure A.5A). Since O-GlcNAcylation promotes protein stability [78, 79], we pretreated 
SH-SY5Y cells with cycloheximide (CHX) to inhibit protein translation [80] and harvested cells 
at different time-points after CHX treatment in relation to control cells. We observed no change 
in NRF2 protein levels in O-GlcNAc-elevated cells between 0 h to 6 h after CHX treatment 
(Figure A.5B). NRF2 binding partner KEAP1-E3-ligase complex (Kelch-like ECH associated 
protein 1) promotes degradation of the transcription factor. However, KEAP1 protein levels did 
not change after TMG and GlcN treatment (Figure A.5C), suggesting that the TMG mediated 
decreased in NRF2 protein level was not due to altered stability of the protein but due to the 
decrease in the transcript.  
MnSOD, a non-NRF2 controlled antioxidant enzyme, is a major antioxidant enzyme 
present in mitochondria and is essential for the removal of superoxide  generated by the ETC 
complexes [81]. MnSOD protein level was decreased in both TMG- and GlcN-treated SH-SY5Y 
cells (Figure A.5E). Because several antioxidant response pathways were down regulated with 
TMG and GlcN treatment, we treated SH-SY5Y cells with 50 µM or 100 µM H2O2 for upwards 
of 7 h to induce oxidative stress [82], and measured cell viability. TMG increased cell viability in 
100 µM H2O2 (Figure A.5F). Total O-GlcNAcylation level was robustly increased after 
oxidative stress induction in control cells (Figure A.5G), and the apoptosis marker, cleaved-poly 
(ADP-ribose) polymerase (PARP) protein, was increased after oxidative stress (Figure A.5G). 




A.5G). Likely, the increased cell viability in TMG-treated cells was due to increased O-
GlcNAcylation mediating other stress response pathways [83]. 
3.3.8 Prolonged Elevations of O-GlcNAcylation Decreased Mitochondrial Respiration and 
ROS Generation in Mice Tissue 
Because long-term TMG treatment reduced mitochondrial respiration in cell lines, we used TMG 
to replicate the cell line data in mice. We intraperitoneally injected TMG into C57B6J mice at a 
concentration of 50 mg/kg [72] every other day for 15 days prior to sacrificing the animals.  
Liver and brain tissues were then used for subsequent experiments (Figure 18A). TMG robustly 
elevated brain O-GlcNAcylation and OGA expression and reduced OGT protein levels (Figure 
18C). Similar results were obtained in the livers of TMG-treated mice (Figure A.6A).   
Next, we purified and pooled mitochondria from four TMG and four control mouse 
brains and performed ex vivo respiration assays [67]. TMG lowered basal respiration (basal, in 
the presence of substrate, but no ADP) as well as phospho-relating respiration (State 3, + ADP), 
resting respiration (State 40, proton leak rate, + oligomycin), and uncoupled respiration (State 3u, 
maximal respiratory rate, + FCCP). Anoxic respiration (+ Antimycin A) was the same between 
control and TMG-treated mouse brain (Figure 18E). TMG reduced liver mitochondrial 
respiration of State 3 and State 40 (Figure A.6B). Superoxide level was lower in TMG-treated 
brain (Figure 18H) and liver (Figure A.6C). Brain NRF2 protein level was decreased in TMG-
injected mice (Figure 18J). Sustained inhibition of OGA in mouse brain and liver tissue 
replicated the data from cell lines suggesting that the metabolic changes seen with TMG were 
independent of cell type and were an adaptive mechanism to OGA inhibition. 
 126 
3.3.9 OGT Knockdown Impaired Mitochondrial Respiration and Increased ROS Generation 
in Mice Liver 
To understand how the loss of OGT affects cellular energetics, we generated conditional OGT 
liver knockout C57B6J mice by intraperitoneal injection of AVV-GFP-Cre virus. Fifteen days 
after viral injection, liver tissue was harvested (Figure 18B). Liver O-GlcNAcylation and OGT 
protein levels were reduced (Figure 18D). OGT knockdown decreased ex vivo basal liver 
respiration, as well as State 3, State 40, and State 3u. No difference was measured in anoxic 
respiration (Figure 18G). In contrast to TMG treatment, the mitochondrial superoxide levels in 
the OGT knockdown mouse livers were increased (Figure 18I). NRF2 protein level and its 






Figure 18: Elevated O-GlcNAcylation decreased mitochondrial respiration and ROS 
generation while OGT liver knockdown impaired mitochondrial respiration and increased 
ROS generation 
(A) Experimental design of TMG dosed mice and (B) liver specific-OGT knockdown mice. 
Total O-GlcNAcylation, OGA, OGT, and GAPDH (loading control) levels in (C) TMG-treated 
mouse brain and (D) OGT-knockdown mouse liver (n=11). Oxygen Consumption Rate (OCR) 
profile on isolated mitochondria from (E) long-term TMG-treated mouse brain and (F) OGT-
knockdown mouse liver. The assays were done using pooled mitochondria from five mice for 
each condition, and the results were replicated in three independent experiments. Mitochondrial 
superoxide level (n=6) in (G) TMG-treated mouse brain showed decreased superoxide levels, but 
(H) OGT-knockdown mouse liver superoxide was increased. (I-J) NRF2, KEAP1, (K-L) TXN, 
and GAPDH (loading control) levels for TMG treated mice (n=8) and OGT-knockdown mice 
(n=6). Average protein level displayed was normalized to GAPDH. * indicates significance p < 





3.3.10 Prolonged O-GlcNAc Elevation Promoted Weight Loss including Reduction of Lean 
Mass, Fat Free Mass, and Water Mass 
Next, we determined whether long-term elevation of O-GlcNAc altered whole body 
composition. Total body weight of TMG-treated mice was lower after the 2-week treatment 
period (Table 7); however, control mice gained weight (Figure 19A). TMG treatment resulted in 
a reduction in lean mass percentage compared to control mice (Figure 19B). Although we did 
not find a significant difference in the body fat mass percentage (Figure A.7A), the free fat mass 
percentage (all other mass other than fat mass) in TMG-treated mice was lower (Figure 19C). 
Furthermore, TMG treatment reduced body water mass percentage (Figure A.7E). 
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Before Injection After Injection 
  Saline TMG Saline TMG 
     
Body weight, g 26.07±0.95 27.44±0.60 26.86±0.88 27.42±0.98 
     
 
p = 0.244 p = 0.579 






3.3.11 Long-Term TMG Treatment Lowered Energy Expenditure and Oxygen Consumption, 
Skewing Mice Toward Carbohydrate Metabolism 
Because TMG down regulated mitochondrial respiration and reduced free fat mass body 
composition, we postulated that the whole-body energy metabolism of the TMG-treated mice 
would be altered. Two-week TMG treatment reduced total energy expenditure (EE) and resting 
EE at nighttime (most active) (Figure 19D-E), but no changes were measured during the 
daytime (less active) (Figure A.7G-H). When these mice entered the night cycle, the average EE 
pattern of TMG-treated mice was higher, then declined back to control levels when they re-
entered the light cycle (Figure A.7Q). TMG-treated mice energy balance (calories from food 
consumption) was not changed during the light or night cycles (Figure A.7B, A.7H).  
TMG treatment resulted in a significantly lower OCR especially during the nighttime (O2 
consumption and CO2 elimination, Figure 19F-G). The OCR was not changed significantly 
during daytime (Figure A.7J-K). The Respiratory Exchange Ratio (RER, ratio of whole-body 
CO2 production to O2 consumption) determines the relative contribution of carbohydrates and 
lipids to overall energy expenditure [84]. The average RER in TMG-treated mice was increased 
during either the daytime or nighttime cycle, but not significantly (Figure A.7C, A.7L). 
However, basal RER during the daytime cycle was increased in the TMG-treated mice (Figure 
A.7M). Hourly RER at day fifteen following TMG-injection was higher during the daytime 
cycle in TMG-treated mice, while nighttime RER values in both control and TMG-treated 
animals were equivalent. Again, when TMG-treated mice re-entered the light cycle, their average 
hourly RER remained significantly higher compared to control mice (Figure 19K).  These data 
showed that TMG-treated mice utilized carbohydrates as their predominant source for energy 
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throughout a 24-hour cycle, even during the inactive daytime cycle when lipid oxidation is 
preferred. 
3.3.12 TMG Treated Mice were Less Active than Control Mice 
Next, we assessed the physical activity of the TMG-treated mice. During the nighttime, TMG-
treated mice had less X-, Y-, and Z-axis beam break activity (Figure A.7D) and total activity 
(sum of X- and Y- axis beam breaks) compared to control mice (Figure 19H, 19L). No changes 
between TMG and saline-treated mice during the daytime cycle were found (Figure 19L, Figure 
A.7N). Although locomotion speed was unchanged (Figure A.7N), TMG-treated mice walked 
significantly less distance than control mice during the nighttime cycle (Figure 19I). The 
distance traveled during the daytime cycle was not different (Figure A.7O). Finally, TMG 
treatment increased the sleep duration during the nighttime cycle compared with saline-treated 







Figure 19: O-GlcNAc elevation altered energy metabolism profile in mice 
Representative plots shown (A) weight, (B) lean mass, and (C) fat mass differences (n=8) for 
mice after two weeks of TMG-treatment (50mg/kg). Nocturnal results of (D) total energy 
expenditure (EE), (E) total resting EE, (F) average oxygen consumption rate, (G) carbon dioxide 
exhaling rate, (H) total activity, (I) pedestrian distance, and (J) sleep duration. (K) Double 
plotted hourly respiration exchange ratio (RER, VCO2/VO2) calculated the last day of TMG 
injection.  Dotted line represents blot replication (n=8, * indicates p < 0.05). (L) Hourly X-beam 
break plot. Permutation test (10,000 cycles) of hourly RER during light cycle (p=0.034) and X-






Our data demonstrate a fundamental role for O-GlcNAcylation in regulating mitochondrial 
function and whole-body energy metabolism. GlcN supplementation increased O-GlcNAcylation 
and induced a phenotype of increased mitochondrial respiration and reduced ROS production. In 
contrast to GlcN, TMG-treated cells or mice became less ETC-dependent, maintaining lower 
oxygen consumption rates due to reduced respiration. Prolonged TMG-treated animals shifted 
their metabolism toward carbohydrate utilization and reduced their physical activity. In contrast, 
decreased respiration caused by prolonged TMG treatment did not impair mitochondrial function 
and generated less ROS.  Loss of O-GlcNAcylation by liver specific OGT knockdown lowered 
and impaired mitochondrial respiration, robustly elevating superoxide levels. Importantly, these 
results support the notion that O-GlcNAcylation in maintaining proper mitochondrial function 
while complete loss of O-GlcNAc negatively impacts cellular energetics.  
Prolonged inhibition of OGA or elevation in OGT substrate availability led to dramatic 
changes in mitochondrial respiration, duplicating results from prolonged GlcN treatment in C. 
elegans and mice [62]. However, genetic ablation of OGT dramatically lowers the basal level of 
O-GlcNAc, producing severe metabolic phenotypes [31-33], while OGT or OGA over-
expression impairs respiration [65]. Recently, RNAi mediated knock-out in HeLa cells of the 
mitochondrial form of OGT (mOGT), which is only expressed in a few mammals including 
primates [85], in HeLa cells caused mitochondrial fragmentation and reduced membrane 
potential, while knock-out of both mOGT and the nuclear and cytoplasmic form of OGT lead to 
a compensatory increase in mitochondrial respiration, partially due to the decrease in 
mitochondrial content [86]. Even though TMG treatment lowered mitochondrial respiration in 
our current study, ROS was not increased, suggesting an intervention that raises both O-GlcNAc 
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and OGA expression promotes a healthier metabolic phenotype than genetic manipulation of 
OGT or OGA alone.  
TMG and to some extent the GlcN-treatment produced a two-stage adaptive process. 
First, total cellular and mitochondrial O-GlcNAc levels increased, promoting increased 
respiration [11] and signaling from the mitochondria to the nucleus via increased ROS 
production [87]. This was followed by O-GlcNAc mediated changes in the transcriptome, 
resulting in longer mitochondria, reduced energetic demand and ROS generation. Many ETC 
complex subunits are heavily modified by O-GlcNAc [12], and short-term elevation of O-
GlcNAc increased mitochondrial respiration and ATP production in rat cardiomyocytes [11, 12]. 
The initial induction of respiration caused by increased O-GlcNAcylation transmits a signal to 
the nucleus that alters gene transcription. After adaptation to sustained elevations in O-GlcNAc, 
mitochondrial respiration decreases. The changes in respiration are due to a combination of 
altered gene expression and ETC function. We observed that both in vivo complex I and IV 
activity were increased after TMG treatment, demonstrating that the decreased respiration was 
not solely due to ETC activity suppression. The mitochondrial membrane was hyperpolarized, 
suggesting that the ETC was functioning at capacity; however, proton recycling from the 
intermembrane space into the inner mitochondrial space was decreased.  Potentially, the slower 
proton-recycling rate was due to suppression of ATP synthase caused by a decrease in ATP 
synthase subunit expression (ATP6) or O-GlcNAcylation of ATP synthase subunits [12].   
The combination of lower mitochondrial respiration, no change in proton leak rate, and 
hyperpolarization of the mitochondrial membrane reduced mitochondrial ROS production. 
Consequently, the decrease in ROS signaling led to lower expression of antioxidant response 




antioxidant and growth programs in response to changes in the environment [87]. TMG or GlcN 
treatment does not preclude the generation of ROS, but the basal ROS level was lowered. Since 
the cell did not need robust antioxidant responses, NRF2 gene programs were reduced. Under 
low ROS conditions, KEAP1 constantly degrades NRF2; however, elevated ROS oxidizes 
cysteine residues on KEAP1 leading to the release of NRF2, translocation into the nucleus, and 
initiation of antioxidant gene expression including NRF2 itself [88]. The decrease in NRF2 
mRNA expression was due to long-term TMG treatment reprograming NRF2 transcription. 
Likely, the transcriptome reprogramming by TMG or GlcN treatment was due to changes in O-
GlcNAc mediated transcriptional and epigenetic regulation. O-GlcNAc not only influences 
chromatin, but also chromatin readers, writers, and erasers, thus complicating the specific roles 
of long-term O-GlcNAc elevation in transcriptional reprogramming [89]. Of note, only specific 
gene networks were affected by long-term increased O-GlcNAcylation, suggesting that the 
combination of elevated O-GlcNAc and OGA expression must target these networks in some 
manner. Future investigation into these mechanisms is warranted.   
The cellular reprogramming caused by elevations in both O-GlcNAc and OGA has a 
consequence on the energetic needs of animals. TMG-treated mice shifted their energy 
metabolism away from oxidative phosphorylation and towards glycolysis. The TMG-treated 
mice did not show a need for greater energy demand since sleep time was increased, movement 
was reduced, and energy expenditure were all lower. TMG treatment-induced metabolic changes 
in the mice would influence chronic diseases. Previously, mitochondrial function was impaired 
under diabetic conditions [30, 90], with O-GlcNAc levels higher in rat diabetic cardiomyocytes 
without the concomitant increase in OGA expression. Importantly, adenoviral overexpression of 
OGA led to improved mitochondrial function and calcium handling in diabetic cardiomyocytes 
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and improved coronary endothelial cell function in diabetic mice [91, 92].  Furthermore, OGA 
overexpression lowered O-GlcNAc levels and improved outcomes in mouse models of stretch-
induced cardiac hypertrophy [93]. Together, these data demonstrate that sustained elevations in 
O-GlcNAc without the concurrent increase in OGA expression was detrimental to cells; 
however, cellular function could be restored with OGA over-expression. 
The combination of increased O-GlcNAcylation and OGA expression could restore some 
metabolic function lost in chronic metabolic diseases such as Alzheimer’s disease (AD). TMG 
and TMG derivatives are actively being investigated as potential therapeutics for AD [94]. The 
argument for inhibiting OGA in AD patients is that the treatment will increase O-GlcNAcylation 
of Tau, preventing Tau phosphorylation and subsequent Tau tangles [95-97]. Treatment with 
TMG does increase Tau O-GlcNAcylation and improve outcomes in animal models of 
Tauopathies [95]. Our data argue for additional metabolic benefits for brain health after 
prolonged TMG treatment. Mitochondrial dysfunction is a characteristic of AD, and the 
mitochondrial cascade hypothesis argues that loss of mitochondrial function over time alters 
metabolite production and increases the generation of ROS causing neuronal damage and cell 
death [20]. Screening of adult children of parents with AD demonstrates a decrease in 
mitochondrial function prior to the onset of any cognitive impairment or increased production of 
beta-amyloid [98]. The TMG-treated animals had lower mitochondrial respiration and ROS 
production, but with a shift toward glycolysis which could slow AD development.   
Long-term TMG treatment shows no adverse effects on animal health [99], nor does 
TMG-treatment promotes insulin resistance like less selective OGA inhibitors [100, 101]. O-
GlcNAcylation dampens insulin signaling by modifying several proteins in the insulin signaling 




contributing to the ablation of insulin signaling [38, 104].  O-GlcNAcylation is increased in 
diabetic tissue, suggesting that the increase in glucose availability induces more flux through the 
HBP, increases O-GlcNAcylation of insulin signaling proteins, and leads to a decrease in 
responsiveness to insulin [105]. Yet TMG treatment of animals increases O-GlcNAc levels 
without producing diabetes [99].  We argue that the combination of increased carbohydrate 
usage, O-GlcNAcylation and OGA expression seen with long-term TMG treatment explains why 
TMG treatment does not induce diabetes and could potentially make these animals more 
sensitive to insulin. 
In conclusion, long-term elevation in O-GlcNAcylation coupled with an increase in OGA 
expression modulates mitochondrial function and reprograms the transcriptome to favor a 
reduction in antioxidant response, and lower ATP production. These profound changes in 
metabolism caused mice to sleep more, move less, reduced body mass, and increased 
carbohydrate metabolism (Figure 7). These physiological changes suggest that long-term 
increases in O-GlcNAcylation followed by a concurrent increase in OGA expression changes the 
metabolic program of animals without causing adverse effects. Potentially, progression of 
chronic metabolic diseases such as diabetes and Alzheimer’s would be positively impacted by a 




Figure 20: O-GlcNAc regulates energy metabolism by reprogramming mitochondrial 
function 
Representative model for prolonged O-GlcNAcylation and OGA expression leading to 
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O-GlcNAc, OGT, OGA, GFAT1 levels of (A) whole cell, (B) cytoplasm and mitochondrial 
content in SH-SY5Y cells, and (C) NT2 whole cell. For whole cell or cytoplasmic extract, actin 
was used as loading control, while VDAC and citrate synthase (CS) was used as a loading 
control for mitochondrial extracts (n=3). (D) OGA, OGT (MGEA5), and GFAT1 transcript levels 
were determined using qRT-PCR (n=3). (E) OGA activity (n=3). (F) Representative graph of the 
bioenergetics profile in SY5Y cells. (G) Maximal respiration rate, (H) reserve capacity rate, and 
(I) ATP production rate (average ± SEM, n=6). (J) Bioenergetics profile of NT2 cells, (K) basal 
respiration rate, (L) leak rate, (M) maximal respiration rate, (N) reserve capacity rate, and (O) 
ATP production rate (average ± SEM, n=6). NT2 cell representative plots showing (P) cellular 
ATP levels (average ± SEM, n=9) and (Q). glycolysis rate (n=6). * indicates significance p < 
0.05.  ** indicates significance p < 0.01. *** indicates significance p < 0.001. 
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Figure A. 2: Prolonged TMG or GlcN treatment alter mitochondrial bioenergetics (cont.) 
Representative plots showing SY5Y (A) COXIV Vmax and (B) CS activity after being 
normalized with total protein concentration (n=3). (C) Mitofusin 1 (MFN1), Mitofusin 2 
(MFN2), and Dynamin-like protein (DLP1) protein levels. Protein levels were first normalized to 
actin level, then normalized to control cells (n=3). * indicates significance p < 0.05.  ** indicates 





Figure A. 3: Transcriptome Alterations from Sustained TMG or GlcN treatment 
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(A) Heat map of top 100 genes with cpm (counts per million) of >10 in at least two of the three 
replicate samples generated from Next Generation RNA-Sequencing (RNA-seq) analysis.  
Volcano plots for (B) TMG and (C) GlcN compared to control cells. Orthogonal validation of 
(D) TFPI2 and GNG1 transcript levels and (E) ATF4 and IGF2 transcript levels (average ± SEM, 
n=3). (F) TFAM protein levels after actin level and control normalization (average ± SEM, n=3). 
Plots obtained from c2 gene sets from GSEA analysis comparing long-term TMG treatment to 
(G) insulin resistance (Sartipy_Normal_At_Insulin_Resistance_Up gene set), (H) aging 
(Demagalhaes_Aging_Up gene set), and (I) metastasis (Jaeger_Metastasis_DN gene set) gene 
sets. * indicates significance p < 0.05.  ** indicates significance p < 0.01. *** indicates 






Figure A. 4: Prolonged TMG or GlcN treatment reduced ROS generation 
(A) Total ROS and (B) superoxide level in NT2 cells (average ± SEM, n=9). (C) NADPH 
oxidase levels after prolonged TMG or GlcN treatment in SH-SY5Y cells (average ± SEM, n=3). 




Figure A. 5: NRF2 localization, protein stability, and acute oxidative stress response were 
not altered by TMG or GlcN treatment 
(A) NRF2 localization was not altered in TMG- or GlcN-treated SH-SY5Y cells. (B) NRF2 
protein stability after cycloheximide treatment with p53 as positive control for the treatment. 




control. (C) KEAP1, (D) TXNRD1, and PRX1 protein levels in TMG- or GlcN-treated SY5Y 
cells. Actin was used as loading control, and the protein levels were further normalized with the 
control. (E) Mitochondrial MnSOD1 protein level is significantly decreased after TMG or GlcN 
treatment in SH-SY5Y cells.  Cells were separated into cytoplasm and mitochondria fraction. 
VDAC was used as the loading control for mitochondrial fraction and actin was used as 
mitochondrial fraction negative control (average ± SEM, n=3).  (F) Cell viability plot after acute 
oxidative stress test in TMG- or GlcN-treated SH-SY5Y cells (average, ± SEM, n=3). (G) O-
GlcNAc, OGA, OGT, NRF2, C-PARP, Catalase, TXNRD1, PRDX1, SOD1 and TXN protein 




Figure A. 6: Long-term TMG injection decreased mitochondrial respiration and ROS 
generation in liver 
(A) Total liver O-GlcNAcylation, OGT, and OGA protein level in prolonged TMG dosed mice 
(average, ± SEM, n=4). GAPDH is the loading control. (B) Mitochondrial respiration (C) and 






Figure A. 7: O-GlcNAc elevation altered energy metabolism in mice 
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(A) Body fat mass differences percentage calculated from the percentage difference of before 
and after injection (saline or TMG) (average, ± SEM, n=8). Representative plots illustrating 
nocturnal (B) energy balance (total energy intake – total energy expenditure), (C) average 
respiratory exchange ratio (RER), (D) total activity based on Y-axis, X-axis, and Z-axis beam 
breaks. (E) Body water mass difference percentage calculated by taking the percentage of the 
differences of water mass before and after injection (saline or TMG) (average, ± SEM, n=8). 
Representative plots of nocturnal (F) mean locomotion speed, (G) diurnal total EE, (H) total 
resting EE, (I) energy balance, (J) average VO2, (K) average VCO2, (L) average RER, (M) 
lowest activity RER, (N) total activity, (O) pedestrian distance, and (P) sleeping hours. (Q) The 
average EE for the last 24 h time after TMG injection was plotted. * indicates significance p < 






Appendix B: O-GlcNAc Cycling is Important in Regulating Mitotic Spindle Organization- 
Part I 
Reproduced with permission from Tan, E.P., Caro, S., Potnis, A., Lanza, C., and Slawson, C. 
(2013). O-linked-N-Acetylglucosamine Cycling Regulates Mitotic Spindle Organization. The 
Journal of Biological Chemistry 288(38):27085-99 
B.1 Introduction 
The segregation of chromosomes into two daughter cells with perfect fidelity is crucial to the 
process of cell division. Daughter cell segregation is highly dependent upon the construction and 
organization of the mitotic spindle [106, 107].  As a cell enters mitosis, the duplicated 
chromosomes start to condense and spindle assembly begins. Microtubules radiate outward from 
the two centrosomes located at opposite poles of the cell and embed themselves into 
kinetochores assembled on the centromere of each chromosome [108]. In this manner, sister 
chromatids are attached to two microtubules from opposite centrosomes, and when the 
separation and segregation of these chromosomes ends, each daughter cell will contain an exact 
copy of all 23 chromosomes [109].  Mitotic success rests on the correct orientation of sister 
chromatids bound to microtubules.  Problems at any point in this extensive yet rapid process are 
detrimental to both subsequent daughter cells.  Defects in correct segregation of sister chromatids 
lead to mitotic catastrophe, apoptosis, or aneuploidy [110].   
Mitotic phosphorylation cascades control spindle assembly and organization [111, 112].   
Initially during prophase, cyclin-dependent kinase 1 (CDK1) phosphorylates proteins involved in 
nuclear envelope breakdown and spindle formation.  Shortly thereafter, Aurora Kinase A (AurA) 
and Aurora Kinase B (AurB) phosphorylate the histone H3 variant CENPA, promoting 
microtubule attachment to kinetochores and chromosome alignment [111].  Polo-like Kinase 1 
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(PLK1) phosphorylates targets at the centrosomes, kinetochores, and kinetochore microtubules 
[113]. At the same time, the Chromosomal Passenger Protein Complex (CPC), composed of the 
proteins AurB, Survivin, Borealin, and the inner centromere protein (INCENP), localize to the 
spindle midzone to ensure the proper phosphorylation of substrates involved in condensation of 
chromosomes, correction of microtubule-kinetochore attachments, and the activation of the 
spindle assembly checkpoint [114-116].    As the enzymatic core of the CPC, activation of AurB 
is of extreme importance during mitosis [117, 118] and altered AurB activity can lead to 
improper chromosome segregation and cell division [119, 120].   
In addition to phosphorylation, the post-translational modification of proteins with O-
linked N-acetylglucosamine (O-GlcNAc) regulates cell cycle progression [121, 122]. O-GlcNAc 
occurs on serine or threonine residues of nuclear and cytoplasmic proteins consisting of the 
addition of a single N-acetylglucosamine moiety [35].  O-GlcNAcylation regulates many cellular 
processes including cell growth and survival [35].  Aberrant O-GlcNAcylation underlies various 
pathologies such as type II diabetes, neurodegenerative diseases and cancer [35].  Two highly 
abundant enzymes add or remove O-GlcNAc in response to the cellular environment in a process 
called O-GlcNAc cycling.  O-GlcNAc transferase (OGT) adds O-GlcNAc to proteins using the 
metabolite UDP-GlcNAc (Uridine Diphospho-N-acetylglucosamine) while O-GlcNAcase (OGA) 
is responsible for its removal [35].  
Increased expression of OGT leads to mitotic defects and an increased incidence of 
aneuploidy [121].  These results are partially due to alterations in mitotic signaling cascades 
[123].  CDK1 activity is severely reduced in cells with elevated OGT levels, due to an increase 
in the inhibitory phosphorylation of CDK1 mediated by alterations in the expression of upstream 




midbody, and together, this signaling complex controls the post-translational state of midbody 
proteins [122]. OGT also associates with the mitotic spindle, and increased OGT expression 
hinders the actions of AurB by reducing phosphorylation of histones at the spindle [124]. These 
data demonstrate the vital role of O-GlcNAcylation in organizing events in mitosis. 
Herein, we address the function of OGT and OGA in regulating the proper construction 
and activity of the mitotic spindle.  We demonstrate that spindle size, shape and function are 
disrupted in OGT or OGA gain of function cells.  The disruption of spindle architecture was 
mediated partially through impairment of spindle signaling pathways. CDK1 inhibitory 
phosphorylation was increased while AurB signaling was dramatically reduced at the spindle 
midzone as judged by histone H3 serine 10 phosphorylation.  Importantly, OGT and OGA gain 
of function induced this phenotype; however, the OGA inhibitor Thiamet-G (TMG) in the gain 
of function cells was able to rescue the disrupted spindle phenotype correlated with an increase 
in histone phosphorylation.  Together, these data suggest a novel mechanism in which the well-




All antibodies were used at a 1:1000 dilution for immunoblotting.  pT288 AurA (1:200 for 
confocal staining, 3079), Survivin (2802), pS7 CENPA (2187), CENPA (2186), Histone H3 
(9717), and pS10 histone H3 (1:500 for confocal staining, 9706) antibodies were all purchased 
from Cell Signaling Technologies. Hec1 (1:200 for confocal staining, ab3613), β-tubulin (1:1000 
for confocal staining, ab6046), pT232 AurB (1:200 for confocal staining, ab61074), PLK1 
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(1:200 for confocal staining, ab17057), pT210 PLK1 (ab39068), pS10 histone H3 (1:5,000 for 
confocal staining, ab5176), INCENP (ab36453), Borealin (ab70910), CDC2 (ab18), pY15 CDC2 
(ab47594), and AurA (ab13824) antibodies were purchased from Abcam.  Actin (A2066), AurB 
(WHOOO9212M3), α-tubulin (1:1000 for confocal staining, T5168) and γ-tubulin (T6557) 
antibodies were purchased from Sigma.  GFP was purchased from Santa Cruz (sc9996).  
Antibodies for OGT (AL-28, Al-35), OGA (341), and O-GlcNAc (110.6) were a gracious gift 
from the laboratory of Gerald Hart in the department of Biological Chemistry at the Johns 
Hopkins University School of Medicine. 
B.2.2 Cell Culture 
HeLa cells were cultured in DMEM (Sigma) supplemented with 10% Fetal Bovine Serum (FBS, 
Gemini) and 1% penicillin/streptomycin (Invitrogen).  Cells were synchronized into M phase 
using the double thymidine release method, which allows for approximately 85-90% of the cells 
synchronization into M phase [121, 122]. Adenoviruses were used as previously described [121, 
125].  Briefly, infections were performed at first thymidine release with each virus at a 
multiplicity of infection (MOI) of 100.  Cells were treated with 10 µM Thiamet-G (TMG, SD 
Specialty Chemicals) at the time of the second thymidine release. Synchronization of HeLa cells 
at metaphase was performed by double thymidine block with 2mM thymidine [121], followed by 
release and treatment with S-trityl-cysteine (Tocris Bioscience) 6 hrs post-release [126]. 
Metaphase-anaphase cells were then harvested by mitotic shake-off 14 hrs. post-thymidine 
release.  Cells were approximately 95% mitotic.  Synchronization of HeLa cells at prophase was 
accomplished by incubation in DMEM media containing nocodazole for 18 hrs followed by 
mitotic shake-off resulting in approximately 95% of the cells in prophase [122].  Infection 




B.2.3 Immunofluorescence Microscopy 
Cells cultured on microscope slides were washed with 1X PBS (Phosphate Buffered Saline, 
Sigma) and then fixed with 4% Paraformaldehyde (Sigma) for 20 min.  The paraformaldehyde 
was replaced by 1X PBS and slides were stored at 4°C.    Cells were then permeabilized with 
0.1% Triton X-100 (Sigma) in cold PBS for 20 min.  Slides were washed with 1X PBS and then 
blocked with a TBST blocking solution (0.2% azide, 0.2% powdered dry milk, 12% chicken 
serum, 1% Bovine Serum Albumin, 100 mM glycine, 0.1% Triton-X 100 in 500mL Tris buffer 
pH 7.5, all reagents from Sigma except dry milk) for 1 hour.  Primary antibody in blocking 
buffer solution was applied overnight.  Slides were washed with TBST and then incubated with 
fluorescent secondary antibodies (1:1000, rabbit Alexa-fluor 488 nm A11008, mouse Alexa-fluor 
488 nm A21202, rabbit Alexa-fluor 568 nm A10042, and mouse Alexa-fluor 568 nm A11004 
Invitrogen) for 1 hour.  DAPI solution (PBS, 0.01% Triton-X 100, 0.001% DAPI, Sigma) was 
applied for 20 min and slides were then washed and mounted on cover slips using ProLong Gold 
Anti-fade (Invitrogen) [122]. 
B.2.4 Cell Lysis and Histone Extraction 
Cells were lysed in NP-40 Lysis Buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1 mM DTT, 40 mM GlcNAc, and 1% NP-40, all reagents from Sigma) on ice for 30 minutes 
with occasional vortexing.  Cellular debris was pelleted and the supernatant removed.  For 
histones, the lysed pellet was washed twice with high salt (500 mM NaCl, Sigma) NP-40 lysis 
buffer and then resuspended in 0.25M HCl and vortexed vigorously for 15 minutes.  The sample 
was pelleted again and the histone-enriched supernatant was transferred into a new tube.  The 
pellet was subjected to the HCl treatment a second time, and the second supernatant added to the 
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first.  Eight volumes of acetone were added to the supernatants and samples were incubated at -
20° overnight.  The acetone-precipitated histones were pelleted and washed with 0.1M HCl in 
acetone and then washed twice more with acetone alone.  Pellets were air-dried and dissolved in 
a small amount of sterile water [127]. 
B.2.5 Immunoblotting 
All electrophoretic separations were performed with 4-15% gradient polyacrylamide gels 
(Criterion Gels, Bio-Rad).  Cell lysates were mixed with protein solubility mix (100mM Tris pH 
6.8, 10mM EDTA, 8% SDS, 50% sucrose, 5% Beta-mercaptoethanol, 0.08% Pyronin-Y, all 
reagents from Sigma) and separated on gels, followed by transfer to PVDF membrane 
(Immobilon, Millipore).  All antibodies were used at a 1:1000 dilution for immunoblots [121]. 
Blots were developed using HRP-conjugated secondary (anti-rabbit HRP 170-6515 and anti-
mouse HRP 170-6516 Bio-Rad, anti-IgM HRP A8786 and anti-IgY HRP A9046 Sigma) and 
chemiluminescent substrate (HyGlo E2400 Denville Scientific). Blots were stripped in 100 mM 
glycine (Sigma) pH 2.5 for 1 hour, washed, and then treated as before.  All western blots were 
repeated a minimum of 3 times using different experimental samples.  For densitometry, images 
were scanned and quantified using ImageJ software (NIH). 
B.2.6 Spindle Measurements 
Measurement of spindle length, width, and angle as well as centrosome distance and HEC 
distribution was performed using ImageJ software (NIH) from multiple experiments. 
B.2.7 Statistical Analysis 
Statistical significance of the western blot densitometry was assessed via pairwise comparison 





B.3.1 Gain of Function of OGT or OGA Disrupts Spindle Architecture 
Since elevated expression of OGT or OGA induces mitotic exit defects and aneuploidy [121-
123], we hypothesized that O-GlcNAc cycling is important for the formation of the mitotic 
spindle.  We synchronized at M phase OGT/OGA gain of function HeLa cells or control cells 
expressing GFP.  OGT gain of function cells showed an increase in total levels of O-GlcNAc, 
while OGA cells lowered O-GlcNAc levels (Figure B.1A).  Synchronized cells were judged 
mitotic by the expression of Cyclin B with actin as a loading control.  Next, we assessed how 
OGT/OGA gain of function affected spindle chromosome condensation. Spindles from each 
condition were measured over the course of 3 separate experiments.  Both OGT and OGA gain 
of function caused an increase in chromosome condensation area (Figure B.1B).  Condensed 
chromosome area was significantly larger in cells expressing both OGT and OGA while OGA 
inhibitor Thiamet-G (TMG) [128] (Figure B.1A-B) treatment significantly decreased 
chromosomal length, although width was larger than control (Figure B.1C-D).  Not only did 
elevated OGT/OGA expression alter chromosome condensation but we also saw an increase in 
cells with multipolar spindles (Figure B.1E). 
 Next, we explored the positioning of the centrosome relative to the spindle midzone in 
cells expressing OGT or OGA.  The distance between each centrosome and the midzone was 
greater in cells with the OGT or OGA gain of function (Figure B.1F); however, the spindle 
angle between the spindle midzone and the two centrosomes was not altered in these cells 
(Figure B.1G) [129]. We then measured the organization of the kinetochore.  HEC1 (Highly 
expressed in Cancer) is a component of the Ndc80/HEC1 complex required for kinetochore 
microtubule attachment to the kinetochore [130].  HEC1 staining at the kinetochore is tightly 
localized to the centromere where the sister chromatids are paired in normal cells (Figure B.1H); 
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however, in OGT and OGA gain of function cells the HEC1 staining is more diffuse and less 
localized to the spindle midzone.  The average area of the HEC1 staining is increased in these 
cells, matching the overall increase in condensation width with OGT/OGA gain of function 
(Figure B.1H).  HEC1 expression was lower in both OGT and OGA gain of function cells 
(Figure B.1J); although TMG had little effect on HEC1 localization (Figure B.1I), expression 






Figure B. 1: OGT or OGA gain of function disrupts spindle architecture 
(A) GFP, OGT or OGA gain of function or OGA inhibitor Thiamet-G treated HeLa cells were 
synchronized to M phase. Western blots were performed for O-GlcNAc, OGA, OGT, GFP, 
cyclin B, and actin. (B-D) DNA (blue) and α-tubulin (green) confocal imaging of M phase gain of 
function OGT/OGA cells, or cells treated with Thiamet-G. Midzone width and length (mean ± SEM, 
replicate number (n): nGFP = 195, nOGT = 193, nOGA = 198, nNT = 195, nTMG = 167, *P < 0.005 
between GFP/NT vs. OGT/OGA or TMG) were quantified using ImageJ software as follows: first, the 
condensed chromatin area color was inverted in order to delineate the edge of the chromatin. Next, the 
chromatin was measured lengthwise and the width was measured 3 times from different sections and 
averaged. Yellow lines are a representative measurement. (E) Multipolar spindles were quantified from 
confocal images of DNA (blue) and γ-tubulin (green) M phase synchronized gain of function OGT/OGA 
cells. (F) DNA (blue) and γ-tubulin (green) were confocal imaged at M phase in OGT/OGA gain of 
function cells. Distance between each centrosome and the midzone was quantified (mean ± SEM, 
replicate number (n): nControl = 93, nOGT = 64, nOGA = 76, *P < 0.005 between Control vs. 
OGT/OGA). (G) Spindle angle measurement schematic in OGT/OGA gain of function cells. The 
perpendicular black lines originating from the centrosomes and the center of the spindle midzone were 
used to calculate spindle angle shown in yellow and plotted as a histogram. (H) DNA (blue) and HEC1 
(red) were confocal imaged at M phase in OGT/OGA gain of function cells. Average width of HEC1 
staining was quantified using ImageJ (mean ± SEM, replicate number (n): nControl = 21, nOGT = 47, 
nOGA = 50, *P < 0.005 between Control vs. OGT/OGA). (I) DNA (blue), α-tubulin (green), and HEC1 
(red) were confocal imaged at M phase in TMG treated cells. (J) Western blot of HEC1 and actin in 






B.3.2 OGA Gain of Function Reduces CPC Expression 
The organization of the spindle is under the control of several mitotic kinases.  CDK1 
phosphorylates substrates during prophase, promoting nuclear envelope breakdown and 
activation of signaling networks regulated by the kinases PLK1, AurA, and AurB (Figure B.2A) 
[131, 132]. In turn, these kinases organize the mitotic spindle by phosphorylating substrates in 
specific regions of the spindle (Figure B.2A) [131, 133].  Increased OGT expression leads to 
increased inhibitory phosphorylation on CDK1 [123], suggesting that O-GlcNAcylation is 
important in the regulation of mitotic signaling events. We first measured whether OGT or OGA 
gain of function disrupts protein expression of AurA or PLK1.  OGA gain of function lowered 
AurA and PLK1 levels while OGT had little effect (Figure B.2B).  Previously, we reported that 
OGT gain of function lowers PLK1 expression slightly at M phase [123]; however, those cells 
were infected at the first thymidine block instead of the first release as in this study.  The 
prolonged OGT over-expression likely promoted the decline in PLK1 expression. TMG 
treatment lowered PLK1 levels slightly (Figure B.2B).  The distribution at the spindle of both 
AurA and PLK1 in OGT/OGA gain of function cells was no different than control (Figure 
B.2C-D). Next, we measured the expression of CPC proteins.  OGA cells expressed lower 
protein levels of INCENP, survivin, and AurB (Figure B.2E).  OGT cells produced little change 
while TMG treatment increased survivin protein expression (Figure B.2E). Localization of 
AurB, survivin and INCENP was no different than control; however, AurB staining was more 






Figure B. 2: Disrupted O-GlcNAc cycling alters spindle protein expression 
(A) Spindle schematic of the locations and area of phosphorylation of mitotic kinases AurA, 
AurB, and PLK1. (B) M phase synchronized GFP/OGT/OGA gain of function or TMG treated 
cells were Western blotted for PLK1, AurA, and actin. (C) DNA (blue), α-tubulin (green), and 
AurA (red) were confocal imaged at M phase in OGT/OGA gain of function cells. (D) DNA 
(blue), α-tubulin (green), and PLK1 (red) were confocal imaged at M phase in OGT/OGA gain 
of function cells. (E) Western blot of CPC proteins AurB, INCENP, borealin, surviving, and 
actin as a load control (F) DNA (blue), INCENP (green), and AurB (red) were confocal imaged 
at M phase in OGT/OGA gain of function cells. (G) AurB width was quantified using ImageJ 
(mean ± SEM, replicate number (n): nControl = 45, nOGT = 35, nOGA = 43, *P < 0.005 
between Control vs. OGA). (H) DNA (blue), INCENP (green), and survivin (red) were confocal 
imaged at M phase in OGT/OGA gain of function cells. 
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B.3.3 Phosphorylation of AurA, AurB, and PLK1 are Normal in the Gain of Function or 
TMG Treated Cells 
Phosphorylation of AurA, PLK1, and AurB is required for full enzymatic activation; therefore, 
we measured whether OGT/OGA gain of function altered the activating phosphorylation on 
AurA, PLK1, and AurB.  Activation of AurA occurs early in prophase and is mediated by AurA 
interactions with TPX2, Ajuba, and Bora [134-136].  This protein complex promotes AurA auto-
phosphorylation at threonine 288 [137, 138].  In OGT/OGA gain of function cells, AurA 
phosphorylation was not significantly different from control cells (Figure B.3A).  Since AurA is 
active in early prophase, we synchronized cells into prophase by nocodazole treatment. We saw a 
slight decline in AurA phosphorylation in these cells (Figure B.3B).  We also measured 
phosphorylation in cells synchronized at the metaphase-anaphase transition after S-trityl-cysteine 
treatment. In these cells we saw no change in phosphorylation (Figure B.3C). Next, we 
measured the activating threonine 210 phosphorylation on PLK1 [139]. We observed no changes 
in PLK1 phosphorylation from M phase, prophase, or metaphase-anaphase synchronized 
OGT/OGA gain of function cells (Figure B.3A-C). These data agree with previous reports 
demonstrating no change in PLK1 phosphorylation in OGT gain of function cells.  Finally, we 
looked at the AurB activating auto-phosphorylation on threonine 232 [140].  We saw no 
difference in AurB phosphorylation under different mitotic synchronization methods (Figure 
B.3A-C).  OGA inhibition had no effect on the activating phosphorylation except for a slight but 
significant decline in phosphorylated PLK in prophase synchronized cells (Figure B.3D-F). We 
saw no disruption of localization at the spindle of phosphorylated AurA and PLK1 in OGT/OGA 






Figure B. 3: The effects OGT/OGA gain of function or TMG treatment on mitotic kinase 
phosphorylation 
(A-C) GFP, OGT, or OGA gain of function cells were synchronized to (A) M phase, (B) 
prophase, (C) and metaphase-anaphase.  Blots were probed for pT210-PLK1, PLK1, pT232-
AurB, AurB, and pT288-AurA, AurA, and actin as a load control.  (D-E) TMG treated cells were 
synchronized to (D) M phase, (E) prophase, (F) and metaphase-anaphase.  Blots were probed for 
pT210-PLK1, PLK1, pT232-AurB, AurB, and pT288-AurA, AurA, and actin as a load control.  
Densitometry of kinase phosphorylation was firtst normalized to the kinases, then to the actin 
level. The densitometries were results from a minimum of 3 experiments, *P < 0.005 between 
GFP/NT vs. OGT/OGA or TMG. (G) DNA (blue), α-tubulin (green), and pT210-PLK1 (red) 
were confocal imaged at M phase in OGT/OGA gain of function cells. (H) DNA (blue), α-






B.3.4 CDK1 Inhibitory Phosphorylation is Altered in OGT/OGA Gain of Function Cells as 
Well as TMG Treated Cells 
Previously, we reported an increase in the inhibitory phosphorylation of CDK1 in OGT gain of 
function cells [123].  Again, we synchronized cells either at M phase, prophase, or metaphase-
anaphase and probed for CDK1 tyrosine 15 phosphorylation.  Similar to previous reports, we 
continued to see a robust significant increase in tyrosine 15 phosphorylation in OGT gain of 
function cells; although, OGA gain of function cells did not have consistently elevated tyrosine 
15 phosphorylation when only synchronized into M phase.  This increase in CDK1 
phosphorylation is consistently elevated in all prophase and metaphase-anaphase extracts 
(Figure B.4A-C).  TMG treated cells had higher levels of CDK1 phosphorylation in M phase 
synchronized cells, although the difference was not statistically significant (Figure B.4D-F); 
however, prophase synchronized cells had significantly lower CDK1 phosphorylation in the 
TMG treated samples, while metaphase-anaphase CDK1 phosphorylation was slightly lower 
compared to control.  The difference in the TMG treated M phase extracts compared to the other 
synchronization methods is interesting and suggests that cells might be populating all the stages 
of M phases including telophase when CDK1 phosphorylation would be higher. 
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Figure B. 4: Altered O-GlcNAc cycling increases CDK1 inhibitory phosphorylation 
(A-C) GFP, OGT, or OGA gain of function cells were synchronized to (D) M phase, (E) 
prophase, or (F) metaphase-anaphase.  Western blots were probed for pY15-CDK1 and CDK1. 
(D-F) TMG treated cells were synchronized to (D) M phase, (E) prophase, or (F) metaphase-
anaphase.  Western blots from TMG treated M phase cells were probed for pY15-CDK1 and 
CDK1.  Densitometry of CDK1 phosphorylation was normalized relative to the level of CDK1 
and actin, then averaged from a minimum of 3 experiments, *P < 0.005 between GFP/NT vs. 





B.3.5 OGT/OGA Gain of Function Cells Significantly Reduced Centromere Protein A 
Phosphorylation  
We next looked to measure the activity of AurA and AurB toward spindle substrates in 
OGT/OGA gain of function cells.  Centromere protein A (CENPA) is a histone variant that is 
phosphorylated at serine 7 by AurA in prophase, which in turn recruits INCENP and AurB to the 
spindle midzone where AurB phosphorylates CENPA serine 7 during late prophase and 
metaphase [111, 141].  CENPA serine 7 phosphorylation was depressed in mitotically 
synchronized OGT/OGA gain of function cells (Figure 5A).  We synchronized cells in prophase 
where AurA is the predominate kinase toward CENPA serine 7 and again saw a slight loss of 
CENPA phosphorylation in the OGT gain of function cells.  CENPA phosphorylation was not 
altered in OGA gain of function cells (Figure 5B).  In order to ascertain the contribution of AurB 
toward CENPA phosphorylation, we measured phosphorylation in cells synchronized at the 
metaphase-anaphase transition.  Serine 7 phosphorylation was significantly decreased in both 
OGT/OGA gain of function cells (Figure 5C). CENPA phosphorylation was not changed in cells 
treated with TMG (Figure 5D-F). 
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Figure B. 5: OGT or OGA gain of function disrupts AurB phosphorylation of CENPA 
(A-C) GFP, OGT, or OGA gain of function cells were synchronized to (A) M phase, (B) 
prophase, (C) and metaphase-anaphase.   Western blots were probed for pS7-CENPA and total 
CENPA. (D-F), TMG treated cells were synchronized to (D) M phase, (E) prophase, (F) and 
metaphase-anaphase. Western blots were probed for pS7- CENPA and total CENPA.  
Densitometry of pS7-CENPA was normalized relative to the level of CENPA and averaged from 






B.3.5 Altered O-GlcNAc Cycling Disturbs Histone H3 Serine 10 Phosphorylation 
We then measured the AurB mediated phosphorylation of serine 10 on histone H3, a marker for 
chromosome condensation [142, 143].  Histone H3 is modified by O-GlcNAc with the highest 
levels of H3 O-GlcNAcylation occurring during G1 phase of the cell cycle [127, 144] while H3 
O-GlcNAcylation appears lower in M phase [127, 145].  Others have reported an increase in O-
GlcNAcylation at M phase [144].  We did not detect any appreciable levels of O-GlcNAc on 
mitotic histones (data not shown).  Since H3 serine 10 phosphorylation (H3S10) is reduced in 
OGT gain of function cells [124], we acid extracted mitotic histones from both OGT and OGA 
gain of function cells. As previously reported [124], we saw a decrease in H3S10 
phosphorylation in OGT gain of function cells at M phase (Figure B.6A).  OGA gain of function 
cells had a significant decrease in H3S10 phosphorylation similar to the loss seen in OGT gain of 
function cells (Figure B.6A).  In prophase synchronized cells, H3S10 phosphorylation was 
reduced, although not to the same extent as M phase synchronized cells (Figure B.6B). 
Metaphase-anaphase synchronized cells demonstrated a sharp reduction in H3S10 
phosphorylation (Figure B.6C). When we visualized H3S10 phosphorylation at the spindle, we 
saw that staining was reduced at the condensed chromatin with some isolated areas being 
phosphorylated (Figure B.6D).  TMG treated mitotically synchronized cells had slightly higher 
H3S10 phosphorylation (Figure B.6E).  H3S10 and Aurora B phosphorylation at the condensed 
chromosomes was not altered in the TMG treated cells (Figure B.6F).  Our results with TMG 
contradict earlier studies demonstrating that the OGA inhibitor PUGNAc reduced H3S10 
phosphorylation [145].  We believe this is due to PUGNAc being a less selective OGA inhibitor 




Figure B. 6: OGT or OGA gain of function lowers AurB phosphorylation of histone H3 
(A-C) GFP, OGT, or OGA gain of function cells were synchronized to (A) M phase, (B) 
prophase, (C) and metaphase-anaphase.   Western blots were probed for pS10 H3 and total H3. 
Western blots were probed for pS10-H3 and total H3.  Densitometry of pS10-H3 was normalized 
relative to the level of H3 and averaged from a minimum of 3 experiments, *P < 0.005 between 
GFP vs. OGT/OGA. (D) DNA (blue), pS10-H3 (green), and AurB (red) were confocal imaged at 
M phase in OGT/OGA gain of function cells. (E) Control or TMG treated cells were 




normalized relative to the level of H3 and averaged from a minimum of 3 experiments.  (F) DNA 




B.3.6 OGA Inhibition Rescues the Disrupted Spindle Phenotype 
OGT and OGA gain of function consistently gave rise to disrupted spindle phenotypes.  Contrary 
to OGT/OGA gain of function cells, TMG treated cells had smaller spindles and higher H3S10 
phosphorylation. We investigated this apparent discrepancy in spindle size between chemical 
inhibition of O-GlcNAc removal and over-expression of the O-GlcNAc cycling enzymes. 
OGT/OGA gain of function or GFP control HeLa cells were synchronized into M phase via the 
double thymidine block method.  We added TMG to these cells at the time of the G1/S release.  
The cells were fixed, stained for tubulin and DNA 10 hours post second thymidine release, and 
chromosome condensation was measured.  We measured spindles for each condition over the 
course of 3 separate experiments.  Condensed chromosome area from gain of function 
OGT/OGA cells was considerably larger than GFP control cells (Figure B.7A).  TMG treatment 
caused a significant reduction in condensation area in GFP control cells; surprisingly, TMG 
reversed the chromosome condensation errors in both the OGT/OGA gain of function cells 
(Figure B.7A).  We then determined if TMG treatment combined with OGT/OGA gain of 
function changed the phosphorylation of AurA, AurB, PLK1, and CDK1.  We saw little 
difference in the phosphorylation status of these kinases (Figure B.7B).  Isolated histones from 
OGT/OGA gain of function cells had significantly lower H3S10 phosphorylation.  Interestingly, 
treatment with TMG produced a trend of partially restored H3S10 phosphorylation that did not, 






Figure B. 7: OGA inhibition rescued disrupted spindle phenotype in OGT/OGA gain of 
function cells 
GFP, OGT, and OGA gain of function cells were synchronized to M phase and treated with 
TMG after second thymidine release. (A) Midzone width and length (mean ± SEM, replicate 
number (n): nGFP = 198, nOGT = 242, nOGA = 178, nTMG/GFP = 213, nTMG/OGT = 235, 
nTMG/OGA = 223, *P < 0.005 GFP vs OGT/OGA, **P < 0.005 GFP/OGT/OGA vs TMG-
GFP/TMG-OGT/TMG-OGA) were quantified using ImageJ software from confocal images 
stained for DNA and α-tubulin. (B). Western blots were probed for O-GlcNAc, OGT, OGA, 
pT210 PLK1, PLK1, pT323-AurB, AurB, pT288-AurA, AurA, pY15-CDK1, CDK1, GFP, and 
actin as a load control.  (C) Western blots were probed for pS10 and total H3. Densitometry of 
H3 phosphorylation was normalized relative to the level of H3 and averaged from a minimum of 






Disruptions in O-GlcNAc levels impair M phase progression, alter mitotic signaling cascades, 
change the distribution of chromatin marks, and promotes aneuploidy [121-124].  We show that 
either an OGT or OGA gain of function impairs the correct assembly of the mitotic spindle.  
Centrosome localization, kinetochore organization, and chromosome condensation are all 
disrupted, which in turn promotes an increase in multipolar spindles through impaired 
cytokinesis. The localization and phosphorylation of the mitotic kinases AurA, AurB, and PLK1 
are not altered, but both CENPA and histone H3 phosphorylation are lower.  Contrary to the 
phenotype of OGT/OGA gain of function cells, the OGA inhibitor TMG produced more 
condensed chromosomes, and rescued the disorganized spindle phenotype seen in OGT/OGA 
gain of function cells. 
 Previous work supports the fact that OGT and OGA gain of function cause a variety of 
spindle defects.  OGT gain of function causes cytokinesis errors resulting in an increase in 
polyploidy; furthermore, this is accompanied by a large increase in chromosomal bridges, 
suggesting segregation defects [121, 124].   The effects of OGT/OGA gain of function on the 
spindle are likely through multiple mechanisms since many cellular processes control spindle 
size and shape, such as histone phosphorylation, tubulin polymerization, and condensin complex 
function [142, 143, 147].  OGA inhibitor TMG did reduce spindle length, although spindle width 
was wider than control cells.  These data suggest that blocking the turnover of O-GlcNAc at the 
spindle with TMG induces structural changes to the spindle. Later when TMG was used in the 
gain of function cells, both DNA width and length were decreased in all samples, suggesting that 
blocking O-GlcNAc cycling will lead to a more condensed spindle phenotype.  The alterations in 
O-GlcNAc cycling rate might be interfering with phosphorylation networks. For example, OGT 
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gain of function significantly alters the phosphorylation of at least one hundred mitotic proteins 
[123].  Disruption in O-GlcNAc cycling likely has some influence on the mitotic 
phosphorylation cascades that control spindle formation, such as CDK1 signaling.  
Next, we explored the possibility that disrupted O-GlcNAc cycling was interfering with 
mitotic phosphorylation cascades.  Our data point to an indirect relationship between the mitotic 
kinases AurA, AurB, and PLK1 with OGT/OGA.  Alteration of O-GlcNAc cycling, either 
through gain of function or chemical inhibition, did not significantly alter the expression or 
phosphorylation of AurA, AurB, and PLK1. The expression of INCENP and survivin was lower 
in the OGA gain of function cells, but both still localized to the spindle.  Importantly, only a 
substoichiometric amount of INCENP is needed to catalyze AurB autophosphorylation, 
suggesting that the amount of INCENP at the spindle in OGA gain of function cells is sufficient 
to activate AurB [140].   On the other hand, survivin protein levels were modestly higher when 
O-GlcNAc levels were elevated.  The increased amount of survivin is due to either prolonged 
stability of the protein or a transcription/translation increase.  Together, these data suggest that 
the CPC is still able to organize and promote AurB auto-phosphorylation as normal when O-
GlcNAc cycling is disrupted.  However, substrates of the CPC, such as serine 10 on histone H3, 
were not efficiently phosphorylated in OGT/OGA gain of function cells.  
Increased OGT expression increases CDK1 inhibitory phosphorylations at threonine 14 
and tyrosine 15 [123].  We demonstrate that OGA gain of function increases tyrosine 15 
phosphorylation when synchronized to either prophase or metaphase-anaphase.  Both OGT and 
OGA cause similar effects on CDK1 phosphorylation, suggesting that increased expression of 
OGT/OGA alters the rate of cycling, and this cycling rate is critical for the control of CDK1 




mitotic and metaphase-anaphase extracts TMG appeared to have no effect.  CDK1 
phosphorylation is an exceedingly complex process.  Multisite phosphorylation on CDK1 
promote ultrasensitivity, the process in which increases in phosphorylation induce a threshold 
input, resulting in a switch like change in function [148].  The kinase-phosphatase system of 
Wee1 and Cdc25 control the phosphorylation of CDK1, but CDK1 activation leads to the 
downstream phosphorylation of these proteins and their inverse activation (Wee1 inhibition and 
Cdc25 activation), which in turn leads to the switch-like activation of CDK1 at M phase [148]. 
The Wee1-Cdc25 system can be restored by the actions of the phosphatase PP2A [149, 150]; 
however, at M phase CDK1 activity creates a feed-forward loop inactivating PP2A through 
phosphorylation [148].  O-GlcNAc cycling is likely affecting not only the Wee1-Cdc25 loop 
[123] but also the PP2A system.  Cdc25 mRNA levels are lower in OGT gain of function cells 
and MYT1 kinase expression, which also controls CDK1 inhibitory phosphorylation, is elevated 
in these cells [123].  Additional control of the CDK1 switch by O-GlcNAc cycling would 
provide cells the ability to integrate changes in O-GlcNAc levels due to environmental signals 
into CDK1 activation and establish an even more sensitive control of CDK1 activation. 
The effect the changes in O-GlcNAc cycling has on mitotic histone phosphorylation is 
likely not due to O-GlcNAcylation of histones.  Indeed, histones are modified by O-GlcNAc and 
several sites have been mapped on H2A, H2B, and H4 [127, 151].  Histone H3 is also O-GlcNAc 
modified although the site has not been mapped by mass spectrometry [127, 145].  O-
GlcNAcylation of histones is lower at M phase [127]. Zhang et al. argue through mutational 
studies that serine 10 is the site of O-GlcNAcylation, since a histone H3 mutant consisting of a 
serine 10 to alanine mutation was not efficiently modified by O-GlcNAc; however, this does not 
definitively argue for serine 10 being the O-GlcNAc site, but rather the serine to alanine 
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mutation impairs OGT activity toward histone H3 [144].  Our data does not support serine 10 
being O-GlcNAcylated in mitotic cells.  Should H3S10 be O-GlcNAcylated at M phase, we 
would anticipate increased H3S10 O-GlcNAcylation in OGT gain of function cells or after TMG 
treatment, but we could not measure H3S10 O-GlcNAcylation after elevation of O-GlcNAc 
levels.  Furthermore, several groups detected less O-GlcNAc on H3 during M phase, suggesting 
that in mitotic cells serine 10 is not the main site of H3 O-GlcNAcylation [127, 145].     
 The reduction of H3S10 phosphorylation in OGT and OGA gain of function cells and the 
partial rescue of H3S10 phosphorylation by TMG suggest that we need to reexamine 
conceptually how O-GlcNAcylation regulates protein function.  In many cases, the addition of 
the O-GlcNAc residue to a protein will have a direct effect on protein activity (Figure B.8A).  
For example, O-GlcNAcylation of calcium/calmodulin-dependent protein kinase IV blocks an 
activating phosphorylation site thereby reducing enzymatic activity [152], whereas O-
GlcNAcylation of phosphofructokinase 1 blocks an allosteric regulation site and reduces 
enzymatic activity [153].  However, our data suggest a model in which O-GlcNAcylation can 
prime a protein for a potential physical interaction with other proteins, but full activation cannot 
be achieved until the O-GlcNAc is removed, which in turn leads to full activation of the protein 
complex (Figure B.8B).   
Both OGT and OGA gain of functions cells have a similar disorganized spindle 
phenotype, while TMG treatment partially rescued this phenotype.  Three possible mechanisms 
could explain these actions: the rate of O-GlcNAc removal is faster in gain of function cells 
leading to a disruption of protein-protein interactions facilitated by the O-GlcNAc modification; 
the over-expressed proteins are interacting with and disrupting other protein-protein interactions; 




gain of function cells would not have any effect on the organization of the spindle, since O-
GlcNAc levels are secondary to the increase in OGT/OGA protein expression; however, TMG 
restores spindle organization and H3S10 phosphorylation, arguing for mechanism one.  TMG is 
a chemical inhibitor and could potentially have off-target effects that we can’t completely rule 
out, but TMG has been demonstrated to be highly specific inhibitor of OGA and induces 
different cellular responses compared to previous generation OGA inhibitors like PUGNAc [128, 
154].   
Therefore, we propose a new model mechanism in which OGT O-GlcNAcylates proteins 
localized at the spindle midzone.  As OGA is found in a complex with OGT [122, 155], OGA is 
therefore targeted to the spindle midzone by OGT.  The O-GlcNAcylated spindle proteins 
facilitate the interaction of the CPC with spindle substrates [122].  Next, OGA removes the 
modification, and maximal activity of the CPC toward H3S10, occurs mediating a physiological 
response (Figure B.8B).  Increased OGT or OGA expression would accelerate O-GlcNAc 
cycling and impair targeting of the CPC to substrates. TMG would elevate O-GlcNAcylation and 
promote the recruitment of the CPC toward spindle substrates like H3S10.  TMG would also 
reduce OGA activity, providing enough time for the CPC to properly organize at the spindle 
midzone and phosphorylate H3S10.  However, prolonged inhibition of OGA could be deleterious 
as well by stabilizing transient interactions or impairing the antagonizing actions of phosphatases 




Figure B. 8: O-GlcNAc cycling regulates spindle function 
 (A) Schematic of O-GlcNAc cycling functioning as an on/off switch with addition of the O-
GlcNAc residue (green) to a protein having direct effect on protein activity. (B) Schematic of O-
GlcNAc cycling acting as a state machine in which the addition of the O-GlcNAc acts as a 
priming stage allowing for other spindle proteins (Protein X, blue) to interact with the O-GlcNAc 





In conclusion the cycling of O-GlcNAc is a critical requirement for proper spindle 
organization.  Alteration in the rate of O-GlcNAc cycling causes disorganized spindles, increases 
centrosome-spindle midzone distance, disrupts kinetochores, and causes an increase in multi-
polar spindles.  A potential contributing factor to the disorganized spindles is the reduction in 
AurB activity toward histone H3.  OGA inhibition can reverse the phenotypes caused by an 
increase in O-GlcNAc cycling, and partially restore AurB activity toward H3. Our data suggest a 
novel mechanism by which O-GlcNAc cycling regulates the function of protein complexes.  
Furthermore, our data suggest a potentially new model of the role of O-GlcNAc cycling in 
regulating biological processes. 
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Appendix C: O-GlcNAc Cycling is Important in Regulating Mitotic Spindle Organization- 
Part II 
Reproduced with permission from Zhang, Z., Tan, E.P., VadenHull, N.J., Peterson, K.R., and 
Slawson, C. (2016). Reduced O-GlcNAcase Expression Promotes Mitotic Errors and Spindle 
Defects. Cell Cycle 15(10):1363-75. 
C.1 Introduction 
O-GlcNAc is a single N-acetyl-glucosamine moiety linked via an oxygen residue to serine and 
threonine amino acids in nuclear, cytoplasmic, and mitochondrial proteins [35].   The 
modification is ubiquitously expressed in all metazoans and is essential for proper growth and 
development [156].  Two unique enzymes add or remove the modification on proteins.  O-
GlcNAc transferase (OGT) catalyzes the addition of N-acetyl-glucosamine to the hydroxyl group 
of serine and threonine residues while O-GlcNAcase catalyzes the removal of the modification 
[156].   O-GlcNAc cycling is the combined addition and removal of the modification.  Dynamic 
cycling of O-GlcNAc is necessary for normal development, and cycling defects are implicated in 
metabolic syndromes, such as diabetes, cancer, and neurodegeneration [38, 40, 157-159].  
Importantly, O-GlcNAc cycling defects have profound consequences for cell cycle progression 
[60]. 
Early studies in Xenopus oocytes demonstrated important roles for O-GlcNAc during 
progesterone mediated maturation.  Microinjection of galactosyltransferase, an enzyme that caps 
terminal N-acetyl-glucosamine preventing OGA removal of the sugar moiety, induces 
maturation defects causing mitotic checkpoint activation and cell death [160].  Oocytes treated 
with the OGA inhibitor PUGNAc failed to mature properly [161], while microinjection of 




blocks the G2/M transition during maturation [163], but microinjection of OGT promotes entry 
into M phase.  Together, these data demonstrate that alteration to the rate of O-GlcNAc cycling 
affect the transition from G2 to M phase in oocytes [164]. 
O-GlcNAc cycling plays an essential role in the regulation of both mitosis and meiosis.  
For example, HeLa cervical cancer cells over-expressing OGT or OGA have delayed exit from 
M phase and increased aneuploidy [121].   Interestingly, OGT localizes to both the mitotic and 
meiotic spindle, suggesting a critical role for O-GlcNAcylation at the spindle [121, 165, 166].  
Numerous spindle and midbody associated proteins are modified by O-GlcNAc [123], 
suggesting that O-GlcNAcylation of spindle proteins is necessary for proper spindle 
development.  The spindle seems especially sensitive to alterations in O-GlcNAc cycling.  Over-
expression of OGT/OGA leads to increased disorder of the spindle chromatids, while OGA 
inhibition with Thiamet-G (TMG) produces smaller more compact spindle chromatids [60].  
Interestingly, TMG treatment can partially rescue the disordered spindle phenotype in both OGT 
and OGA over-expressing cells arguing that cells maintain a certain homeostatic level of O-
GlcNAc cycling at the spindle.  Disruptions in O-GlcNAc cycling likely have a pluripotent effect 
on spindle machinery.  Increased O-GlcNAc cycling alters the phosphorylation of spindle 
proteins by mitotic kinases Aurora B and Polo Like Kinase 1 [122, 123].  Moreover, besides 
phosphorylation, impaired O-GlcNAc cycling disrupts other post-translational modifications on 
spindle proteins, such as methylation and acetylation [123, 124].  Together, these data 
demonstrate the essential role for O-GlcNAcylation in regulating cell cycle progression and 
spindle formation.  Importantly, these data demonstrate that maintaining a homeostatic level of 
O-GlcNAc cycling at the spindle is crucial for organizing the spindle architecture, maintaining 
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the proper post-translational state of spindle proteins, and promoting proper segregation of the 
chromatids to the daughter cells. 
Both OGT and OGA are essential genes, and a complete knockout of either gene would 
lead to senescence and cell death [167-169]; therefore, we generated OGA knockdowns cell lines 
with approximately 30% reduction in OGA activity.  Now, we show that OGA knockdown cells 
have mitotic progression defects, altered spindle chromatid packing, and an increase in 
multipolar spindles. Furthermore, OGA knockdown cells displayed altered inhibitory 
phosphorylation on CDK1 (Y-15), which is required for inactivation of the Cyclin B/CDK1 
complex [148].  Reduced OGA expression increased O-GlcNAcylation of EWS (Ewing Sarcoma 
Breakpoint Region 1 Protein), mislocalization of EWS at the spindle, and misalignment of the 
spindle midzone.  These data demonstrate the importance of OGA for the proper progression and 




Antibodies for immunoblotting: OGT (AL-34, rabbit) and OGA (345, chicken) antibodies were 
gracious gifts from the Laboratory of Gerald Hart in the Department of Biological Chemistry at 
the Johns Hopkins University School of Medicine. O-linked N-acetylglucosamine antibody 
[RL2] (ab2739), β-tubulin (ab6046), NuMA (ab36999), pY15-CDK1 (ab47594), CDK1 (ab18), 
INCENP (ab12183), Shugoshin (ab58023), Aurora B (ab2254), pS10-Histone H3 (ab5176), and 
pT3-Histone H3 (ab78351) were purchased from Abcam. Survivin (2802), Histone H3 (5192), 
and pAurora A (Thr288)/ pAurora B (Thr232) /pAurora C (Thr198) (D13A11) antibodies were 




(T5168), Cyclin A (C4710), Cyclin B (C8831), Cyclin D (SAB4502602), and EWS (E4533) 
antibodies were purchased from Sigma.  EWS (sc28327) antibody for western blotting was 
purchased from Santa Cruz.  Goat anti-rabbit IgG HRP (170-6515) and goat anti-mouse IgG 
HRP (170-6516) were purchased from Bio-Rad. 
C.2.2 Cell Culture and Generation of OGA Stable Knockdown Cells 
HeLa cells were cultured in DMEM (D5796, Sigma) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS, 100-106, Gemini) and 1% Penicillin-Streptomycin (P4333, Sigma) and 
incubated at 37 °C, 5% CO2 in a 95% humidified incubator.  Cell synchronization was performed 
as described previously [60].  
 Stable OGA knockdown cells lines were generated via electroporation.  Briefly, two TRC 
lentiviral human OGA shRNA constructs 040 and 877 (RHS3979, Clone TRCN0000134040 and 
TRCN0000135877, Open Biosystem) and TRC lentiviral eGFP shRNA (RHS4459, Open 
Biosystem) were electroporated into HeLa cells by Ingenio Electroporation Solution (MIR 
50114, Mirus) respectively according to manufacturer’s instruction. HeLa cells were placed at 1 
x 106 cells/ml in 100 mm dish and incubated overnight. Next day, cells were trypsinized and 
resuspended in Ingenio Electroporation Solution at 3 x 106 cells/ml.  250 µl of cell suspension 
was mixed with 5 µg of shRNA plasmid in a 0.4 cm electroporation cuvette (EC4, Midsci), and 
subjected to electroporation at voltage of 260 V and capacitance of 950 µF using exponential 
decay electroporator Gene Pulser Xcell Total System (1652660, Biorad). The cell mixture was 
immediately transferred to 2.5 ml of pre-warmed complete medium in a 6-well-plate and 
incubated for 48 hr.   After 48 hr, puromycin (P8833, Sigma) was added to the medium at 1 
mg/ml and continuously thereafter to generate the stable knock down cell lines. 
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C.2.3 Immunoprecipitation 
Control or OGA knockdown HeLa cells were lysed on ice for 20 min in Nonidet P-40 (NP-40) 
Lysis Buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 40 mM 
GlcNAc, and 1% Nonidet P-40) supplemented with 1 mM PMSF, 1 mM sodium fluoride, 1 mM 
β-glycerophosphate, and 1X protease inhibitor cocktail I (leupeptin 1 mg/ml, antipain 1 mg/ml, 
benzamidine 10 mg/ml and 0.1% aprotinin).   For immune precipitations, 0.5 mg of cell lysates 
were incubated with 0.5 µg of antibody in 1 ml reaction volume overnight while rotating at 4°C. 
Next, approximately 20 µl Protein G Sepharose 4 Fast Flow (17-0618-01, GE) slurry was added 
into each reaction, followed by end-to-end rotating at 4°C for 2 hr. Beads were washed 3 x 1 ml 
NP-40 Lysis Buffer supplemented with NaCl to a final concentration of 0.5 M.  Washed beads 
were mixed with 20 µL 2X protein solubility mixture (50 mM Tris-HCl, pH 6.8, 5 mM EDTA, 
4% SDS, 25% sucrose, 2.5% β-mercaptoethanol, 0.04% Pyronin-Y). Cell lysates were also 
mixed with 4X protein solubility mixture as input.  The beads and input were heated at 95 °C for 
2 min and subjected to immune blotting [60]. 
C.2.5 Immune Blotting 
SDS-PAGE was performed with 4-15% gradient Criterion TGX Precast Gels (567-1084, Bio-
Rad) and separated at 140 volts, followed by transfer to PVDF membrane (Immobilon, 
Millipore) at 0.4 Amps.  Membranes were blocked with 3% BSA in TBST (25 mM Tris-HCl pH 
7.6, 150 mM NaCl, 0.05 % Tween-20) at room temperature for 10 min, then incubated with 
primary antibody (1:1000) overnight at 4 °C. Membranes were washed with TBST for 5 x 5 min 
and incubated with HRP- conjugated secondary for 1 hr at RT (1:10,000), then washed again 
with TBST and developed using chemiluminescent substrate (HyGlo E2400; Denville 




incubation with other primary antibodies. All immunoblotting results were repeated a minimum 
of three independent experiments. 
C.2.6 Total RNA Isolation and RT-PCR 
A minimum of 2 x 106 cells were resuspended in 1 mL TRI reagent solution (AM9738, Ambion) 
then incubated at room temperature for 5 min. Next, RNA was extracted using chloroform 
followed by a centrifugation.  The upper phase containing RNA was collected and incubated 
with isopropanol.  After centrifugation, precipitated RNA was washed once with 70% ethanol, 
air-dried and dissolved in nuclease free water. 
1 µg of total RNA was mixed with iScript Reverse Transcription (RT) Supermix (170-
8841, Bio-Rad). RNA was converted into cDNA using random primers according to the 
manufacturer’s instructions.  Briefly, samples were incubated in a thermal cycler (Model 2720, 
Applied Biosystems) using the following protocol: priming 5 min at 25 °C, RT 30 min at 42 °C, 
and RT inactivation 5 min at 85 °C. cDNA products were diluted with 100 µl of nuclease free 
water and analyzed by qPCR [68]. 
C.2.7 qPCR Assay 
cDNA samples were analyzed by qPCR using SsoAdvanced Universal SYBR Green Supermix 
(172-5271, Bio-Rad) according to manufacturer’s instruction. 2 µl of cDNA samples, SYBR 
Green Supermix, nuclease-free water, and primers for OGA were mixed for a total reaction 
volume of 20 µl.  OGA primers were TTCACTGAAGGCTAATGGCTCCCG and 
ATGTCACAGGCTCCGACCAAGT. Next, the mixture was loaded into a 96-well PCR plate 
(AVRT-LP, MIDSCI) and loaded into a CFX96 Touch Real-Time PCR Detection System (185-
5195, Bio-Rad). The qPCR protocol was the following: polymerase activation and DNA 
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denaturation 30 s at 95 °C, annealing/extension 5 s at 95 °C and 30 s at 60 °C, amplification with 
40 cycles, and melt curve 65-95 °C with 0.5 °C increment 5 s/step [68]. 
C.2.8 OGA Activity Assay 
Whole cell lysates (60ug/reaction) were mixed with OGA reaction buffer for a total of 200 µl volume per 
reaction. O-GlcNAcase activity was assayed with 10 µl of 500 mM sodium cacodylate, pH 6.4, 3% 
bovine serum albumin, and 2 µl of 100 mM p-Nitrophenyl-N-acetyl-β-D-glucosaminide (pNP-O-GlcNAc, 
as substrate) at 37 °C for a total of two hours.   The reactions were stopped with 100 µl of 500 mM 
sodium carbonate every 30 min and the absorbance at 400 nm was measured after all the reactions were 
stopped. Specific activity was calculated as described previously [170]. 
C.2.9 Flow Cytometry 
Double thymidine block synchronized HeLa cells were released and harvested at different time 
points (0 hr, 3 hr, 6 hr, 9 hr, and 12 hr) by trypsin digestion.  Cells were washed in PBS, pelleted, 
and then resuspended in 1 ml of ice-cold PBS and followed by fixing with ice-cold 70% ethanol.  
Samples were stored at -20 °C until further use. Fixed cells were washed with ice-cold PBS and 
resuspended in PBS containing 0.1% (v/v) NP-40, 1 mg/ml RNase A, and 0.2% (w/v) propidium 
iodide [121].  Subsequently, cell cycle stages of cells were acquired by FACSDiva software 
using a BD LSRII at the University of Kansas Medical Center Flow Cytometry Core Laboratory.   
Data were analyzed using FlowJo. 
C.2.10 Histone Purification 
Histones were purified as described previously [60].  Briefly, cells were harvested and lysed, 
followed by acid extraction of the histones.  After histones were quantified by Bradford assay, 5 
µg of histone extract was separated by SDS-PAGE and probed for either histone phosphorylation 




C.2.11 Immunofluorescence Microscopy 
Control or OGA KD cells were cultured on microscope slides and synchronized into G1/S by 
double thymidine block.  9 hours after G1/S release, cells were washed with 1X PBS fixation, 
followed by fixation with 4% paraformaldehyde (158127, Sigma) for 20 min. Cells were 
permeabilized with 0.1% Triton X-100 (T8787, Sigma) in PBS for 20 min and washed with 1X 
PBS prior to blocking with a TBST blocking solution (0.2% azide, 0.2% powdered dry milk, 
12% chicken serum, 1% bovine serum albumin, 100 mM glycine, 0.1% Triton X-100 in Tris 
buffer pH 7.5, all reagents from Sigma except dry milk, Sun Fresh Supermarket) for 1 hr [60].  
Slides were incubated with primary antibody (1:200 to 1:1000 depending on antibody) in 
blocking buffer overnight.  Slides were 5 x 5 min washed with TBST and then incubated with 
fluorescent secondary antibodies (1:1000, rabbit Alexa-fluor 488 nm A11008, mouse Alexa-fluor 
488 nm A21202, rabbit Alexa-fluor 568 nm A10042, or mouse Alexa-fluor 568 nm A11004 
Invitrogen) for 1 hr. Slides were again washed 5 x 5 min in TBST.  Slides were then places in a 
DAPI solution (PBS, 0.01% Triton X-100, 0.001% DAPI, Sigma) for 20 min followed by 2 
washes with PBS.  Slides were mounted on cover slips using ProLong Gold Anti-fade (P36930, 
Invitrogen) [171]. 
C.2.12 Image Analysis 
Image analysis was performed as previously described using ImageJ software (NIH) [60]. 
C.2.13 Statistical Analysis 
Statistical significance for the qPCR, OGA activity and spindle midzone width and length were 
assessed via SPSS-Statistics software by performing Paired-Samples T Test. 
C.3 Results 
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C.3.1 Stable Knockdown of OGA Causes Cell Cycle Progression Defects 
In order to understand the role of OGA activity on the cell cycle, we made stable OGA 
knockdown HeLa cells producing either GFP (control) or OGA (lines 040 and 877) knockdowns.  
The OGA knockdown (KD) cells 040 and 877 had approximately 30% reduction in the protein 
expression of OGA compared to control (Figure C.1A).  Total cellular O-GlcNAc levels are not 
significantly affected by the reduction in OGA expression (Figure C.1A).  Often a large 
expression change in OGT or OGA leads to concomitant change of the other O-GlcNAc cycling 
enzyme [68].  However, we do not see a significant reduction in OGT protein levels (Figure 
C.1A).  Both 040 and 877 cells had reduced mRNA expression of the more common long form 
splice variant of OGA in these cells (Figure C.1B), while total OGA enzymatic activity was 





Figure C. 1: OGA expression is reduced in cell lines 040 and 877 
(A) Stable shRNA mediated OGA knockdown HeLa cells lines were established with a 
significant decrease in OGA protein expression as judged by western blot.  OGT protein 
expression was not significantly changed while total O-GlcNAc levels did increased slightly. 
(B), OGA mRNA is lower in both the 040 and 877 knockdown lines. (C) OGA enzymatic 
activity was significantly decreased in the stable OGA KD lines compared to the control cells.  




Next, HeLa cells were synchronized in G1/S phase [121] and then released into S phase, 
in which we then harvested time points every three hours up to 12 hours.  Both the OGA 040 and 
877 lines had increased O-GlcNAcylation and reduced OGA expression compared to control as 
judged by western blotting (Figure C.2A).  Released cells were also harvested for cell cycle 
stage analysis by flow cytometry.  Control and both OGA 040 and 877 cells moved through S 
phase at the same rate as control; however, both 040 and 877 cells displayed higher incidence of 
delayed M phase progression compared to the control cells (Figure C.2B).  These OGA KD 
cells had prolonged M phase escape, corroborating previous finding demonstrating that over-





Figure C. 2: OGA KD cell lines show mitotic exit defects 
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(A) HeLa OGA KD and control cells were synchronized into G1/S by double thymidine block 
and released.  Time points were harvested every 3 hours post-release, and western blots for total 
O-GlcNAc, OGT, and OGA were performed while α-tubulin was used as a load control.  (B) 
Control and OGA KD cells were again synchronized by double thymidine block and released 
into S phase.  Cells were fixed every 3 hours, and DNA content was measured by flow 
cytometry.  12 hours post-release 44% of OGA 040 cells and 63% of OGA 877 cells were still in 
mitosis compared to 31% of cells in the control sample.  All experiments were performed with at 





Subsequently, we again released cells from G1/S phase and probed time points for the 
expression of cyclins and phosphorylation of G1/S phase checkpoint protein RB.  Cyclin A had 
prolonged expression patterns in the OGA KD cells suggesting defects in G2/M progression, 
while cyclin D expression was lower in the OGA KD cells, suggesting fewer cells progressing 
though G1 phase (Figure C.3A).  Cyclin B expression was initially higher in the two knockdown 
cells, but then decreased below control levels only to increase again at the 12 hour release point.  
Likely, cyclin B protein levels are altered due to the defects in mitotic progression.  These results 
confirm that the OGA KD cells are progressing slower through M phase.  The phosphorylation 
of G1/S checkpoint point protein RB was also higher in these cells compared to control (Figure 
C.3B) demonstrating a higher percentage of OGA knockdown cells in S or M phase.  These 








Control and OGA KD cells were synchronized into G1/S by double thymidine block and 
released.  Time points were harvested every 3 hours for western blot analysis.  (A) In the OGA 
040 and 877 cells, expression of cyclin A, B, and D are altered.  Cyclin A has higher maximal 
expression in both OGA KD cell lines, while Cyclin B expression is higher at time zero for both 
OGA 040 and 877.  Cyclin D expression is lower in both 040 and 877 cell lines compared to 
control.  Expression of actin was used as a load control.  (B) Phosphorylated RB and RB 
Western blots were performed as in (A).  RB phosphorylation is elevated in the later time points 
in the OGA KD cells.  Graphs show normalized densitometric analysis for phosphorylation of 
RB, or Cyclin(s) A, B, or D protein expression. Signals were first normalized with actin then 
normalized with each of its time-point matched control as indicated (n = 3-4; *, p < 0.05 versus 
control). Data are expressed as means ± S.E. Ctrl = Control, 040 = OGA040, 877 = OGA877.  
All experiments were performed with at least 3 biological replicates. 
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C.3.2 OGA Knockdown Shortens Spindle Chromatids and Increases Multi-polar Spindles 
Previously, we demonstrated that over-expression of OGT or OGA caused defects in spindle 
formation [60].  In these cells, spindles were elongated and poorly condensed. The spindle 
defects caused by OGT and OGA over-expression increased the population of aneuploid cells 
[121].  In order to determine if OGA knockdown cells produced defective spindles and increased 
aneuploidy, we stained OGA knockdown and control cells for β-tubulin and DNA and counted 
the number of cells with aberrant spindles or that were multinucleated (Figure C.4A).   Both 
OGA KD cell lines had an increase in multipolar spindles compared to control (Figure C.4B).  
These data corroborate previous experiments performed in colorectal carcinoma cells in which 
OGA knockdown caused an increase in polyploidy [172].  Next, we measured the length and 
width of the condensed DNA in metaphase spindles.  Both OGA 040 and 877 showed a 
significant reduction in the length and width of the condensed chromatid DNA compared to 
control cells (Figure C.4C-E).  Interestingly, these results are opposite to OGT and OGA over-
expression studies and are more similar to cells treated with Thiamet-G (TMG), a selective OGA 
inhibitor, suggesting that reduced O-GlcNAc cycling either caused by OGA inhibition or OGA 






Figure C. 4: Multipolar spindles and chromatid compaction are increased in OGA 
knockdown cells 
 (A) Cells were imaged for β-tubulin and DNA.  For each cell line, 200 cells were counted and 
the percentage of cells with multipolar spindles was determined.  (B) Both 040 and 877 cell lines 
have an increased percentage of multipolar spindles compared to control cells.  (C) Cells were 
again stained for β-tubulin and DNA, and cells without visible signs of multipolar spindles were 
used in the measurement of chromatid length and width.  (D) For each cell line, 200 cells at 
metaphase-anaphase had their chromatid length measure using ImageJ.  OGA knockdown cells 
had significantly shorter spindle chromatids than control.  (E) For spindle chromatid width, 
samples were measured across the two ends and middle of the DNA and averaged.   Both 040 
and 877 OGA knockdown cells had significantly thinner spindle chromatids then control cells (* 





C.3.3 OGA Knockdowns Influences Mitotic Signaling Cascades 
Alterations in mitotic O-GlcNAcylation increase the inhibitory phosphorylation on Cyclin 
Dependent Kinase 1 (CDK1) at threonine 14 (T14) and tyrosine 15 (Y15) [60, 123].  
Phosphorylation at these sites inhibits CDK1 activity and links CDK1 activation to O-GlcNAc 
cycling.  Therefore, we probed mitotic OGA KD cells for CDK1 Y15 phosphorylation and found 
that both OGA KD cell lines increased CDK1 Y15 phosphorylation (Figure C.5A).  
Interestingly, we did not see the increase in CDK1 Y15 phosphorylation in the OGA KD lines 
when cells were synchronized at prophase using nocodazole (Figure C.5B).  Importantly, 
inhibitory phosphorylation in the OGA KD cells was lower, suggesting that the effect of OGA 
KD on CDK1 activation occurs later in M phase.  Synchronization into metaphase-anaphase by 
thymidine release and treatment with kinesin inhibitor S-trityl-cysteine increased CDK1 
inhibitory Y15 phosphorylation in both OGA KD cell lines (Figure C.5C). 
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 (A-C) Cells were synchronized into M phase by double thymidine block and harvested 9 hours 
post release (A) overnight treatment with nocodazole to synchronize cells into prophase (B) or 
treatment 6 post-release from double thymidine block with STC and harvested 14 hours post-
release (C). Lysates were probed for phosphorylated Y15 CDK1 and total CDK1.  Graphs show 
densitometry values of phosphorylation of CDK1 in OGA knockdown samples at the different 
stages of M phase. Signals were normalized first with CDK1 then followed by the control for 
each sample as indicated (n = 3; *, p < 0.05 versus control). Data are presented as means ± S.E.  
All experiments were performed with at least 3 biological replicates. 
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Spindle associated kinases like Aurora B kinase (AurB) interact with OGT and OGA at 
M phase [122, 123], and disruptions in O-GlcNAcylation affect the phosphorylation of AurB 
substrates such as vimentin and histones [60, 122].  Therefore, we measured the expression of 
AurB and AurB interacting partners in double thymidine released control and OGA KD cells.   
As a result, there was no significant difference in the expression of AurB or AurB interacting 
partners INCENP, Survivin (part of the chromosomal passenger protein complex, CPC), and 
Shugoshin; nor did we see changes in AurB activating phosphorylation (Figure C.6A).  No 
change was seen in the localization of AurB, INCENP, or Survivin at the mitotic spindle (Figure 






Figure C. 6: OGA knockdown had little effect on the expression or localization of the 
chromosomal passenger protein complex 
(A) Protein expression of AurB and the other components of the CPC were unchanged in the 
OGA KD cells. (B) Localization of AurB and INCENP is unchanged in the OGA KD cells. (C) 
Localization of Survivin was reduced at the spindle midzone in the OGA KD cells. All 
experiments were performed with at least 3 biological replicates. 
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OGT and OGA over-expression reduces AurB phosphorylation of histone H3 serine 10 
[60].  When histone H3 serine 10 (pS10H3) and threonine 3 phosphorylation (pT3H3) were 
measured in cells synchronized at M phase, prophase, or metaphase-anaphase, there were no 
significant differences in histone phosphorylation in 040 cells.  Whereas, there was a significant 






Figure C. 7: OGA 877 KD cells have reduced histone H3 phosphorylation 
Cells were synchronized into M phase by double thymidine block and release A, prophase by 
nocodazole treatment B, or metaphase-anaphase with STC. C, Histones were purified by acid 
extraction and phosphorylation of histone H3 Serine 10 and Threonine 3 was measured. H3 T3 
phosphorylation was lower in the double thymidine block and released 877 cells.  Graphs of 
normalized densitometric analysis for phosphorylation of S10H3 or T3H3 to total histone H3 (n 
= 3; *, p < 0.05 versus control). Data are expressed as means ± S.E.  All experiments were 





C.3.4 OGA Knockdown Increases Mitotic O-GlcNAcylation of NuMA and EWS and Disrupts 
EWS Spindle Localization 
We next explored the O-GlcNAcylation status of two known O-GlcNAc modified proteins, 
NuMA (Nuclear Mitotic Apparatus Protein) and EWS (Ewing Sarcoma Breakpoint Region 1 
Protein), in the OGA knockdown cells [123, 173].  NuMA is a centrosome protein involved in 
organizing the centrosome to the cells cortex.  We previously identified O-GlcNAc sites on 
NuMA and demonstrated that changes in OGT expression caused NuMA to localize to the cortex 
[123, 174].  We immunoprecipitated NuMA from prophase extracts and measured the level of O-
GlcNAcylation on the protein.  O-GlcNAc on NuMA was significantly increased in the OGA 
KD cells compared to control (Figure C.8A).   These data demonstrate that reduced O-GlcNAc 
cycling increases O-GlcNAcylation on a spindle associated protein.  
EWS is a RNA and DNA binding protein involved in numerous cellular functions; in 
particular, EWS helps recruits AurB to the spindle midzone during M phase [171].  Since 
previous report suggested that EWS is involved in organizing the spindle, we then measured O-
GlcNAcylation and the localization of EWS to metaphase-anaphase spindles [175]. EWS O-
GlcNAcylation was significantly increased on EWS in the OGA KD cells (Figure C.8B).  Next, 
to demonstrate whether the localization of EWS is affected in OGA KD cells, we performed 
immunocytochemistry using anti-EWS antibody.  As a result, EWS was evenly distributed 
throughout the cytoplasm in metaphase control cells.  However, spindle localization of EWS was 
no longer associating with the center of the dividing cell (Figure C.9A).  Scoring of the cells 
with the aberrant distribution of EWS demonstrated that there is a higher percentage of cells with 
aberrant localization of EWS in both OGA KD 040 and 877 cells compared to control.  This 
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result suggests that normal level of O-GlcNAc cycling is required for proper localization of EWS 





Figure C. 8: NuMA and EWS O-GlcNAcylation increases in OGA knockdown cells 
 (A-B) NuMA and EWS were precipitated from prophase extracts using specific antibodies to 
NuMA or EWS.  Blots were then probed for O-GlcNAc using the RL-2 O-GlcNAc antibody.  
Both NuMA and EWS O-GlcNAcylation were increased in 040 and 877 OGA knockdown cells.   
All experiments were performed with at least 3 biological replicates. 
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Figure C. 9: EWS spindle localization is disrupted in OGA knockdown cells 
(A) (Left) EWS visualized with an anti-EWS antibody. Area with clustered EWS signal is shown 
with white line.  Area with sparse EWS signal is shown with dashed white line. (Right) merged 
images of DNA stained with DAPI (blue) and EWS (green) visualized with an anti-EWS 







We generated two stable OGA knockdown cell lines in order to understand the effect of reduced 
O-GlcNAc removal on cell cycle progression and M phase dynamics.  Both cell lines had an 
approximate 20-30% reduction in activity and protein expression (Figure 1).  Although the OGA 
KD cells grow at a normal rate as control, the KD cells show mitotic progression defects when 
synchronized into G1/S and released (Figure C.2), and the expression of Cyclins D, A, and B 
was disrupted in these cells (Figure C.3).  At M phase, the inhibitory phosphorylation of CDK1 
was also increased (Figure C.5).  KD cells had more compact chromatids, misaligned spindles, 
and had higher incidence of anueploidy than control.  Finally, EWS was mislocalized from the 
spindle (Figure C.4 and C.9). Together, these data demonstrate the importance of O-GlcNAc 
cycling in regulating mitotic progression and spindle function.   
Recently, several labs have generated OGA embryonic knockout mice [168, 176].  The 
loss of OGA led to almost complete perinatal lethality in these animals with a variety of 
developmental defects [168, 176]. OGA -/- MEF (mouse embryonic fibroblast) demonstrated 
reduced growth rates, failure to resume cell cycle progression after serum starvation-reactivation, 
and these cells had an increase in polyploidy [168].  Interestingly, OGA knockdowns in 
colorectal cancer cells also had an increase in polyploidy [172].  Our data corroborates the 
mitotic defects seen in either OGA knockout mice or knockdown cells.  Clearly, OGA has an 
important role in maintaining the fidelity of mitotic progression. Since OGA 040 and 877 KD 
cells had tighter chromatid packing at the spindle midzone correlating with chromatid packing 
after OGA inhibition [60],  these data suggest that maintaining a homeostatic level of O-GlcNAc 
is necessary for chromatid packing at the midzone. Likely the rate of O-GlcNAc cycling is a 
regulatory mechanism for chromatid condensation. 
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Previously, we proposed that the rate of O-GlcNAc cycling was critical for proper mitotic 
progression [60].  We demonstrated that faster cycling caused by either over-expression of OGT 
or OGA led to large, unstructured chromatids at metaphase; however, pharmacological inhibition 
of OGA with Thiamet-G (TMG) produced tighter spindle chromatids, and treatment of 
OGT/OGA over-expressing cells with TMG partially restored spindle chromatid compaction 
[60].  The OGA KD cell lines 040 and 877 phenocopied the TMG treated cells demonstrating 
more compact spindle chromatids.  Treatment with TMG slows O-GlcNAc cycling by blocking 
the removal of O-GlcNAc and establishes a state of increased O-GlcNAcylation.  OGA 
knockdown also reduces O-GlcNAc cycling and increased O-GlcNAcylation.  We previously 
proposed that increased O-GlcNAcylation caused specifically by reduced O-GlcNAc cycling 
would promote protein-protein interactions, but these O-GlcNAc mediated protein complexes 
would not be fully functional until the O-GlcNAc was removed [60]. The reduced O-GlcNAc 
cycling rate of the OGA KD cells is potentially promoting increased protein-protein interactions 
at the spindle and causing the more compact chromatid structure.  However, the more compact 
chromatid structure is not without consequence.  The OGA KD cells have a higher rate of 
multipolar spindles (Figure C.4B) than the control cells leading to loss of chromatid segregation 
fidelity.   These data support the argument that O-GlcNAc cycling rates are critical for proper 
spindle development and function, and alterations in O-GlcNAc cycling will reduce segregation 
fidelity and promote aneuploidy.   
Since O-GlcNAc affects numerous cellular pathways, the chromatid spindle phenotype is 
likely due to numerous factors.  However, we did demonstrate increased EWS O-GlcNAcylation 
and mislocalization at the spindle (Figure C.8B and C.9).  EWS is a multi-functional protein that 




Although we saw no disruption in AurB midzone localization, we did measure an increase in 
midzone alignment errors.  These data suggest that O-GlcNAcylation controls EWS spindle 
localization and potentially EWS spindle function.  Because we cannot entirely exclude the 
possibility of O-GlcNAcylation of other unknown protein impairing the AurB alignment, future 
studies are required to identify the causal mechanisms of this phenotype.   
Importantly, disruption in the rate of O-GlcNAc cycling either by over-expression of 
OGT/OGA, knockdown of OGA, or pharmacological inhibition of OGA modulates CDK1 
inhibitory phosphorylation [60, 123].  CDK1 is the master regulator of M phase entry and is 
regulated not just by Cyclin B expression but also by inhibitory and activating phosphorylations 
[148].  Due to the importance of CDK1 in initiating mitotic entry, CDK1 activation is likely tied 
to O-GlcNAc homeostasis.  Alterations in O-GlcNAc homeostasis either through nutritional flux, 
stress, or disease development could signal to the cell to reduce CDK1 activity until cellular 
conditions improve.  How O-GlcNAc homeostasis regulates CDK1 phosphorylation is unclear 
but likely resides in the upstream kinases or phosphatases that regulate CDK1 inhibitory 
phosphorylation.  Further investigation into O-GlcNAc control of CDK1 is warranted. 
In conclusion, these data demonstrate the key role of OGA function in promoting cell 
cycle progression and spindle fidelity.  These data argue that in the case of mitotic progression 
the cycling rates of O-GlcNAc are more important for biological function than absolute 
stoichiometry of O-GlcNAc on proteins.  Therefore, understanding the interactions of OGT and 
OGA with the mitotic machinery will provide new insight into the critical role for O-GlcNAc in 
controlling mammalian mitosis. 
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Appendix D: O-GlcNAc Cycling Regulation 
Reproduced with permission from Zhang, Z., Tan, E.P., VadenHull, N.J., Peterson, K.R., and 
Slawson, C. (2014). O-GlcNAcase Expression is Sensitive to Changes in O-GlcNAc 
Homeostasis. Frontier Endocrinology 5:206. 
D.1 Introduction 
O-linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification (PTM) first 
discovered by Gerald W. Hart and Carmen-Rosa Torres in 1984 when they used bovine milk 
galactosyltransferase (GalT1) to probe for terminal N-acetylglucosamine moieties on 
glycoconjugates of T-cells [177]. O-GlcNAc is a reversible modification that is ubiquitously 
expressed in higher eukaryotes and involves the attachment of a single β-N-acetylglucosamine 
residue to serine or threonine residues in nuclear and cytosolic proteins. O-GlcNAc transferase 
(OGT) is the enzyme that adds the O-GlcNAc modification, whereas, O-GlcNAcase (OGA) 
removes it [35]. Because uridine diphosphate-N-acetyl-glucosamine (UDP-GlcNAc), the end 
point of the hexosamine biosynthetic pathway is the high-energy donor substrate for OGT, O-
GlcNAcylation is sensitive to nutrient availability [156]. Furthermore, the removal and addition 
of O-GlcNAc termed O-GlcNAc cycling is a highly dynamic process, and O-GlcNAc cycling 
rates affect transcription regulatory pathways, cell cycle progression, and respiration [35, 36, 
156, 157]. More importantly, an imbalance in the homeostasis of O-GlcNAc contributes to the 
development of diseases, including cancer, diabetes, and Alzheimer’s [35, 36, 178, 179]. 
Since O-GlcNAcylation plays a significant role in regulating a wide panel of cellular 
processes, understanding the regulation of OGT and OGA is important. Several studies report 
that the expression of OGT and OGA is sensitive to changes in total cellular O-GlcNAc levels 




protein expression to decrease and OGA protein expression to increase [121]. A rapid decrease 
in OGA protein expression occurs in mice embryonic fibroblasts when OGT is knocked out 
[180]. Although we know that alterations to homeostatic levels of O-GlcNAc affect OGT and 
OGA expressions the mechanism by, through which cells adjust OGT and OGA expression as O-
GlcNAc levels fluctuate is still unclear.  
To further address how cells adjust OGT and OGA protein expression in response to 
alterations in O-GlcNAc levels, we measured in different cell lines OGT and OGA protein and 
mRNA expression and stability after pharmacological inhibition of OGA. In these experiments 
we are able to show that the OGA mRNA levels are more sensitive compared to OGT in 
response to the alterations in O-GlcNAc. Altogether, our data show that the expression of OGT 
and especially OGA is sensitive to changes in O-GlcNAc levels, and OGA expression is critical 
in maintaining cellular O-GlcNAc homeostasis. 
D.2 Methods 
D.2.1 Antibodies and Reagents 
All primary and secondary antibodies used for immunoblotting were used at a 1:1000 and 
1:10,000 dilution respectively. Anti-O-linked N-acetylglucosamine antibody [RL2] (ab2739) was 
purchased from Abcam. Antibodies for OGT (AL-34) and OGA (345) were gracious gifts from 
the laboratory of Gerald Hart in the Department of Biological Chemistry at the Johns Hopkins 
University School of Medicine. Actin (A2066) antibody and anti-chicken IgY HRP (A9046) 
were was purchased from Sigma. ChIP grade mouse (G3A1) mAb IgG1 isotype control (5415) 
and RNA polymerase II antibody, clone CTD4H8 (05-623) were purchased from Cell Signaling 
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Technologies and Millipore, respectively. Anti-rabbit HRP (170-6515) and anti-mouse HRP 
(170-6516) were purchased from Bio-Rad. 
 All reagents were purchased form Sigma unless otherwise noted. Cycloheximide (CHX, 
C7698, Sigma) was used at 50 µg/ml for HeLa cells and 25 µg/ml for K562 cells [181, 182]. 
Actinomycin D (AMD, A1410, Sigma) was used at 0.5 µg/ml for HeLa cells and 5 µg/ml for 
K562 cells [182, 183].  
D.2.2 Cell Culture 
HeLa cells and SH-SY5Y neuroblastoma cells were cultured in DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS, Gemini) and 1% penicillin/streptomycin 
(Invitrogen). K562 cells were cultured in RPMI-1640 (Invitrogen) supplemented with 10% 
fetal bovine serum, 1X MEM non-essential amino acids solution (Invitrogen), 1 mM sodium 
pyruvate (Invitrogen), 2.5 mM HEPES, and 1% penicillin/streptomycin. Cells were treated with 
10 µM Thiamet-G (TMG, S.D. Specialty Chemicals) for 6 hrs, 8 hrs, 24 hrs or 48 hrs with fresh 
TMG supplied daily. Cells were also pretreated with CHX and AMD for 4 hr and 0.5 hr 
respectively, followed by TMG treatment for 8 hr and 6 hr respectively. Cells were infected with 
OGT, OGA, or GFP virus at a multiplicity of infection (MOI) of 75 for 24 hr. After different 
treatments, cells were harvested for western blot, quantitative PCR (qPCR) or chromatin 
immunoprecipitation (ChIP) assay. 
D.2.3 Immunoblotting 
Cells were lysed on ice for 30 min in Nonidet P-40 (NP-40) Lysis Buffer (20 mM Tris-HCl, pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 40 mM GlcNAc, and 1% Nonidet P-40) with 1 
mM PMSF, 1 mM sodium fluoride, 1 mM β-glycerophosphate, and 1X protease inhibitor 




Cell lysates were mixed with 4X protein solubility mixture (100 mM Tris-HCl, pH 6.8, 10 mM 
EDTA, 8% SDS, 50% sucrose, 5% β-mercaptoethanol, 0.08% Pyronin-Y). All electrophoresis 
was performed with 4–15% gradient polyacrylamide gels (Criterion Gels, Bio-Rad) and 
separated at 120 volts, followed by transfer to PVDF membrane (Immobilon, Millipore) at 0.4 
Amps. Blots were blocked by 3% BSA in TBST (25mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.05 
% Tween-20) at RT for 20 min, then incubated with primary antibody at 4 °C overnight. After 
washing with TBST for 5 X 5 min, blots were incubated with HRP- conjugated secondary for 1 
hr at room temperature, then washed with TBST again and developed using chemiluminescent 
substrate (HyGlo E2400; Denville Scientific). Blots were stripped in 200 mM glycine, pH 2.5 at 
room temperature for 1 hr and probed with different primary antibodies. All immunoblotting 
results were repeated in three independent experiments [60]. OGA and OGT relative protein 
levels were measured by analyzing the bands density using ImageJ 1.48 
(http://imagej.nih.gov/ij/download.html) then normalized to the density of actin. All experiments 
were repeated three times and average relative fold changes were calculated.  
D.2.4 Total RNA Isolation and RT-PCR 
Total RNA was isolated by TRI reagent solution (AM9738, Ambion) according to manufacture’s 
instruction. Briefly, 2 x 106 cells were resuspended by 1 mL TRI Reagent Solution.  Then 200 µl 
of chloroform was added to extract RNA. After spinning down, upper phase containing total 
RNA was collected and incubated with an equal amount of isopropanol. RNA pellets were then 
precipitated by centrifugation, washed once with 70% ethanol, air-dried and dissolved in 
nuclease free water (Invitrogen).  
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 RNA concentration was measured by Nanodrop 2000c (Thermo) and 1 µg of total RNA 
was used for reverse transcription (RT) using iScript Reverse Transcription Supermix (170-8841, 
Bio-Rad) following manufacturer’s instruction. 10 µl of each completed reaction mix was 
incubated in a thermal cycler (Model 2720, Applied Biosystems) using the following protocol: 
priming 5 min at 25 °C, RT 30 min at 42 °C and RT inactivation 5 min at 85°C. cDNA products 
were diluted with 90 µl nuclease free water and analyzed by qPCR.  All qPCR results were 
repeated in three independent experiments [184]. 
D.2.5 ChIP Assay 
K562 cells were harvested by centrifugation at 1,000 g for 5 min and washed twice with 1X 
PBS. Cells were then cross-linked by 2 mM EGS (21565, Pierce) in PBS at room temperature for 
30 min, followed by 1% formaldehyde (BP531-25, Fisher) for another 10 min. Cross-linking 
reaction was terminated by 125 mM glycine. Cell pellets were collected and lysed on ice for 30 
min by cell lysis buffer (10 mM Tris-HCl, pH 8.1, 10 mM NaCl, 0.5% NP-40) with protease 
inhibitors. Chromatin was collected by spinning down and the pellets were resuspended in cold 
nuclear lysis buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS, 25% glycerol) with 
protease inhibitors. 300 µl of nuclear lysis buffer was used to resuspend chromatin from 2 x 106 
cells.  
 Chromatin DNA was sheared to the size of 100-300 bp by sonication (Model Q800R, 
Active Motif) with the following protocol: amplification 75%, pulse On 15 s, pulse Off 45 s, 
temperature 3°C. 200 µl of sheared chromatin was diluted by adding 1 ml of ChIP buffer (20 
mM Tris-HCl pH8.1, 1.2% Triton X-100, 1.2 mM EDTA, 20 mM NaCl) with protease 
inhibitors. 2 µg of control IgG and specific antibody was added to diluted chromatin, 




diluted chromatin was saved as input and processed later. Next day, 30µl of PBS washed M-280 
sheep anti-mouse IgG Dynabeads (11204D, Invitrogen) was add to the chromatin, followed by 
rotating at 4 °C for 4 hr. Dynabeads were separated by DynaMag-2 Magnet (12321D, Invitrogen) 
and subsequently washed with 1 ml of the following buffer for 5 min at 4 °C: wash buffer 1 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl), wash 
buffer 2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 300 mM NaCl), 
wash buffer 3 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM 
NaCl), wash buffer 4 (0.25 M LiCl, 1% NP-40, 1% Sodium Deoxycholate, 1 mM EDTA, 10 mM 
Tris-HCl pH 8.0) and TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). 
Complexes were eluted from beads with 500 µl elution buffer (1% SDS, 0.1 M NaHCO3, 
40 mM Tris-HCl, pH 8.0, 10 mM EDTA) and added with 200 mM NaCl. Eluates and inputs 
were treated at the same time with RNase A (EN0531, Thermo) at 65°C overnight, followed by 
proteinase K (25530-031, Invitrogen) treatment for 2 hr. DNA was extracted by 
phenol/chloroform/isoamyl alcohol (AC327111000, Fisher) and precipitated by glycogen 
(10814-010, Invitrogen) and ethanol [185]. DNA pellets were air dried, dissolved in 50 µl 
nuclease free water, and analyzed by qPCR. 
D.2.6 qPCR Assay 
cDNA or ChIP DNA samples were analyzed by qPCR using SsoAdvanced Universal SYBR 
Green Supermix (172-5271, Bio-Rad) according to manufacturer’s instruction. Briefly, 2 µl of 
cDNA or 5 µl of ChIP DNA samples, SYBR green supermix, nuclease free water, and primers 
(Table 1) for the target gene were mixed with a total reaction volume of 20 µl. A 96-well PCR 
plate (AVRT-LP, Midsci) with the mixture was loaded to CFX96 Touch Real-Time PCR 
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Detection System (185-5195, Bio-Rad) with the following protocol: polymerase activation and 
DNA denaturation 30 s at 95°C, amplification denaturation 5 s at 95 °C, and annealing 30 s at 
60°C or 62°C  with 40 cycles, and melt curve 65°C-95°C with 0.5°C increment 5 s/step. 
D.2.1 Data Analysis 
Quantification cycle (Cq) value was recorder by CFX Manager™ software. For cDNA qPCR 
data, dynamic range of RT and amplification efficiency was evaluated before using ∆∆Cq 
method to calculate relative gene expression change. For ChIP DNA qPCR data, Cq value was 
normalized to percentage of input. Data generated in three independent experiments was 
presented as means ± standard error and analyzed using two-tailed Student t test with P < 0.05 as 
significant difference. 
D.3 Results 
D.3.1 Alterations in O-GlcNAc Levels Changes the Protein Expression of OGT and OGA 
Previous reports demonstrated that different pharmacological inhibitors of OGA, PUGNAc and 
GlcNAc-thiazoline, rapidly increase the protein expression of OGA [121, 122].  We explored 
this phenomenon using another highly selective inhibitor of OGA Thiamet-G (TMG)[128].  We 
altered the O-GlcNAc levels of SH-SY5Y neuroblastoma, HeLa cervical carcinoma, and K562 
leukemia cells with TMG and measured O-GlcNAc, OGT, and OGA levels at various time 
points up to 48 hrs of TMG treatment.  OGA protein expression increased while OGT protein 
expression decreased gradually in the prolonged TMG treatment time points (Figure D.1A-C). 
Additionally in SY5Y cells, we used adenoviral-mediated OGT or OGA infection to alter O-
GlcNAc levels. Green Fluorescent Protein (GFP) was used as a control for the adenoviral 
infection. Cells over-expressing OGT showed an elevation in O-GlcNAc levels and a slight 




showed a decrease in O-GlcNAc levels and a slight increase in OGT protein expression 
compared to control (Figure D.1D). 
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Figure D. 1: OGA protein level was increased after TMG treatment 
(A) SH-SY5Y neuroblastoma cells,  (B) HeLa cervical cells, and (C) K562 leukemia cells were 
treated with 10 µM TMG for indicated time. (D) SH-SY5Y cells were infected with GFP, OGT, 
and OGA adeno-virus at 75 MOI for 24 hours. Cells were lysed, overall O-GlcNAc level, OGA 
and OGT protein levels were analyzed by western blot with actin as a loading control.  Average 





D.3.2 TMG Does Not Stabilize OGA Protein 
In order to explore the reason why TMG increases OGA protein level, we asked the question 
does TMG increase OGA protein stability. We pretreated cells with cyclohexamide (CHX) to 
inhibit protein translation [186]. We treated HeLa (Figure D.2A) and K562 (Figure 2B) cells 
with TMG and observed a robust increase in OGA protein level (Figure D.2A-B, Lane 2) 
compared to control cells without any treatment (Figure 2A and B, Lane 1). When HeLa cells 
were treated with CHX, OGT protein levels were dramatically decreased compared to control, 
and we did not observe much of a decrease in OGA protein expression (Figure D.2A, Lane 3). 
However, both OGT and OGA protein levels were dramatically decreased after CHX treatment 
in K562 cells (Figure D.2B, Lane 3) compared to control. Combination of CHX and TMG did 
not change the OGA or OGT protein levels (Figure D.2A-B, Lane 4) compared to CHX 
treatment only, suggesting that the TMG-mediated increase in OGA protein expression was not 
due to increased stability of the protein. 
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Figure D. 2: TMG does not stabilize OGA protein 
(A) HeLa cells and (B) K562 cells were treated with TMG, CHX (protein translation inhibitor), 
and CHX+TMG. Cells were lysed, overall O-GlcNAc level, OGA and OGT protein level were 





D.3.3 TMG Transcript Level is Increased After TMG Treatment 
Next, we investigated if OGT or OGA transcript level were altered after TMG treatment. We 
analyzed OGA mRNA level in SH-SY5Y (Figure D.3A), HeLa (Figure D.3B) and K562 
(Figure 3C) cells. We found OGA mRNA level was increased from 6 hrs TMG treatment in all 
three cell lines, and was still elevated above control after 48 hr TMG treatment (Figure D.3A-
C). The OGA mRNA level corresponded with the increase in protein level in Figure D.1. 
However, the OGT mRNA level did not significantly change (Figure D.3D-F). We also 
demonstrated that the corresponding OGA and OGT mRNA levels increased slightly, but not 






Figure D. 3: OGA mRNA level was increased after TMG treatment 
After TMG treatment, relative OGA mRNA level in (A) SH-SY5Y, (B) HeLa, and (C) K562 
cells, as well as OGT mRNA level in (D) SH-SY5Y, (E) HeLa, and (F) K562 cells were 
analyzed by qPCR. Both (G) OGA mRNA level and (H) OGT mRNA level in SH-SY5Y cells 
infected with GFP, OGT, and OGA adenovirus at 75 MOI for 24 hr respectively were also 
analyzed by qPCR. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) served as internal 
control. * indicates P < 0.05 and ** indicates P < 0.01, compared with control (TMG 0 hr or 
GFP), n=3, Student t-test.  
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D.3.4 TMG Does Not Stabilize OGA mRNA 
Next, we asked the question is increased OGA mRNA level after TMG treatment due to 
stabilized OGA mRNA.  Actinomycin D (AMD), a RNA synthesis inhibitor was used to test 
OGA mRNA stability. TMG treated HeLa cells showed an increase of OGA mRNA level 
compared to control cells without any treatment (Figure D.4A). When cells were treated with 
AMD, both OGA and OGT mRNA levels were dramatically decreased compared to control 
(Figure 4A and B). Combination of AMD and TMG did not change the OGA and OGT mRNA 
levels compared to AMD treatment only (Figure D.4A-B). The same results were observed 





Figure D. 4: TMG does not stabilize OGA mRNA 
HeLa cells (A and B) and K562 cells (C and D) were treated with TMG, AMD (RNA 
transcription inhibitor), and AMD+TMG, respectively. (A) OGA (A and C) and OGT (B and D) 
mRNA level were analyzed by qPCR, with HPRT as internal control. * indicates P < 0.05 and ** 
indicates P < 0.01, compared with control, n=3, Student t-test. 
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D.3.5 RNA Pol II Occupancy is Decreased at OGA Transcription Start Site (TSS) After 48 hrs 
TMG Treatment 
We next investigated RNA Pol II occupancy at the OGA TSS via RNA Pol II chromatin 
immunoprecipitation. In control K562 cells, RNA Pol II was bound to OGA TSS with less 
binding at upstream (-1000) and downstream (+2700) of the TSS. However, after 48 hr TMG 
treatment, RNA Pol II occupancy was decreased at the OGA TSS compared to control cells 





Figure D. 5: RNA Pol II occupancy at OGA TSS was decreased after 48 hrs TMG 
treatment in K562 cells 
 (A) RNA Pol II ChIP assay was performed on control and 48 hrs TMG treated cells. ChIP DNA 
was analyzed by qPCR using a set of primer targeting 1000bp upstream of OGA TSS (-1000), 
OGA TSS (0) and +700bp downstream of OGA TSS (+2700). * indicates P < 0.05, n=3, Student 




The production of uridine diphosphate-N-acetyl-glucosamine (UDG-GlcNAc), the substrate for 
OGT, integrates various metabolic substrates allowing the O-GlcNAc modification to act as a 
nutrient sensor [156].  Consequently, cells are sensitive to changes in O-GlcNAc levels due to 
nutritional and metabolic flux and will adjust cellular functions accordingly.  Possibly, prolonged 
alterations in homeostatic levels of O-GlcNAc will cause the protein expression of OGT and 
OGA to change in an effort to restore O-GlcNAc homeostasis [156]. Exactly how cells sense 
alterations to homeostatic levels of O-GlcNAc and adjust OGT and OGA expression to 
compensate for the changes in O-GlcNAcylation is unclear.  For example, pharmacological 
inhibition of OGA rapidly increases cellular O-GlcNAc levels; however, the protein expression 
of OGA will also increase in response to the elevation of O-GlcNAc [121, 122].  We sought to 
explore the mechanism as to how OGT and OGA protein expression changes in response to 
alterations in cellular O-GlcNAc levels.  In agreement with previous reports, we found an 
increase in OGA protein expression as quickly as 8 hr in HeLa cells and 24 hr in K562 and 
SY5Y cells after treatment with TMG.  OGT protein expression also decreased at these later time 
points (Figure D.1).  Due to the fact that increased levels of O-GlcNAc can increase the stability 
of proteins such as p53 [187] and TET (ten-eleven translocation) [188], we postulated that 
increased O-GlcNAc could stabilize OGA.  K562 or HeLa cells exposed to cycloheximide in the 
presence of TMG showed no difference in the stability of either OGT or OGA (Figure D.2) 
suggesting that the increase in OGA protein expression was not due to increased stability and 
more likely to an increase of OGA transcripts. 
 Importantly, decreased O-GlcNAc levels do not necessarily increase OGT levels in all 




activity with 6-diazo-5-oxo-L-norleucine (DON) in HeLa cells lowered O-GlcNAc levels but did 
not increase OGT protein expression [121].  On the other hand, OGA protein levels quickly 
decreased after Cre-mediated knockout of OGT in mouse embryonic fibroblasts [180], but OGA 
knockdown in colon cancer cells did not significantly decrease OGT protein expression [172]. 
Changes in OGA protein expression appear more sensitive to changes in O-GlcNAc than OGT in 
HeLa cells, while both OGT and OGA expression significantly change in SY5Y cells  (Figure 
D.1).  Over-expression of OGA did not substantially influence OGT protein expression (Figure 
D.1), and OGT over-expression did not change OGA expression (Figure D.1). Recently the 
development of a selective OGT inhibitor allowed for a dramatic reduction in cellular O-
GlcNAcylation [189], which in turn caused OGA protein expression to rapidly decrease with 
only a minimal increase in OGT protein expression [189].  The dynamic change in OGA protein 
expression was seen in the development of disease as well.  In red blood cells of prediabetic 
individuals, OGA expression was significantly increased [190], and OGA protein levels 
correlated with increased blood glucose in these prediabetic patients. These data suggest that 
higher blood glucose levels promote increased flux through the hexosamine biosynthetic 
pathway leading to elevated OGT activity, followed by OGA protein levels increasing to restore 
cellular O-GlcNAc homeostasis in erythrocyte precursor cells. Together, these data support the 
hypothesis that if OGT acts as a nutrient sensor allowing for rapid changes in O-GlcNAcylation 
due to alterations to either the extracellular or intracellular environment, then OGA should be 
less sensitive to nutrient changes and more sensitive to acute or chronic changes in O-
GlcNAcylation.  
 In order to respond to acute or chronic changes in O-GlcNAc levels, cells rapidly and 
dramatically alter the expression of OGA mRNA (Figure D.3).  In the case of OGT, we did not 
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detect a significant change in OGT mRNA levels after TMG treatment.  The rapid increase in 
OGA mRNA levels after TMG treatment would argue that either OGA transcripts were more 
stable or transcriptional activity at the OGA promoter was increasing. We tested transcript 
stability by inhibiting RNA polymerase II with AMD [183].  Interestingly, OGA and OGT 
transcript levels were not more stable after TMG treatment in the presence of AMD (Figure D.4) 
suggesting that the increase in OGA mRNA levels with TMG was due to an increase in OGA 
gene transcription.  
Next, we performed ChIP at the OGA promoter with an antibody that recognized all 
forms of RNA Pol II (phosphorylated and non-phosphorylated forms).  After 48 hrs of prolonged 
TMG treatment in K562 cells, total RNA Pol II at the promoter was decreased compared to the 
control samples (Figure D.5).  Although we expected to find an increase of RNA Pol II 
occupancy at the OGA promoter, the observed decrease might be due to the prolonged TMG 
treatment.  We have yet to explore RNA Pol II occupancy at the OGA promoter after an acute 
TMG treatment (for example 6 hrs), which might yield a different result and needs to be studied 
further.  The mRNA levels of OGA in K562 cells did begin to decrease at the 48-hr TMG 
treatment, suggesting that the OGA promoter might become inactive after prolonged TMG 
treatment.   
 Many transcription factors are modified by O-GlcNAc [35] and likely alteration of the O-
GlcNAcylation level of a transcription factor could mediate the change in OGA transcription. 
We used the predictive software TFSEARCH 
(http://www.cbrc.jp/research/db/TFSEARCH.html) to identify potential transcription factor 
binding sites in the first 1000 base pairs upstream of the OGA transcription start site [191].  




predicted transcription factors.  Due to the essential and ubiquitous expression of OGA [156], we 
anticipated that several housekeeping transcription factors might bind to this region, but we 
found only few of these.  Interestingly, both GATA and MZF are important transcription factors 
regulating hemopoietic development [184, 192].  Perhaps the increased in OGA expression in 
prediabetic red blood cells [190] was partially due to changes in either of these two proteins.  O-
GlcNAcylation changes might lead to alteration of GATA or MZF occupancy at the OGA 
promoter.  Some GATA family members are modified by O-GlcNAc [193]; thus, this presents an 
interesting avenue to explore in more detail. 
 Together, our data demonstrate that OGA protein and mRNA expression is sensitive to 
cellular levels of O-GlcNAc. Some disease states have OGA expression uncoupled from O-
GlcNAc levels [194].  In many different cancers, O-GlcNAc homeostasis appears to be disrupted 
with increased OGT protein expression and O-GlcNAc levels [195]. Several pancreatic cancer 
cell lines have increased O-GlcNAc levels when compared to an immortalized control cell line; 
importantly, OGT protein expression was increased while OGA protein expression was 
decreased [194]. The uncoupling of OGA expression to O-GlcNAc homeostasis could be an 
indicator of cancer progression and suggests that an increase of OGA protein expression would 
be beneficial therapeutically.  Determining how O-GlcNAc regulates OGA expression and 
transcription will be crucial for understanding the biology of O-GlcNAcylation and how O-
GlcNAc homeostasis is disrupted in disease.  
 
 
 
 
